



US 20030190635A1

(19) **United States**

(12) **Patent Application Publication**
McSwiggen

(10) **Pub. No.: US 2003/0190635 A1**

(43) **Pub. Date: Oct. 9, 2003**

(54) **RNA INTERFERENCE MEDIATED
TREATMENT OF ALZHEIMER'S DISEASE
USING SHORT INTERFERING RNA**

filed on Mar. 11, 2002. Provisional application No.
60/386,782, filed on Jun. 6, 2002.

Publication Classification

(76) Inventor: **James A. McSwiggen**, Boulder, CO
(US)

(51) **Int. Cl.⁷** **C12Q 1/68**; C07H 21/04;
C07H 21/02; A61K 48/00

(52) **U.S. Cl.** **435/6**; 435/375; 514/44; 536/23.2

Correspondence Address:
**MCDONNELL BOEHNNEN HULBERT &
BERGHOFF**
300 SOUTH WACKER DRIVE
SUITE 3200
CHICAGO, IL 60606 (US)

(57) **ABSTRACT**


(21) Appl. No.: **10/205,309**

(22) Filed: **Jul. 25, 2002**

Related U.S. Application Data

(60) Provisional application No. 60/358,580, filed on Feb.
20, 2002. Provisional application No. 60/363,124,

The present invention concerns methods and reagents useful
in modulating gene expression in a variety of applications,
including use in therapeutic, diagnostic, target validation,
and genomic discovery applications associated with Alzhe-
mer's disease. Specifically, the invention relates to small
interfering RNA (siRNA) molecules capable of mediating
RNA interference (RNAi) against beta-secretase (BACE),
PIN-1, presenillin-1 (PS-1) and presenillin-2 (PS-2)
polypeptide and polynucleotide targets.


Figure 1

= SOLID SUPPORT


R = TERMINAL PROTECTING GROUP

FOR EXAMPLE:


DIMETHOXYTRITYL (DMT)



(1) = CLEAVABLE LINKER

(FOR EXAMPLE: NUCLEOTIDE SUCCINATE OR
INVERTED DEOXYABASIC SUCCINATE)

(2) = CLEAVABLE LINKER

(FOR EXAMPLE: NUCLEOTIDE SUCCINATE OR
INVERTED DEOXYABASIC SUCCINATE)

INVERTED DEOXYABASIC SUCCINATE LINKAGE


Figure 2

Figure 3





Figure 5




lower case = 2'-O-Methyl; *italic lower case* = 2'-deoxy-2'-fluoro

iB = INVERTED DEOXYABASIC

S = PHOSPHOROTHIOATE OR PHOSPHORODITHIOATE

Figure 5




lower case = 2'-O-Methyl; *italic lower case* = 2'-deoxy-2'-fluoro

iB = INVERTED DEOXYABASIC

S = PHOSPHOROTHIOATE OR PHOSPHORODITHIOATE

Figure 6



RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING RNA

BACKGROUND OF THE INVENTION

[0001] The present invention concerns methods and reagents useful in modulating gene expression associated with Alzheimer's disease in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to short interfering nucleic acid molecules capable of mediating RNA interference (RNAi) against beta-secretase (BACE), pin-1, presenilin 1 (PS-1) and presenilin 2 (PS-2) expression.

[0002] The following is a discussion of relevant art pertaining to RNAi. The discussion is provided only for understanding of the invention that follows. The summary is not an admission that any of the work described below is prior art to the claimed invention.

[0003] RNA interference refers to the process of sequence-specific post transcriptional gene silencing in animals mediated by short interfering RNAs (siRNA) (Fire et al., 1998, *Nature*, 391, 806). The corresponding process in plants is commonly referred to as post transcriptional gene silencing or RNA silencing and is also referred to as quelling in fungi. The process of post transcriptional gene silencing is thought to be an evolutionarily conserved cellular defense mechanism used to prevent the expression of foreign genes which is commonly shared by diverse flora and phyla (Fire et al., 1999, *Trends Genet.*, 15, 358). Such protection from foreign gene expression may have evolved in response to the production of double stranded RNAs (dsRNA) derived from viral infection or the random integration of transposon elements into a host genome via a cellular response that specifically destroys homologous single stranded RNA or viral genomic RNA. The presence of dsRNA in cells triggers the RNAi response though a mechanism that has yet to be fully characterized. This mechanism appears to be different from the interferon response that results from dsRNA mediated activation of protein kinase PKR and 2',5'-oligoadenylate synthetase resulting in non-specific cleavage of mRNA by ribonuclease L.

[0004] The presence of long dsRNAs in cells stimulates the activity of a ribonuclease III enzyme referred to as dicer. Dicer is involved in the processing of the dsRNA into short pieces of dsRNA known as short interfering RNAs (siRNA) (Berstein et al., 2001, *Nature*, 409, 363). Short interfering RNAs derived from dicer activity are typically about 21-23 nucleotides in length and comprise about 19 base pair duplexes. Dicer has also been implicated in the excision of 21 and 22 nucleotide small temporal RNAs (stRNA) from precursor RNA of conserved structure that are implicated in translational control (Hutvagner et al., 2001, *Science*, 293, 834). The RNAi response also features an endonuclease complex containing a siRNA, commonly referred to as an RNA-induced silencing complex (RISC), which mediates cleavage of single stranded RNA having sequence complementary to the antisense strand of the siRNA duplex. Cleavage of the target RNA takes place in the middle of the region complementary to the antisense strand of the siRNA duplex (Elbashir et al., 2001, *Genes Dev.*, 15, 188).

[0005] Short interfering RNA mediated RNAi has been studied in a variety of systems. Fire et al., 1998, *Nature*, 391,

806, were the first to observe RNAi in *C. Elegans*. Wianny and Goetz, 1999, *Nature Cell Biol.*, 2, 70, describe RNAi mediated by dsRNA in mouse embryos. Hammond et al., 2000, *Nature*, 404, 293, describe RNAi in Drosophila cells transfected with dsRNA. Elbashir et al., 2001, *Nature*, 411, 494, describe RNAi induced by introduction of duplexes of synthetic 21-nucleotide RNAs in cultured mammalian cells including human embryonic kidney and HeLa cells. Recent work in Drosophila embryonic lysates (Elbashir et al., 2001, *EMBO J.*, 20, 6877) has revealed certain requirements for siRNA length, structure, chemical composition, and sequence that are essential to mediate efficient RNAi activity. These studies have shown that 21 nucleotide siRNA duplexes are most active when containing two nucleotide 3'-overhangs. Furthermore, complete substitution of one or both siRNA strands with 2'-deoxy (2'-H) or 2'-O-methyl nucleotides abolishes RNAi activity, whereas substitution of the 3'-terminal siRNA overhang nucleotides with deoxy nucleotides (2'-H) was shown to be tolerated. Single mismatch sequences in the center of the siRNA duplex were also shown to abolish RNAi activity. In addition, these studies also indicate that the position of the cleavage site in the target RNA is defined by the 5'-end of the siRNA guide sequence rather than the 3'-end (Elbashir et al., 2001, *EMBO J.*, 20, 6877). Other studies have indicated that a 5'-phosphate on the target-complementary strand of a siRNA duplex is required for siRNA activity and that ATP is utilized to maintain the 5'-phosphate moiety on the siRNA (Nykanen et al., 2001, *Cell*, 107, 309).

[0006] Studies have shown that replacing the 3'-overhanging segments of a 21-mer siRNA duplex having 2 nucleotide 3' overhangs with deoxyribonucleotides does not have an adverse effect on RNAi activity. Replacing up to 4 nucleotides on each end of the siRNA with deoxyribonucleotides has been reported to be well tolerated whereas complete substitution with deoxyribonucleotides results in no RNAi activity (Elbashir et al., 2001, *EMBO J.*, 20, 6877). In addition, Elbashir et al., supra, also report that substitution of siRNA with 2'-O-methyl nucleotides completely abolishes RNAi activity. Li et al., International PCT Publication No. WO 00/44914, and Beach et al., International PCT Publication No. WO 01/68836 both suggest that siRNA "may include modifications to either the phosphate-sugar back bone or the nucleoside to include at least one of a nitrogen or sulfur heteroatom", however neither application teaches to what extent these modifications are tolerated in siRNA molecules nor provide any examples of such modified siRNA. Kreutzer and Limmer, Canadian Patent Application No. 2,359,180, also describe certain chemical modifications for use in dsRNA constructs in order to counteract activation of double stranded-RNA-dependent protein kinase PKR, specifically 2'-amino or 2'-O-methyl nucleotides, and nucleotides containing a 2'-O or 4'-C methylene bridge. However, Kreutzer and Limmer similarly fail to show to what extent these modifications are tolerated in siRNA molecules nor do they provide any examples of such modified siRNA.

[0007] Parrish et al., 2000, *Molecular Cell*, 6, 1977-1087, tested certain chemical modifications targeting the unc-22 gene in *C. elegans* using long (>25 nt) siRNA transcripts. The authors describe the introduction of thiophosphate residues into these siRNA transcripts by incorporating thiophosphate nucleotide analogs with T7 and T3 RNA polymerase and observed that "RNAs with two [phosphorothioate]

modified bases also had substantial decreases in effectiveness as RNAi triggers (data not shown); [phosphorothioate] modification of more than two residues greatly destabilized the RNAs in vitro and we were not able to assay interference activities." Id. at 1081. The authors also tested certain modifications at the 2'-position of the nucleotide sugar in the long siRNA transcripts and observed that substituting deoxynucleotides for ribonucleotides "produced a substantial decrease in interference activity", especially in the case of Uridine to Thymidine and/or Cytidine to deoxy-Cytidine substitutions. Id. In addition, the authors tested certain base modifications, including substituting 4-thiouracil, 5-bromouracil, 5-iodouracil, 3-(aminoallyl)uracil for uracil, and inosine for guanosine in sense and antisense strands of the siRNA, and found that whereas 4-thiouracil and 5-bromouracil were all well tolerated, inosine "produced a substantial decrease in interference activity" when incorporated in either strand. Incorporation of 5-iodouracil and 3-(aminoallyl)uracil in the antisense strand resulted in substantial decrease in RNAi activity as well.

[0008] Beach et al., International PCT Publication No. WO 01/68836, describes specific methods for attenuating gene expression using endogenously derived dsRNA. Tuschl et al., International PCT Publication No. WO 01/75164, describes a *Drosophila* in vitro RNAi system and the use of specific siRNA molecules for certain functional genomic and certain therapeutic applications; although Tuschl, 2001, *Chem. Biochem.*, 2, 239-245, doubts that RNAi can be used to cure genetic diseases or viral infection due "to the danger of activating interferon response". Li et al., International PCT Publication No. WO 00/44914, describes the use of specific dsRNAs for use in attenuating the expression of certain target genes. Zernicka-Goetz et al., International PCT Publication No. WO 01/36646, describes certain methods for inhibiting the expression of particular genes in mammalian cells using certain dsRNA molecules. Fire et al., International PCT Publication No. WO 99/32619, describes particular methods for introducing certain dsRNA molecules into cells for use in inhibiting gene expression. Plactinck et al., International PCT Publication No. WO 00/01846, describes certain methods for identifying specific genes responsible for conferring a particular phenotype in a cell using specific dsRNA molecules. Mello et al., International PCT Publication No. WO 01/29058, describes the identification of specific genes involved in dsRNA mediated RNAi. Deschamps Depaillette et al., International PCT Publication No. WO 99/07409, describes specific compositions consisting of particular dsRNA molecules combined with certain anti-viral agents. Driscoll et al., International PCT Publication No. WO 01/49844, describes specific DNA constructs for use in facilitating gene silencing in targeted organisms. Parrish et al., 2000, *Molecular Cell*, 6, 1977-1087, describes specific chemically modified siRNA constructs targeting the unc-22 gene of *C. elegans*. Tuschl et al., International PCT Publication No. WO 02/44321, describe certain synthetic siRNA constructs.

[0009] Alzheimer's disease (AD) is a progressive, degenerative disease of the brain which affects approximately 4 million people in the United States alone. An estimated 14 million Americans will have Alzheimer's disease by the middle of the next century if no cure or definitive prevention of the disease is found. Nearly one out of ten people over age 65 and nearly half of those over 85 have Alzheimer's disease. Alzheimer's disease is not confined to the elderly, a

small percentage of people in their 30's and 40's are afflicted with early onset AD. Alzheimer's disease is the most common form of dementia, and amounts to the third most expensive disease in the US following heart disease and cancer. An estimated 100 billion dollars are spent annually on Alzheimer's disease (National Alzheimer's Association, 1999).

[0010] Alzheimer's disease is characterized by the progressive formation of insoluble plaques and vascular deposits in the brain consisting of the 4 kD amyloid β peptide ($A\beta$). These plaques are characterized by dystrophic neurites that show profound synaptic loss, neurofibrillary tangle formation, and gliosis. $A\beta$ arises from the proteolytic cleavage of the large type I transmembrane protein, β -amyloid precursor protein (APP) (Kang et al., 1987, *Nature*, 325, 733). Processing of APP to generate $A\beta$ requires two sites of cleavage by a β -secretase and a γ -secretase. β -secretase cleavage of APP results in the cytoplasmic release of a 100 kD soluble amino-terminal fragment, APPs β , leaving behind a 12 kD transmembrane carboxy-terminal fragment, C99. Alternately, APP can be cleaved by a α -secretase to generate cytoplasmic APPs α and transmembrane C83 fragments. Both remaining transmembrane fragments, C99 and C83, can be further cleaved by a γ -secretase, leading to the release and secretion of Alzheimer's related $A\beta$ and a non-pathogenic peptide, p3, respectively (Vassar et al., 1999, *Science*, 286, 735-741). Early onset familial Alzheimer's disease is characterized by mutant APP protein with a Met to Leu substitution at position P1, characterized as the "Swedish" familial mutation (Mullan et al., 1992, *Nature Genet.*, 1, 345). This APP mutation is characterized by a dramatic enhancement in β -secretase cleavage (Citron et al., 1992, *Nature*, 360, 672).

[0011] The identification of β -secretase, and γ -secretase constituents involved in the release of β -amyloid protein is of primary importance in the development of treatment strategies for Alzheimer's disease. Characterization of α -secretase is also important in this regard since α -secretase cleavage may compete with β -secretase cleavage resulting in non-pathogenic vs. pathogenic protein production. Involvement of the two metalloproteases, ADAM 10, and TACE has been demonstrated in α -cleavage of AAP (Buxbaum et al., 1999, *J. Biol. Chem.*, 273, 27765, and Lammich et al., 1999, *Proc. Natl. Acad. Sci. U.S.A.*, 96, 3922). Studies of γ -secretase activity have demonstrated presenilin dependence (De Strooper et al., 1998, *Nature*, 391, 387, and De Strooper et al., 1999, *Nature*, 398, 518), and as such, presenilins have been proposed as γ -secretase even though presenilin does not present proteolytic activity (Wolfe et al., 1999, *Nature*, 398, 513).

[0012] Recently, Vassar et al., 1999, supra reported β -secretase cleavage of AAP by the transmembrane aspartic protease beta site APP cleaving enzyme, BACE. While other potential candidates for β -secretase have been proposed (for review see Evin et al., 1999, *Proc. Natl. Acad. Sci. U.S.A.*, 96, 3922), none have demonstrated the full range of characteristics expected from this enzyme. Vassar et al, supra, demonstrate that BACE expression and localization are as expected for β -secretase, that BACE overexpression in cells results in increased β -secretase cleavage of APP and Swedish APP, that isolated BACE demonstrates site specific proteolytic activity on APP derived peptide substrates, and

that antisense mediated endogenous BACE inhibition results in dramatically reduced β -secretase activity.

[0013] Current treatment strategies for Alzheimer's disease rely on either the prevention or the alleviation of symptoms and/or the slowing down of disease progression. Two drugs approved in the treatment of Alzheimer's, donepezil (Aricept®) and tacrine (Cognex®), both cholinomimetics, attempt to slow the loss of cognitive ability by increasing the amount of acetylcholine available to the brain. Antioxidant therapy through the use of antioxidant compounds such as alpha-tocopherol (vitamin E), melatonin, and selegiline (Eldepryl®) attempt to slow disease progression by minimizing free radical damage. Estrogen replacement therapy is thought to incur a possible preventative benefit in the development of Alzheimer's disease based on limited data. The use of anti-inflammatory drugs may be associated with a reduced risk of Alzheimer's as well. Calcium channel blockers such as Nimodipine® are considered to have a potential benefit in treating Alzheimer's disease due to protection of nerve cells from calcium overload, thereby prolonging nerve cell survival. Nootropic compounds, such as acetyl-L-carnitine (Alcar®) and insulin, have been proposed to have some benefit in treating Alzheimer's due to enhancement of cognitive and memory function based on cellular metabolism.

[0014] Whereby the above treatment strategies may all improve quality of life in Alzheimer's patients, there exists an unmet need in the comprehensive treatment and prevention of this disease. As such, there exists the need for therapeutics effective in reversing the physiological changes associated with Alzheimer's disease, specifically, therapeutics that can eliminate and/or reverse the deposition of amyloid β peptide. The use of compounds to modulate the expression of proteases that are instrumental in the release of amyloid β peptide, namely β -secretase (BACE), and γ -secretase (presenilin), is of therapeutic significance.

[0015] McSwiggen et al., International PCT Publication No. WO 01/16312, describes nucleic acid mediated inhibition of BACE, PS-1, and PS-2 expression.

SUMMARY OF THE INVENTION

[0016] One embodiment of the invention provides a short interfering RNA (siRNA) molecule that down regulates expression of a beta site APP-cleaving enzyme (BACE) gene by RNA interference. The siRNA molecule can be adapted for use to treat Alzheimer's disease. The siRNA molecule can comprise a sense region and an antisense region. The antisense region can comprise sequence complementary to an RNA sequence encoding BACE and the sense region can comprise sequence complementary to the antisense region.

[0017] The siRNA molecule can be assembled from two nucleic acid fragments wherein one fragment comprises the sense region and the second fragment comprises the antisense region of said siRNA molecule. The sense region and antisense region can be covalently connected via a linker molecule. The linker molecule can be a polynucleotide linker or a non-nucleotide linker.

[0018] The antisense region can comprise a sequence complementary to sequence having any of SEQ ID NOs. 1-325. The antisense region can also comprise sequence

having any of SEQ ID NOs. 326-650, 664, 666, 668, 670, 672, or 674. The sense region can comprise sequence having any of SEQ ID NOs. 1-325, 663, 665, 667, 669, 671, or 673. The sense region can comprise a sequence of SEQ ID NO. 651 and the antisense region can comprise a sequence of SEQ ID NO. 652. The sense region can comprise a sequence of SEQ ID NO. 653 and the antisense region can comprise a sequence of SEQ ID NO. 654. The sense region can comprise a sequence of SEQ ID NO. 655 and the antisense region can comprise a sequence of SEQ ID NO. 656. The sense region can comprise a sequence of SEQ ID NO. 657 and the antisense region can comprise a sequence of SEQ ID NO. 658. The sense region can comprise a sequence of SEQ ID NO. 659 and the antisense region can comprise a sequence of SEQ ID NO. 660. The sense region can comprise a sequence of SEQ ID NO. 661 and the antisense region can comprise a sequence of SEQ ID NO. 662.


[0019] The sense region of a siRNA molecule of the invention can comprise a 3'-terminal overhang and the antisense region can comprise a 3'-terminal overhang. The 3'-terminal overhangs each can comprise about 2 nucleotides. The antisense region of the 3'-terminal nucleotide overhang can be complementary to RNA encoding BACE.

[0020] The sense region of a siRNA molecule can comprise one or more 2'-O-methyl modified pyrimidine nucleotides. The sense region can comprise a terminal cap moiety at the 5'-end, 3'-end, or both 5' and 3' ends of said sense region.

[0021] The antisense region of a siRNA molecule can comprise one or more 2'-deoxy-2'-fluoro modified pyrimidine nucleotides. The antisense region can also comprise a phosphorothioate internucleotide linkage at the 3' end of said antisense region. The antisense region can comprise between about one and about five phosphorothioate internucleotide linkages at the 5' end of said antisense region.


[0022] The 3'-terminal nucleotide overhangs of a siRNA molecule can comprise ribonucleotides or deoxyribonucleotides that are chemically modified at a nucleic acid sugar, base, or backbone. The 3'-terminal nucleotide overhangs can also comprise one or more universal base ribonucleotides. Additionally, the 3'-terminal nucleotide overhangs can comprise one or more acyclic nucleotides.

[0023] The 3'-terminal nucleotide overhangs can comprise nucleotides comprising internucleotide linkages having Formula I:



[0024] wherein each R1 and R2 is independently any nucleotide, non-nucleotide, or polynucleotide which can be naturally occurring or chemically modified, each X and Y is independently O, S, N, alkyl, or substituted alkyl, each Z and W is independently O, S, N, alkyl, substituted alkyl, O-alkyl, S-alkyl, alkaryl, or aralkyl, and wherein W, X, Y and Z are not all O.

[0025] The 3'-terminal nucleotide overhangs can comprise nucleotides or non-nucleotides having Formula II:



[0026] wherein each R3, R4, R5, R6, R7, R8, R10, R11 and R12 is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF₃, OCF₃, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO₂, NO₂, N₃, NH₂, aminoalkyl, aminoacid, aminoacyl, ONH₂, O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, or group having Formula I; R9 is O, S, CH₂, S=O, CHF, or CF₂, and B is a nucleosidic base or any other non-naturally occurring base that can be complementary or non-complementary to BACE RNA or a non-nucleosidic base or any other non-naturally occurring universal base that can be complementary or non-complementary to BACE RNA.

[0027] Another embodiment of the invention provides an expression vector comprising a nucleic acid sequence encoding at least one siRNA molecule of the invention in a manner that allows expression of the nucleic acid molecule. The expression vector can be in a mammalian cell, such as a human cell. The siRNA molecule can comprise a sense region and an antisense region. The antisense region can comprise sequence complementary to an RNA sequence encoding BACE and the sense region comprises sequence complementary to the antisense region. The siRNA molecule can comprise two distinct strands having complementarity sense and antisense regions or can comprise a single strand having complementary sense and antisense regions.

[0028] Therefore, this invention relates to compounds, compositions, and methods useful for modulating beta-secretase (BACE), PIN-1, presenillin 1 (PS-1) and/or presenillin 2 (PS-2) function and/or gene expression in a cell by RNA interference (RNAi) using short interfering RNA (siRNA). In particular, the instant invention features siRNA molecules and methods to modulate the expression of BACE, PIN-1, PS-1 and/or PS-2 RNA. The siRNA of the invention can be unmodified or chemically modified. The siRNA of the instant invention can be chemically synthesized, expressed from a vector or enzymatically synthesized. The instant invention also features various chemically modified synthetic short interfering RNA (siRNA) molecules capable of modulating BACE, PIN-1, PS-1 and/or PS-2 gene expression/activity in cells by RNA interference (RNAi). The use of chemically modified siRNA is expected to improve various properties of native siRNA molecules through increased resistance to nuclease degradation in vivo and/or improved cellular uptake. The siRNA molecules of the instant invention provide useful reagents and methods for a

variety of therapeutic, diagnostic, agricultural, target validation, genomic discovery, genetic engineering and pharmacogenomic applications.

[0029] In one embodiment, the invention features one or more siRNA molecules and methods that independently or in combination modulate the expression of gene(s) encoding proteins associated with Alzheimer's disease and other neurodegenerative disorders or conditions such as dementia, and stroke/cardiovascular accident (CVA). Specifically, the present invention features siRNA molecules that modulate the expression of proteins associated with Alzheimer's disease and related pathologies, for example BACE (such as Genbank Accession No. NM_012104), PIN-1 (such as Genbank Accession No. NM_006222), PS-1 (such as Genbank Accession No. L76517) and/or PS-2 (such as Genbank Accession No. L43964).

[0030] The description below of the various aspects and embodiments is provided with reference to the exemplary BACE protein, including components or subunits thereof. However, the various aspects and embodiments are also directed to other genes which express other BACE related proteins or other proteins associated with Alzheimer's disease, such as PIN-1, PS-1 and PS-2. Those additional genes can be analyzed for target sites using the methods described for BACE herein. Thus, the inhibition and the effects of such inhibition of the other genes can be performed as described herein.

[0031] In one embodiment, the invention features a siRNA molecule which down regulates expression of a BACE gene, for example, wherein the BACE gene comprises BACE encoding sequence.

[0032] In one embodiment, the invention features a siRNA molecule having RNAi activity against BACE RNA, wherein the siRNA molecule comprises a sequence complementary to any RNA having BACE encoding sequence, for example Genbank Accession No. NM_012104. In another embodiment, the invention features a siRNA molecule having RNAi activity against PIN-1 RNA, wherein the siRNA molecule comprises a sequence complementary to any RNA having PIN-1 encoding sequence, for example Genbank Accession No. NM_006222. In another embodiment, the invention features a siRNA molecule having RNAi activity against PS-1 RNA, wherein the siRNA molecule comprises a sequence complementary to any RNA having PS-1 encoding sequence, for example Genbank Accession No. L76517. In another embodiment, the invention features a siRNA molecule having RNAi activity against PS-2 RNA, wherein the siRNA molecule comprises a sequence complementary to any RNA having PS-2 encoding sequence, for example Genbank Accession No. L43964.

[0033] In another embodiment, the invention features a siRNA molecule comprising sequences selected from the group consisting of SEQ ID NOs: 1-650. In yet another embodiment, the invention features a siRNA molecule comprising a sequence, for example the antisense sequence of the siRNA construct, complementary to a sequence or portion of sequence comprising Genbank Accession Nos. NM_012104 (BACE), NM_006222 (PIN-1), L76517 (PS-1) and/or L43964 (PS-2).


[0034] In one embodiment, a siRNA molecule of the invention has RNAi activity that modulates expression of RNA encoded by a BACE, PIN-1, PS-1, and/or PS-2 gene(s).

[0035] In one embodiment, nucleic acid molecules of the invention that act as mediators of the RNA interference gene silencing response are double stranded RNA molecules. In another embodiment, the siRNA molecules of the invention consist of duplexes containing about 19 base pairs between oligonucleotides comprising about 19 to about 25 nucleotides (e.g., about 19, 20, 21, 22, 23, 24, or 25). In yet another embodiment, siRNA molecules of the invention comprise duplexes with overhanging ends of 1-3 (e.g., 1, 2, or 3) nucleotides, for example 21 nucleotide duplexes with 19 base pairs and 2 nucleotide 3'-overhangs. These nucleotide overhangs in the antisense strand are optionally complementary to the target sequence.

[0036] In one embodiment, the invention features chemically modified siRNA constructs having specificity for BACE expressing nucleic acid molecules. Non-limiting examples of such chemical modifications include without limitation phosphorothioate internucleotide linkages, 2'-O-methyl ribonucleotides, 2'-deoxy-2'-fluoro ribonucleotides, "universal base" nucleotides, 5-C-methyl nucleotides, and inverted deoxyabasic residue incorporation. These chemical modifications, when used in various siRNA constructs, are shown to preserve RNAi activity in cells while at the same time, dramatically increasing the serum stability of these compounds. Furthermore, contrary to the data published by Parrish et al., supra, applicant demonstrates that multiple (greater than one) phosphorothioate substitutions are well tolerated and confer substantial increases in serum stability for modified siRNA constructs. Chemical modifications of the siRNA constructs can also be used to improve the stability of the interaction with the target RNA sequence and to improve nuclease resistance.

[0037] In a non-limiting example, the introduction of chemically modified nucleotides into nucleic acid molecules will provide a powerful tool in overcoming potential limitations of in vivo stability and bioavailability inherent to native RNA molecules that are delivered exogenously. For example, the use of chemically modified nucleic acid molecules can enable a lower dose of a particular nucleic acid molecule for a given therapeutic effect since chemically modified nucleic acid molecules tend to have a longer half-life in serum. Furthermore, certain chemical modifications can improve the bioavailability of nucleic acid molecules by targeting particular cells or tissues and/or improving cellular uptake of the nucleic acid molecule. Therefore, even if the activity of a chemically modified nucleic acid molecule is reduced as compared to a native nucleic acid molecule, for example when compared to an all RNA nucleic acid molecule, the overall activity of the modified nucleic acid molecule can be greater than the native molecule due to improved stability and/or delivery of the molecule. Unlike native unmodified siRNA, chemically modified siRNA can also minimize the possibility of activating interferon activity in humans.


[0038] In one embodiment, the invention features a chemically modified short interfering RNA (siRNA) molecule capable of mediating RNA interference (RNAi) against BACE inside a cell, wherein the chemical modification comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) nucleotides comprising a backbone modified internucleotide linkage having Formula I:



[0039] wherein each R1 and R2 is independently any nucleotide, non-nucleotide, or polynucleotide which can be naturally occurring or chemically modified, each X and Y is independently O, S, N, alkyl, or substituted alkyl, each Z and W is independently O, S, N, alkyl, substituted alkyl, O-alkyl, S-alkyl, alkaryl, or aralkyl, and wherein W, X, Y and Z are not all O.

[0040] The chemically modified internucleotide linkages having Formula I, for example wherein any Z, W, X, and/or Y independently comprises a sulphur atom, can be present in one or both oligonucleotide strands of the siRNA duplex, for example in the sense strand, antisense strand, or both strands. The siRNA molecules of the invention can comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) chemically modified internucleotide linkages having Formula I at the 3'-end, 5'-end, or both 3' and 5'-ends of the sense strand, antisense strand, or both strands. For example, an exemplary siRNA molecule of the invention can comprise between about 1 and about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) chemically modified internucleotide linkages having Formula I at the 5'-end of the sense strand, antisense strand, or both strands. In another non-limiting example, an exemplary siRNA molecule of the invention can comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) pyrimidine nucleotides with chemically modified internucleotide linkages having Formula I in the sense strand, antisense strand, or both strands. In yet another non-limiting example, an exemplary siRNA molecule of the invention can comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) purine nucleotides with chemically modified internucleotide linkages having Formula I in the sense strand, antisense strand, or both strands. In another embodiment, a siRNA molecule of the invention having internucleotide linkage(s) of Formula I also comprises a chemically modified nucleotide or non-nucleotide having any of Formulae II, III, V, or VI.

[0041] In one embodiment, the invention features a chemically modified short interfering RNA (siRNA) molecule capable of mediating RNA interference (RNAi) against BACE inside a cell, wherein the chemical modification comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) nucleotides or non-nucleotides having Formula II:




[0042] wherein each R3, R4, R5, R6, R7, R8, R10, R11 and R12 is independently H, OH, alkyl, substi-

tuted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF₃, OCF₃, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO₂, NO₂, N₃, NH₂, aminoalkyl, aminoacid, aminoacyl, ONH₂, O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, or group having Formula I; R₉ is O, S, CH₂, S=O, CHF, or CF₂, and B is a nucleosidic base such as adenine, guanine, uracil, cytosine, thymine, 2-aminoadenosine, 5-methylcytosine, 2,6-diaminopurine, or any other non-naturally occurring base that can be employed to be complementary or non-complementary to RNA or a non-nucleosidic base such as phenyl, naphthyl, 3-nitropyrrole, 5-nitroindole, nebularine, pyridone, pyridinone, or any other non-naturally occurring universal base that can be employed to be complementary or non-complementary to RNA.

[0043] The chemically modified nucleotide or non-nucleotide of Formula II can be present in one or both oligonucleotide strands of the siRNA duplex, for example in the sense strand, antisense strand, or both strands. The siRNA molecules of the invention can comprise one or more chemically modified nucleotide or non-nucleotide of Formula II at the 3'-end, 5'-end, or both 3' and 5'-ends of the sense strand, antisense strand, or both strands. For example, an exemplary siRNA molecule of the invention can comprise between about 1 and about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) chemically modified nucleotide or non-nucleotide of Formula II at the 5'-end of the sense strand, antisense strand, or both strands. In another non-limiting example, an exemplary siRNA molecule of the invention can comprise between about 1 and about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) chemically modified nucleotide or non-nucleotide of Formula II at the 3'-end of the sense strand, antisense strand, or both strands.

[0044] In one embodiment, the invention features a chemically modified short interfering RNA (siRNA) molecule capable of mediating RNA interference (RNAi) against BACE inside a cell, wherein the chemical modification comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) nucleotides or non-nucleotides having Formula III:




[0045] wherein each R₃, R₄, R₅, R₆, R₇, R₈, R₁₀, R₁₁ and R₁₂ is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF₃, OCF₃, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO₂, NO₂, N₃, NH₂, aminoalkyl, aminoacid, aminoacyl, ONH₂,

O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, or group having Formula I; R₉ is O, S, CH₂, S=O, CHF, or CF₂, and B is a nucleosidic base such as adenine, guanine, uracil, cytosine, thymine, 2-aminoadenosine, 5-methylcytosine, 2,6-diaminopurine, or any other non-naturally occurring base that can be complementary or non-complementary to RNA or a non-nucleosidic base such as phenyl, naphthyl, 3-nitropyrrole, 5-nitroindole, nebularine, pyridone, pyridinone, or any other non-naturally occurring universal base that can be complementary or non-complementary to RNA.

[0046] The chemically modified nucleotide or non-nucleotide of Formula III can be present in one or both oligonucleotide strands of the siRNA duplex, for example in the sense strand, antisense strand, or both strands. The siRNA molecules of the invention can comprise one or more chemically modified nucleotide or non-nucleotide of Formula III at the 3'-end, 5'-end, or both 3' and 5'-ends of the sense strand, antisense strand, or both strands. For example, an exemplary siRNA molecule of the invention can comprise between about 1 and about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) chemically modified nucleotide or non-nucleotide of Formula III at the 5'-end of the sense strand, antisense strand, or both strands. In another non-limiting example, an exemplary siRNA molecule of the invention can comprise between about 1 and about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) chemically modified nucleotide or non-nucleotide of Formula III at the 3'-end of the sense strand, antisense strand, or both strands.

[0047] In another embodiment, a siRNA molecule of the invention comprises a nucleotide having Formula II or III, wherein the nucleotide having Formula II or III is in an inverted configuration. For example, the nucleotide having Formula II or III is connected to the siRNA construct in a 3',3', 3'-2', 2'-3', or 5',5' configuration, such as at the 3'-end, 5'-end, or both 3' and 5' ends of one or both siRNA strands.

[0048] In one embodiment, the invention features a chemically modified short interfering RNA (siRNA) molecule capable of mediating RNA interference (RNAi) against BACE inside a cell, wherein the chemical modification comprises a 5'-terminal phosphate group having Formula IV:



[0049] wherein each X and Y is independently O, S, N, alkyl, substituted alkyl, or alkylhalo; each Z and W is independently O, S, N, alkyl, substituted alkyl, O-alkyl, S-alkyl, alkaryl, aralkyl, or alkylhalo; and wherein W, X, Y and Z are not all O.

[0050] In one embodiment, the invention features a siRNA molecule having a 5'-terminal phosphate group having Formula IV on the target-complementary strand, for example a strand complementary to BACE RNA, wherein the siRNA molecule comprises an all RNA siRNA molecule. In another embodiment, the invention features a siRNA molecule hav-

ing a 5'-terminal phosphate group having Formula IV on the target-complementary strand wherein the siRNA molecule also comprises 1-3 (e.g., 1, 2, or 3) nucleotide 3'-overhangs having between about 1 and about 4 (e.g., about 1, 2, 3, or 4) deoxyribonucleotides on the 3'-end of one or both strands. In another embodiment, a 5'-terminal phosphate group having Formula IV is present on the target-complementary strand of a siRNA molecule of the invention, for example a siRNA molecule having chemical modifications having Formula I, Formula II and/or Formula III.

[0051] In one embodiment, the invention features a chemically modified short interfering RNA (siRNA) molecule capable of mediating RNA interference (RNAi) against BACE inside a cell, wherein the chemical modification comprises one or more phosphorothioate internucleotide linkages. For example, in a non-limiting example, the invention features a chemically modified short interfering RNA (siRNA) having about 1, 2, 3, 4, 5, 6, 7, 8 or more phosphorothioate internucleotide linkages in one siRNA strand. In yet another embodiment, the invention features a chemically modified short interfering RNA (siRNA) individually having about 1, 2, 3, 4, 5, 6, 7, 8 or more phosphorothioate internucleotide linkages in both siRNA strands. The phosphorothioate internucleotide linkages can be present in one or both oligonucleotide strands of the siRNA duplex, for example in the sense strand, antisense strand, or both strands. The siRNA molecules of the invention can comprise one or more phosphorothioate internucleotide linkages at the 3'-end, 5'-end, or both 3' and 5'-ends of the sense strand, antisense strand, or both strands. For example, an exemplary siRNA molecule of the invention can comprise between about 1 and about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) consecutive phosphorothioate internucleotide linkages at the 5'-end of the sense strand, antisense strand, or both strands. In another non-limiting example, an exemplary siRNA molecule of the invention can comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) pyrimidine phosphorothioate internucleotide linkages in the sense strand, antisense strand, or both strands. In yet another non-limiting example, an exemplary siRNA molecule of the invention can comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) purine phosphorothioate internucleotide linkages in the sense strand, antisense strand, or both strands.

[0052] In one embodiment, the invention features a siRNA molecule, wherein the sense strand comprises one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3', 5', or both 3' and 5'-ends of the sense strand; and wherein the antisense strand comprises any of between 1 and 10 or more, specifically about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3', 5', or both 3' and 5'-ends of the antisense strand. In another embodiment, one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more pyrimidine nucleotides of the sense and/or antisense siRNA stand are chemically modified with 2'-deoxy, 2'-O-methyl and/or

2'-deoxy-2'-fluoro nucleotides, with or without one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more phosphorothioate internucleotide linkages and/or a terminal cap molecule at the 3', 5', or both 3' and 5'-ends, being present in the same or different strand.

[0053] In another embodiment, the invention features a siRNA molecule, wherein the sense strand comprises between about 1 and about 5, specifically about 1, 2, 3, 4, or 5 phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3', 5', or both 3' and 5'-ends of the sense strand; and wherein the antisense strand comprises any of between about 1 and about 5 or more, specifically about 1, 2, 3, 4, 5, or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3', 5', or both 3' and 5'-ends of the antisense strand. In another embodiment, one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more pyrimidine nucleotides of the sense and/or antisense siRNA stand are chemically modified with 2'-deoxy, 2'-O-methyl and/or 2'-deoxy-2'-fluoro nucleotides, with or without between about 1 and about 5 or more, for example about 1, 2, 3, 4, 5 or more phosphorothioate internucleotide linkages and/or a terminal cap molecule at the 3', 5', or both 3' and 5'-ends, being present in the same or different strand.

[0054] In one embodiment, the invention features a siRNA molecule, wherein the antisense strand comprises one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more phosphorothioate internucleotide linkages, and/or between one or more (e.g., about 1, 2, 3, 4, 5, or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3', 5', or both 3' and 5'-ends of the sense strand; and wherein the antisense strand comprises any of between about 1 and about 10, specifically about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3', 5', or both 3' and 5'-ends of the antisense strand. In another embodiment, one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more pyrimidine nucleotides of the sense and/or antisense siRNA stand are chemically modified with 2'-deoxy, 2'-O-methyl and/or 2'-deoxy-2'-fluoro nucleotides, with or without one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more phosphorothioate internucleotide linkages and/or a terminal cap molecule at the 3', 5', or both 3' and 5'-ends, being present in the same or different strand.

[0055] In another embodiment, the invention features a siRNA molecule, wherein the antisense strand comprises between about 1 and about 5 or more, specifically about 1, 2, 3, 4, 5 or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5 or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5 or more) universal base modified nucleotides, and optionally a terminal cap mol-

ecule at the 3', 5', or both 3' and 5'-ends of the sense strand; and wherein the antisense strand comprises any of between about 1 and about 5 or more, specifically about 1, 2, 3, 4, 5 or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3', 5', or both 3' and 5'-ends of the antisense strand. In another embodiment, one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more pyrimidine nucleotides of the sense and/or antisense siRNA stand are chemically modified with 2'-deoxy, 2'-O-methyl and/or 2'-deoxy-2'-fluoro nucleotides, with or without between about 1 and about 5, for example about 1, 2, 3, 4, 5 or more phosphorothioate internucleotide linkages and/or a terminal cap molecule at the 3', 5', or both 3' and 5'-ends, being present in the same or different strand.

[0056] In one embodiment, the invention features a chemically modified short interfering RNA (siRNA) molecule having between about 1 and about 5, specifically 1, 2, 3, 4, 5 or more phosphorothioate internucleotide linkages in each strand of the siRNA molecule.

[0057] In another embodiment, the invention features a siRNA molecule comprising 2'-5' internucleotide linkages. The 2'-5' internucleotide linkage(s) can be at the 5'-end, 3'-end, or both 5' and 3' ends of one or both siRNA sequence strands. In addition, the 2'-5' internucleotide linkage(s) can be present at various other positions within one or both siRNA sequence strands, for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more including every internucleotide linkage of a pyrimidine nucleotide in one or both strands of the siRNA molecule can comprise a 2'-5' internucleotide linkage, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more including every internucleotide linkage of a purine nucleotide in one or both strands of the siRNA molecule can comprise a 2'-5' internucleotide linkage.

[0058] In another embodiment, a chemically modified siRNA molecule of the invention comprises a duplex having two strands, one or both of which can be chemically modified, wherein each strand is between about 18 and about 27 (e.g., about 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27) nucleotides in length, wherein the duplex has between about 18 and about 23 (e.g., about 18, 19, 20, 21, 22, or 23) base pairs, and wherein the chemical modification comprises a structure having Formula I, Formula II, Formula III and/or Formula IV. For example, an exemplary chemically modified siRNA molecule of the invention comprises a duplex having two strands, one or both of which can be chemically modified with a chemical modification having Formula I, Formula II, Formula III, and/or Formula IV, wherein each strand consists of 21 nucleotides, each having 2 nucleotide 3'-overhangs, and wherein the duplex has 19 base pairs.

[0059] In another embodiment, a siRNA molecule of the invention comprises a single stranded hairpin structure, wherein the siRNA is between about 36 and about 70 (e.g., about 36, 40, 45, 50, 55, 60, 65, or 70) nucleotides in length having between about 18 and about 23 (e.g., about 18, 19, 20, 21, 22, or 23) base pairs, and wherein the siRNA can include a chemical modification comprising a structure having Formula I, Formula II, Formula III and/or Formula IV. For example, an exemplary chemically modified siRNA molecule of the invention comprises a linear oligonucleotide


having between about 42 and about 50 (e.g., about 42, 43, 44, 45, 46, 47, 48, 49, or 50) nucleotides that is chemically modified with a chemical modification having Formula I, Formula II, Formula III, and/or Formula IV, wherein the linear oligonucleotide forms a hairpin structure having 19 base pairs and a 2 nucleotide 3'-overhang.

[0060] In another embodiment, a linear hairpin siRNA molecule of the invention contains a stem loop motif, wherein the loop portion of the siRNA molecule is biodegradable. For example, a linear hairpin siRNA molecule of the invention is designed such that degradation of the loop portion of the siRNA molecule in vivo can generate a double stranded siRNA molecule with 3'-overhangs, such as 3'-overhangs comprising about 2 nucleotides.

[0061] In another embodiment, a siRNA molecule of the invention comprises a circular nucleic acid molecule, wherein the siRNA is between about 38 and about 70 (e.g., about 38, 40, 45, 50, 55, 60, 65, or 70) nucleotides in length having between about 18 and about 23 (e.g., about 18, 19, 20, 21, 22, or 23) base pairs, and wherein the siRNA can include a chemical modification, which comprises a structure having Formula I, Formula II, Formula III and/or Formula IV. For example, an exemplary chemically modified siRNA molecule of the invention comprises a circular oligonucleotide having between about 42 and about 50 (e.g., about 42, 43, 44, 45, 46, 47, 48, 49, or 50) nucleotides that is chemically modified with a chemical modification having Formula I, Formula II, Formula III, and/or Formula IV, wherein the circular oligonucleotide forms a dumbbell shaped structure having 19 base pairs and 2 loops.

[0062] In another embodiment, a circular siRNA molecule of the invention contains two loop motifs, wherein one or both loop portions of the siRNA molecule is biodegradable. For example, a circular siRNA molecule of the invention is designed such that degradation of the loop portions of the siRNA molecule in vivo can generate a double stranded siRNA molecule with 3'-overhangs, such as 3'-overhangs comprising about 2 nucleotides.


[0063] In one embodiment, a siRNA molecule of the invention comprises at least one (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) abasic residue, for example a compound having Formula V:



[0064] wherein each R3, R4, R5, R6, R7, R8, R10, R11, R12, and R13 is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF3, OCF3, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO2, NO2, N3, NH2, aminoalkyl, aminoacid, aminoacyl, ONH2, O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkyl-

lamino, polyalkylamino, substituted silyl, or group having Formula I; R₉ is O, S, CH₂, S=O, CHF, or CF₂.

[0065] In one embodiment, a siRNA molecule of the invention comprises at least one (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) inverted abasic residue, for example a compound having Formula VI:



[0066] wherein each R₃, R₄, R₅, R₆, R₇, R₈, R₁₀, R₁₁, R₁₂, and R₁₃ is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF₃, OCF₃, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO₂, NO₂, NH₂, aminoalkyl, aminoacid, aminoacyl, ONH₂, O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, or group having Formula I; R₉ is O, S, CH₂, S=O, CHF, or CF₂, and either R₂, R₃, R₈ or R₁₃ serve as points of attachment to the siRNA molecule of the invention.

[0067] In another embodiment, a siRNA molecule of the invention comprises an abasic residue having Formula II or III, wherein the abasic residue having Formula II or III is connected to the siRNA construct in a 3',3', 3'-2', 2'-3', or 5',5' configuration, such as at the 3'-end, 5'-end, or both 3' and 5' ends of one or both siRNA strands.

[0068] In one embodiment, a siRNA molecule of the invention comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) locked nucleic acid (LNA) nucleotides, for example at the 5'-end, 3'-end, 5' and 3'-end, or any combination thereof, of the siRNA molecule.

[0069] In another embodiment, a siRNA molecule of the invention comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) acyclic nucleotides, for example at the 5'-end, 3'-end, 5' and 3'-end, or any combination thereof, of the siRNA molecule.

[0070] In one embodiment, the invention features a chemically modified short interfering RNA (siRNA) molecule capable of mediating RNA interference (RNAi) against BACE inside a cell, wherein the chemical modification comprises a conjugate covalently attached to the siRNA molecule. In another embodiment, the conjugate is covalently attached to the siRNA molecule via a biodegradable linker. In one embodiment, the conjugate molecule is attached at the 3'-end of either the sense strand, antisense strand, or both strands of the siRNA. In another embodiment, the conjugate molecule is attached at the 5'-end of either the sense strand, antisense strand, or both strands of the siRNA. In yet another embodiment, the conjugate molecule is attached both the 3'-end and 5'-end of either the

sense strand, antisense strand, or both strands of the siRNA, or any combination thereof. In one embodiment, a conjugate molecule of the invention comprises a molecule that facilitates delivery of a siRNA molecule into a biological system such as a cell. In another embodiment, the conjugate molecule attached to the siRNA is a poly ethylene glycol, human serum albumin, or a ligand for a cellular receptor that can mediate cellular uptake. Examples of specific conjugate molecules contemplated by the instant invention that can be attached to siRNA molecules are described in Vargeese et al., U.S. Ser. No. 60/311,865, incorporated by reference herein.

[0071] In one embodiment, the invention features a siRNA molecule capable of mediating RNA interference (RNAi) against BACE inside a cell, wherein one or both strands of the siRNA comprise ribonucleotides at positions within the siRNA that are critical for siRNA mediated RNAi in a cell. All other positions within the siRNA can include chemically modified nucleotides and/or non-nucleotides such as nucleotides and or non-nucleotides having Formula I, II, III, IV, V, or VI, or any combination thereof to the extent that the ability of the siRNA molecule to support RNAi activity in a cell is maintained.

[0072] In one embodiment, the invention features a method for modulating the expression of a BACE gene within a cell, comprising: (a) synthesizing a siRNA molecule of the invention, which can be chemically modified, wherein one of the siRNA strands includes a sequence complementary to RNA of the BACE gene; and (b) introducing the siRNA molecule into a cell under conditions suitable to modulate the expression of the BACE gene in the cell.

[0073] In one embodiment, the invention features a method for modulating the expression of a BACE gene within a cell, comprising: (a) synthesizing a siRNA molecule of the invention, which can be chemically modified, wherein one of the siRNA strands includes a sequence complementary to RNA of the BACE gene and wherein the sense strand sequence of the siRNA is identical to the complementary sequence of the BACE RNA; and (b) introducing the siRNA molecule into a cell under conditions suitable to modulate the expression of the BACE gene in the cell.

[0074] In another embodiment, the invention features a method for modulating the expression of more than one BACE gene within a cell, comprising: (a) synthesizing siRNA molecules of the invention, which can be chemically modified, wherein one of the siRNA strands includes a sequence complementary to RNA of the BACE genes; and (b) introducing the siRNA molecules into a cell under conditions suitable to modulate the expression of the BACE genes in the cell.

[0075] In another embodiment, the invention features a method for modulating the expression of more than one BACE gene within a cell, comprising: (a) synthesizing a siRNA molecule of the invention, which can be chemically modified, wherein one of the siRNA strands includes a sequence complementary to RNA of the BACE gene and wherein the sense strand sequence of the siRNA is identical to the complementary sequence of the BACE RNA; and (b) introducing the siRNA molecules into a cell under conditions suitable to modulate the expression of the BACE genes in the cell.

[0076] In one embodiment, the invention features a method of modulating the expression of a BACE gene in a tissue explant, comprising: (a) synthesizing a siRNA molecule of the invention, which can be chemically modified, wherein one of the siRNA strands includes a sequence complementary to RNA of the BACE gene; (b) introducing the siRNA molecule into a cell of the tissue explant derived from a particular organism under conditions suitable to modulate the expression of the BACE gene in the tissue explant, and (c) optionally introducing the tissue explant back into the organism the tissue was derived from or into another organism under conditions suitable to modulate the expression of the BACE gene in that organism.

[0077] In one embodiment, the invention features a method of modulating the expression of a BACE gene in a tissue explant, comprising: (a) synthesizing a siRNA molecule of the invention, which can be chemically modified, wherein one of the siRNA strands includes a sequence complementary to RNA of the BACE gene and wherein the sense strand sequence of the siRNA is identical to the complementary sequence of the BACE RNA; (b) introducing the siRNA molecule into a cell of the tissue explant derived from a particular organism under conditions suitable to modulate the expression of the BACE gene in the tissue explant, and (c) optionally introducing the tissue explant back into the organism the tissue was derived from or into another organism under conditions suitable to modulate the expression of the BACE gene in that organism.

[0078] In another embodiment, the invention features a method of modulating the expression of more than one BACE gene in a tissue explant, comprising: (a) synthesizing siRNA molecules of the invention, which can be chemically modified, wherein one of the siRNA strands includes a sequence complementary to RNA of the BACE genes; (b) introducing the siRNA molecules into a cell of the tissue explant derived from a particular organism under conditions suitable to modulate the expression of the BACE genes in the tissue explant, and (c) optionally introducing the tissue explant back into the organism the tissue was derived from or into another organism under conditions suitable to modulate the expression of the BACE genes in that organism.

[0079] In one embodiment, the invention features a method of modulating the expression of a BACE gene in an organism, comprising: (a) synthesizing a siRNA molecule of the invention, which can be chemically modified, wherein one of the siRNA strands includes a sequence complementary to RNA of the BACE gene; and (b) introducing the siRNA molecule into the organism under conditions suitable to modulate the expression of the BACE gene in the organism.

[0080] In another embodiment, the invention features a method of modulating the expression of more than one BACE gene in an organism, comprising: (a) synthesizing siRNA molecules of the invention, which can be chemically modified, wherein one of the siRNA strands includes a sequence complementary to RNA of the BACE genes; and (b) introducing the siRNA molecules into the organism under conditions suitable to modulate the expression of the BACE genes in the organism.

[0081] The siRNA molecules of the invention can be designed to inhibit BACE gene expression through RNAi targeting of a variety of RNA molecules. In one embodi-

ment, the siRNA molecules of the invention are used to target various RNAs corresponding to a target gene. Non-limiting examples of such RNAs include messenger RNA (mRNA), alternate RNA splice variants of target gene(s), post-transcriptionally modified RNA of target gene(s), pre-mRNA of target gene(s), and/or RNA templates used for BACE activity. If alternate splicing produces a family of transcripts that are distinguished by usage of appropriate exons, the instant invention can be used to inhibit gene expression through the appropriate exons to specifically inhibit or to distinguish among the functions of gene family members. For example, a protein that contains an alternatively spliced transmembrane domain can be expressed in both membrane bound and secreted forms. Use of the invention to target the exon containing the transmembrane domain can be used to determine the functional consequences of pharmaceutical targeting of membrane bound as opposed to the secreted form of the protein. Non-limiting examples of applications of the invention relating to targeting these RNA molecules include therapeutic pharmaceutical applications, pharmaceutical discovery applications, molecular diagnostic and gene function applications, and gene mapping, for example using single nucleotide polymorphism mapping with siRNA molecules of the invention. Such applications can be implemented using known gene sequences or from partial sequences available from an expressed sequence tag (EST).

[0082] In another embodiment, the siRNA molecules of the invention are used to target conserved sequences corresponding to a gene family or gene families such as BACE genes. As such, siRNA molecules targeting multiple BACE targets can provide increased therapeutic effect. In addition, siRNA can be used to characterize pathways of gene function in a variety of applications. For example, the present invention can be used to inhibit the activity of target gene(s) in a pathway to determine the function of uncharacterized gene(s) in gene function analysis, mRNA function analysis, or translational analysis. The invention can be used to determine potential target gene pathways involved in various diseases and conditions toward pharmaceutical development. The invention can be used to understand pathways of gene expression involved in development, such as prenatal development, postnatal development and/or aging.

[0083] In one embodiment, siRNA molecule(s) and/or methods of the invention are used to inhibit the expression of gene(s) that encode RNA referred to by Genbank Accession number, for example BACE genes such as Genbank Accession Nos. NM_012104 (BACE), NM_006222 (PIN-1), L76517 (PS-1) and/or L43964 (PS-2). Such sequences are readily obtained using these Genbank Accession numbers.

[0084] In one embodiment, the invention features a method comprising: (a) analyzing the sequence of a RNA target encoded by a BACE gene; (b) synthesizing one or more sets of siRNA molecules having sequence complementary to one or more regions of the RNA of (a); and (c) assaying the siRNA molecules of (b) under conditions suitable to determine RNAi targets within the target RNA sequence. In another embodiment, the siRNA molecules of (b) have strands of a fixed length, for example about 23 nucleotides in length. In yet another embodiment, the siRNA molecules of (b) are of differing length, for example having

strands of about 19 to about 25 (e.g., about 19, 20, 21, 22, 23, 24, or 25) nucleotides in length.

[0085] In one embodiment, the invention features a composition comprising a siRNA molecule of the invention, which can be chemically modified, in a pharmaceutically acceptable carrier or diluent. In another embodiment, the invention features a pharmaceutical composition comprising siRNA molecules of the invention, which can be chemically modified, targeting one or more genes in a pharmaceutically acceptable carrier or diluent. In another embodiment, the invention features a method for treating or preventing a disease or condition in a subject, comprising administering to the subject a composition of the invention under conditions suitable for the treatment or prevention of the disease or condition in the subject, alone or in conjunction with one or more other therapeutic compounds. In yet another embodiment, the invention features a method for reducing or preventing tissue rejection in a subject comprising administering to the subject a composition of the invention under conditions suitable for the reduction or prevention of tissue rejection in the subject.

[0086] In another embodiment, the invention features a method for validating a BACE gene target, comprising: (a) synthesizing a siRNA molecule of the invention, which can be chemically modified, wherein one of the siRNA strands includes a sequence complementary to RNA of a BACE target gene; (b) introducing the siRNA molecule into a cell, tissue, or organism under conditions suitable for modulating expression of the BACE target gene in the cell, tissue, or organism; and (c) determining the function of the gene by assaying for any phenotypic change in the cell, tissue, or organism.

[0087] In one embodiment, the invention features a kit containing a siRNA molecule of the invention, which can be chemically modified, that can be used to modulate the expression of a BACE target gene in a cell, tissue, or organism. In another embodiment, the invention features a kit containing more than one siRNA molecule of the invention, which can be chemically modified, that can be used to modulate the expression of more than one BACE target gene in a cell, tissue, or organism.

[0088] In one embodiment, the invention features a cell containing one or more siRNA molecules of the invention, which can be chemically modified. In another embodiment, the cell containing a siRNA molecule of the invention is a mammalian cell. In yet another embodiment, the cell containing a siRNA molecule of the invention is a human cell.

[0089] In one embodiment, the synthesis of a siRNA molecule of the invention, which can be chemically modified, comprises: (a) synthesis of two complementary strands of the siRNA molecule; (b) annealing the two complementary strands together under conditions suitable to obtain a double stranded siRNA molecule. In another embodiment, synthesis of the two complementary strands of the siRNA molecule is by solid phase oligonucleotide synthesis. In yet another embodiment, synthesis of the two complementary strands of the siRNA molecule is by solid phase tandem oligonucleotide synthesis.

[0090] In one embodiment, the invention features a method for synthesizing a siRNA duplex molecule comprising: (a) synthesizing a first oligonucleotide sequence strand

of the siRNA molecule, wherein the first oligonucleotide sequence strand comprises a cleavable linker molecule that can be used as a scaffold for the synthesis of the second oligonucleotide sequence strand of the siRNA; (b) synthesizing the second oligonucleotide sequence strand of siRNA on the scaffold of the first oligonucleotide sequence strand, wherein the second oligonucleotide sequence strand further comprises a chemical moiety than can be used to purify the siRNA duplex; (c) cleaving the linker molecule of (a) under conditions suitable for the two siRNA oligonucleotide strands to hybridize and form a stable duplex; and (d) purifying the siRNA duplex utilizing the chemical moiety of the second oligonucleotide sequence strand. In another embodiment, cleavage of the linker molecule in (c) above takes place during deprotection of the oligonucleotide, for example under hydrolysis conditions using an alkylamine base such as methylamine. In another embodiment, the method of synthesis comprises solid phase synthesis on a solid support such as controlled pore glass (CPG) or polystyrene, wherein the first sequence of (a) is synthesized on a cleavable linker, such as a succinyl linker, using the solid support as a scaffold. The cleavable linker in (a) used as a scaffold for synthesizing the second strand can comprise similar reactivity as the solid support derivatized linker, such that cleavage of the solid support derivatized linker and the cleavable linker of (a) takes place concomitantly. In another embodiment, the chemical moiety of (b) that can be used to isolate the attached oligonucleotide sequence comprises a trityl group, for example a dimethoxytrityl group, which can be employed in a trityl-on synthesis strategy as described herein. In yet another embodiment, the chemical moiety, such as a dimethoxytrityl group, is removed during purification, for example using acidic conditions.

[0091] In a further embodiment, the method for siRNA synthesis is a solution phase synthesis or hybrid phase synthesis wherein both strands of the siRNA duplex are synthesized in tandem using a cleavable linker attached to the first sequence which acts a scaffold for synthesis of the second sequence. Cleavage of the linker under conditions suitable for hybridization of the separate siRNA sequence strands results in formation of the double stranded siRNA molecule.

[0092] In another embodiment, the invention features a method for synthesizing a siRNA duplex molecule comprising: (a) synthesizing one oligonucleotide sequence strand of the siRNA molecule, wherein the sequence comprises a cleavable linker molecule that can be used as a scaffold for the synthesis of another oligonucleotide sequence; (b) synthesizing a second oligonucleotide sequence having complementarity to the first sequence strand on the scaffold of (a), wherein the second sequence comprises the other strand of the double stranded siRNA molecule and wherein the second sequence further comprises a chemical moiety than can be used to isolate the attached oligonucleotide sequence; (c) purifying the product of (b) utilizing the chemical moiety of the second oligonucleotide sequence strand under conditions suitable for isolating the full length sequence comprising both siRNA oligonucleotide strands connected by the cleavable linker; and (d) under conditions suitable for the two siRNA oligonucleotide strands to hybridize and form a stable duplex. In another embodiment, cleavage of the linker molecule in (c) above takes place during deprotection of the oligonucleotide, for example under hydrolysis conditions. In another embodiment, cleavage of the linker molecule in (c)

above takes place after deprotection of the oligonucleotide. In another embodiment, the method of synthesis comprises solid phase synthesis on a solid support such as controlled pore glass (CPG) or polystyrene, wherein the first sequence of (a) is synthesized on a cleavable linker, such as a succinyl linker, using the solid support as a scaffold. The cleavable linker in (a) used as a scaffold for synthesizing the second strand can comprise similar reactivity or differing reactivity as the solid support derivatized linker, such that cleavage of the solid support derivatized linker and the cleavable linker of (a) takes place either concomitantly or sequentially. In another embodiment, the chemical moiety of (b) that can be used to isolate the attached oligonucleotide sequence comprises a trityl group, for example a dimethoxytrityl group.

[0093] In another embodiment, the invention features a method for making a double stranded siRNA molecule in a single synthetic process, comprising: (a) synthesizing an oligonucleotide having a first and a second sequence, wherein the first sequence is complementary to the second sequence, and the first oligonucleotide sequence is linked to the second sequence via a cleavable linker, and wherein a terminal 5'-protecting group, for example a 5'-O-dimethoxytrityl group (5'-O-DMT) remains on the oligonucleotide having the second sequence; (b) deprotecting the oligonucleotide whereby the deprotection results in the cleavage of the linker joining the two oligonucleotide sequences; and (c) purifying the product of (b) under conditions suitable for isolating the double stranded siRNA molecule, for example using a trityl-on synthesis strategy as described herein.

[0094] In one embodiment, the invention features siRNA constructs that mediate RNAi against BACE, wherein the siRNA construct comprises one or more chemical modifications, for example one or more chemical modifications having Formula I, II, III, IV, or V, that increases the nuclease resistance of the siRNA construct.

[0095] In another embodiment, the invention features a method for generating siRNA molecules with increased nuclease resistance comprising (a) introducing nucleotides having any of Formula I-VI into a siRNA molecule, and (b) assaying the siRNA molecule of step (a) under conditions suitable for isolating siRNA molecules having increased nuclease resistance.

[0096] In one embodiment, the invention features siRNA constructs that mediate RNAi against BACE, wherein the siRNA construct comprises one or more chemical modifications described herein that modulates the binding affinity between the sense and antisense strands of the siRNA construct.

[0097] In another embodiment, the invention features a method for generating siRNA molecules with increased binding affinity between the sense and antisense strands of the siRNA molecule comprising (a) introducing nucleotides having any of Formula I-VI into a siRNA molecule, and (b) assaying the siRNA molecule of step (a) under conditions suitable for isolating siRNA molecules having increased binding affinity between the sense and antisense strands of the siRNA molecule.

[0098] In one embodiment, the invention features siRNA constructs that mediate RNAi against BACE, wherein the siRNA construct comprises one or more chemical modifications described herein that modulates the binding affinity

between the antisense strand of the siRNA construct and a complementary target RNA sequence within a cell.

[0099] In another embodiment, the invention features a method for generating siRNA molecules with increased binding affinity between the antisense strand of the siRNA molecule and a complementary target RNA sequence, comprising (a) introducing nucleotides having any of Formula I-VI into a siRNA molecule, and (b) assaying the siRNA molecule of step (a) under conditions suitable for isolating siRNA molecules having increased binding affinity between the antisense strand of the siRNA molecule and a complementary target RNA sequence.

[0100] In one embodiment, the invention features siRNA constructs that mediate RNAi against BACE, wherein the siRNA construct comprises one or more chemical modifications described herein that modulate the polymerase activity of a cellular polymerase capable of generating additional endogenous siRNA molecules having sequence homology to the chemically modified siRNA construct.

[0101] In another embodiment, the invention features a method for generating siRNA molecules capable of mediating increased polymerase activity of a cellular polymerase capable of generating additional endogenous siRNA molecules having sequence homology to the chemically modified siRNA molecule comprising (a) introducing nucleotides having any of Formula I-VI into a siRNA molecule, and (b) assaying the siRNA molecule of step (a) under conditions suitable for isolating siRNA molecules capable of mediating increased polymerase activity of a cellular polymerase capable of generating additional endogenous siRNA molecules having sequence homology to the chemically modified siRNA molecule.

[0102] In one embodiment, the invention features chemically modified siRNA constructs that mediate RNAi against BACE in a cell, wherein the chemical modifications do not significantly effect the interaction of siRNA with a target RNA molecule and/or proteins or other factors that are essential for RNAi in a manner that would decrease the efficacy of RNAi mediated by such siRNA constructs.

[0103] In another embodiment, the invention features a method for generating siRNA molecules with improved RNAi activity against BACE, comprising (a) introducing nucleotides having any of Formula I-VI into a siRNA molecule, and (b) assaying the siRNA molecule of step (a) under conditions suitable for isolating siRNA molecules having improved RNAi activity.

[0104] In yet another embodiment, the invention features a method for generating siRNA molecules with improved RNAi activity against a BACE target RNA, comprising (a) introducing nucleotides having any of Formula I-VI into a siRNA molecule, and (b) assaying the siRNA molecule of step (a) under conditions suitable for isolating siRNA molecules having improved RNAi activity against the target RNA.

[0105] In one embodiment, the invention features siRNA constructs that mediate RNAi against BACE, wherein the siRNA construct comprises one or more chemical modifications described herein that modulates the cellular uptake of the siRNA construct.

[0106] In another embodiment, the invention features a method for generating siRNA molecules against BACE with

improved cellular uptake, comprising (a) introducing nucleotides having any of Formula I-VI into a siRNA molecule, and (b) assaying the siRNA molecule of step (a) under conditions suitable for isolating siRNA molecules having improved cellular uptake.

[0107] In one embodiment, the invention features siRNA constructs that mediate RNAi against BACE, wherein the siRNA construct comprises one or more chemical modifications described herein that increases the bioavailability of the siRNA construct, for example by attaching polymeric conjugates such as polyethyleneglycol or equivalent conjugates that improve the pharmacokinetics of the siRNA construct, or by attaching conjugates that target specific tissue types or cell types in vivo. Non-limiting examples of such conjugates are described in Vargeese et al., U.S. Ser. No. 60/311,865 incorporated by reference herein.

[0108] In one embodiment, the invention features a method for generating siRNA molecules of the invention with improved bioavailability, comprising (a) introducing a conjugate into the structure of a siRNA molecule, and (b) assaying the siRNA molecule of step (a) under conditions suitable for isolating siRNA molecules having improved bioavailability. Such conjugates can include ligands for cellular receptors such as peptides derived from naturally occurring protein ligands, protein localization sequences including cellular ZIP code sequences, antibodies, nucleic acid aptamers, vitamins and other co-factors such as folate and N-acetylgalactosamine, polymers such as polyethyleneglycol (PEG), phospholipids, polyamines such as spermine or spermidine, and others.

[0109] In another embodiment, the invention features a method for generating siRNA molecules of the invention with improved bioavailability, comprising (a) introducing an excipient formulation to a siRNA molecule, and (b) assaying the siRNA molecule of step (a) under conditions suitable for isolating siRNA molecules having improved bioavailability. Such excipients include polymers such as cyclodextrins, lipids, cationic lipids, polyamines, phospholipids, and others.

[0110] In another embodiment, the invention features a method for generating siRNA molecules of the invention with improved bioavailability, comprising (a) introducing nucleotides having any of Formula I-VI into a siRNA molecule, and (b) assaying the siRNA molecule of step (a) under conditions suitable for isolating siRNA molecules having improved bioavailability.

[0111] In another embodiment, polyethylene glycol (PEG) can be covalently attached to siRNA compounds of the present invention. The attached PEG can be any molecular weight, preferably from about 2,000 to about 50,000 daltons (Da).

[0112] The present invention can be used alone or as a component of a kit having at least one of the reagents necessary to carry out the in vitro or in vivo introduction of RNA to test samples and/or subjects. For example, preferred components of the kit include the siRNA and a vehicle that promotes introduction of the siRNA. Such a kit can also include instructions to allow a user of the kit to practice the invention.

[0113] The term "short interfering RNA" or "siRNA" as used herein refers to a double stranded nucleic acid molecule

capable of RNA interference "RNAi", see for example Bass, 2001, *Nature*, 411, 428-429; Elbashir et al., 2001, *Nature*, 411, 494-498; and Kreutzer et al., International PCT Publication No. WO 00/44895; Zernicka-Goetz et al., International PCT Publication No. WO 01/36646; Fire, International PCT Publication No. WO 99/32619; Plaetinck et al., International PCT Publication No. WO 00/01846; Mello and Fire, International PCT Publication No. WO 01/29058; Deschamps-Depaillette, International PCT Publication No. WO 99/07409; and Li et al., International PCT Publication No. WO 00/44914. As used herein, siRNA molecules need not be limited to those molecules containing only RNA, but further encompasses chemically modified nucleotides and non-nucleotides.

[0114] By "modulate" is meant that the expression of the gene, or level of RNA molecule or equivalent RNA molecules encoding one or more proteins or protein subunits, or activity of one or more proteins or protein subunits is up regulated or down regulated, such that expression, level, or activity is greater than or less than that observed in the absence of the modulator. For example, the term "modulate" can mean "inhibit," but the use of the word "modulate" is not limited to this definition.

[0115] By "inhibit" it is meant that the activity of a gene expression product or level of RNAs or equivalent RNAs encoding one or more gene products is reduced below that observed in the absence of the nucleic acid molecule of the invention. In one embodiment, inhibition with a siRNA molecule preferably is below that level observed in the presence of an inactive or attenuated molecule that is unable to mediate an RNAi response. In another embodiment, inhibition of gene expression with the siRNA molecule of the instant invention is greater in the presence of the siRNA molecule than in its absence.

[0116] By "gene" or "target gene" is meant, a nucleic acid that encodes an RNA, for example, nucleic acid sequences including, but not limited to, structural genes encoding a polypeptide. The target gene can be a gene derived from a cell, an endogenous gene, a transgene, or exogenous genes such as genes of a pathogen, for example a virus, which is present in the cell after infection thereof. The cell containing the target gene can be derived from or contained in any organism, for example a plant, animal, protozoan, virus, bacterium, or fungus. Non-limiting examples of plants include monocots, dicots, or gymnosperms. Non-limiting examples of animals include vertebrates or invertebrates. Non-limiting examples of fungi include molds or yeasts.

[0117] By "BACE" as used herein is meant, any protein, peptide, or polypeptide, having beta-secretase activity, such as that involved in generating beta-amyloid.

[0118] By "presenillin" or "PS", eg "PS-1" or "PS-2" as used herein is meant, any protein, peptide, or polypeptide having gamma-secretase activity, such as that involved in generating beta-amyloid.

[0119] By "PIN-1" as used herein is meant, any protein, peptide, or polypeptide having peptidyl-prolyl cis/trans isomerase activity, such as that involved in the development of Neurofibrillary Tangles.

[0120] By "highly conserved sequence region" is meant, a nucleotide sequence of one or more regions in a target gene

does not vary significantly from one generation to the other or from one biological system to the other.

[0121] By “complementarity” or “complementary” is meant that a nucleic acid can form hydrogen bond(s) with another nucleic acid sequence by either traditional Watson-Crick or other non-traditional types of interaction. In reference to the nucleic molecules of the present invention, the binding free energy for a nucleic acid molecule with its complementary sequence is sufficient to allow the relevant function of the nucleic acid to proceed, e.g., RNAi activity. For example, the degree of complementarity between the sense and antisense strand of the siRNA construct can be the same or different from the degree of complementarity between the antisense strand of the siRNA and the target RNA sequence. Complementarity to the target sequence of less than 100% in the antisense strand of the siRNA duplex, including point mutations, is reported not to be tolerated when these changes are located between the 3'-end and the middle of the antisense siRNA (completely abolishes siRNA activity), whereas mutations near the 5'-end of the antisense siRNA strand can exhibit a small degree of RNAi activity (Elbashir et al., 2001, *The EMBO Journal*, 20, 6877-6888). Determination of binding free energies for nucleic acid molecules is well known in the art (see, e.g., Turner et al., 1987, *CSH Symp. Quant. Biol.* LII pp. 123-133; Frier et al., 1986, *Proc. Nat. Acad. Sci. USA* 83:9373-9377; Turner et al., 1987, *J. Am. Chem. Soc.* 109:3783-3785). A percent complementarity indicates the percentage of contiguous residues in a nucleic acid molecule that can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, 10 out of 10 being 50%, 60%, 70%, 80%, 90%, and 100% complementary). “Perfectly complementary” means that all the contiguous residues of a nucleic acid sequence will hydrogen bond with the same number of contiguous residues in a second nucleic acid sequence.

[0122] The siRNA molecules of the invention represent a novel therapeutic approach to treat a variety of pathologic indications, including Alzheimer's disease, dementia, stroke (CVA) and any other diseases or conditions that are related to the levels of BACE in a cell or tissue, alone or in combination with other therapies. The reduction of BACE expression (specifically BACE RNA levels) and thus reduction in the level of the respective protein relieves, to some extent, the symptoms of the disease or condition.

[0123] In one embodiment of the present invention, each sequence of a siRNA molecule of the invention is independently about 18 to about 24 nucleotides in length, in specific embodiments about 18, 19, 20, 21, 22, 23, or 24 nucleotides in length. In another embodiment, the siRNA duplexes of the invention independently comprise between about 17 and about 23 (e.g., about 17, 18, 19, 20, 21, 22, or 23) base pairs. In yet another embodiment, siRNA molecules of the invention comprising hairpin or circular structures are about 35 to about 55 (e.g., about 35, 40, 45, 50, or 55) nucleotides in length, or about 38 to about 44 (e.g., about 38, 39, 40, 41, 42, 43, or 44) nucleotides in length and comprising about 16 to about 22 (e.g., about 16, 17, 18, 19, 20, 21, or 22) base pairs. Exemplary siRNA molecules of the invention are shown in Table I (all sequences are shown 5'-3') and/or FIGS. 4 and 5.

[0124] As used herein “cell” is used in its usual biological sense, and does not refer to an entire multicellular organism,

e.g., specifically does not refer to a human. The cell can be present in an organism, e.g., mammals such as humans, cows, sheep, apes, monkeys, swine, dogs, and cats. The cell can be eukaryotic (e.g., a mammalian cell). The cell can be of somatic or germ line origin, totipotent or pluripotent, dividing or non-dividing. The cell can also be derived from or can comprise a gamete or embryo, a stem cell, or a fully differentiated cell.

[0125] The siRNA molecules of the invention are added directly, or can be complexed with cationic lipids, packaged within liposomes, or otherwise delivered to target cells or tissues. The nucleic acid or nucleic acid complexes can be locally administered to relevant tissues ex vivo, or in vivo through injection, infusion pump or stent, with or without their incorporation in biopolymers. In particular embodiments, the nucleic acid molecules of the invention comprise sequences shown in Table I and/or FIGS. 4 and 5. Examples of such nucleic acid molecules consist essentially of sequences defined in this table.

[0126] In another aspect, the invention provides mammalian cells containing one or more siRNA molecules of this invention. The one or more siRNA molecules can independently be targeted to the same or different sites.

[0127] By “RNA” is meant a molecule comprising at least one ribonucleotide residue. By “ribonucleotide” is meant a nucleotide with a hydroxyl group at the 2' position of a β -D-ribo-furanose moiety. The terms include double stranded RNA, single stranded RNA, isolated RNA such as partially purified RNA, essentially pure RNA, synthetic RNA, recombinantly produced RNA, as well as altered RNA that differs from naturally occurring RNA by the addition, deletion, substitution and/or alteration of one or more nucleotides. Such alterations can include addition of non-nucleotide material, such as to the end(s) of the siRNA or internally, for example at one or more nucleotides of the RNA. Nucleotides in the RNA molecules of the instant invention can also comprise non-standard nucleotides, such as non-naturally occurring nucleotides or chemically synthesized nucleotides or deoxynucleotides. These altered RNAs can be referred to as analogs or analogs of naturally-occurring RNA.

[0128] By “subject” is meant an organism, which is a donor or recipient of explanted cells or the cells themselves. “Subject” also refers to an organism to which the nucleic acid molecules of the invention can be administered. In one embodiment, a subject is a mammal or mammalian cells. In another embodiment, a subject is a human or human cells.

[0129] The term “phosphorothioate” as used herein refers to an internucleotide linkage having Formula I, wherein Z and/or W comprise a sulfur atom. Hence, the term phosphorothioate refers to both phosphorothioate and phosphorodithioate internucleotide linkages.

[0130] The term “universal base” as used herein refers to nucleotide base analogs that form base pairs with each of the natural DNA/RNA bases with little discrimination between them. Non-limiting examples of universal bases include C-phenyl, C-naphthyl and other aromatic derivatives, inosine, azole carboxamides, and nitroazole derivatives such as 3-nitropyrrole, 4-nitroindole, 5-nitroindole, and 6-nitroindole as known in the art (see for example Loakes, 2001, *Nucleic Acids Research*, 29, 2437-2447).

[0131] The term “acyclic nucleotide” as used herein refers to any nucleotide having an acyclic ribose sugar, for example where any of the ribose carbons (C1, C2, C3, C4, or C5), are independently or in combination absent from the nucleotide.

[0132] The nucleic acid molecules of the instant invention, individually, or in combination or in conjunction with other drugs, can be used to treat diseases or conditions discussed herein. For example, to treat a particular disease or condition, the siRNA molecules can be administered to a subject or can be administered to other appropriate cells evident to those skilled in the art, individually or in combination with one or more drugs under conditions suitable for the treatment.

[0133] In a further embodiment, the siRNA molecules can be used in combination with other known treatments to treat conditions or diseases discussed above. For example, the described molecules could be used in combination with one or more known therapeutic agents to treat a disease or condition. Non-limiting examples of other therapeutic agents that can be readily combined with a siRNA molecule of the invention are enzymatic nucleic acid molecules, allosteric nucleic acid molecules, antisense, decoy, or aptamer nucleic acid molecules, antibodies such as monoclonal antibodies, small molecules, and other organic and/or inorganic compounds including metals, salts and ions.

[0134] In one embodiment, the invention features an expression vector comprising a nucleic acid sequence encoding at least one siRNA molecule of the invention, in a manner which allows expression of the siRNA molecule. For example, the vector can contain sequence(s) encoding both strands of a siRNA molecule comprising a duplex. The vector can also contain sequence(s) encoding a single nucleic acid molecule that is self complementary and thus forms a siRNA molecule. Non-limiting examples of such expression vectors are described in Paul et al., 2002, *Nature Biotechnology*, 19, 505; Miyagishi and Taira, 2002, *Nature Biotechnology*, 19, 497; Lee et al., 2002, *Nature Biotechnology*, 19, 500; and Novina et al., 2002, *Nature Medicine*, advance online publication doi:10.1038/nm725.

[0135] In another embodiment, the invention features a mammalian cell, for example, a human cell, including an expression vector of the invention.

[0136] In yet another embodiment, the expression vector of the invention comprises a sequence for a siRNA molecule having complementarity to a RNA molecule referred to by a Genbank Accession numbers, for example BACE genes such as Genbank Accession Nos. NM_012104 (BACE), NM_006222 (PIN-1), L76517 (PS-1) and/or L43964 (PS-2).

[0137] In one embodiment, an expression vector of the invention comprises a nucleic acid sequence encoding two or more siRNA molecules, which can be the same or different.

[0138] In another aspect of the invention, siRNA molecules that interact with target RNA molecules and down-regulate gene encoding target RNA molecules (for example target RNA molecules referred to by Genbank Accession numbers herein) are expressed from transcription units inserted into DNA or RNA vectors. The recombinant vectors can be DNA plasmids or viral vectors. siRNA expressing

viral vectors can be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus. The recombinant vectors capable of expressing the siRNA molecules can be delivered as described herein, and persist in target cells. Alternatively, viral vectors can be used that provide for transient expression of siRNA molecules. Such vectors can be repeatedly administered as necessary. Once expressed, the siRNA molecules bind and down-regulate gene function or expression via RNA interference (RNAi). Delivery of siRNA expressing vectors can be systemic, such as by intravenous or intramuscular administration, by administration to target cells ex-planted from a subject followed by reintroduction into the subject, or by any other means that would allow for introduction into the desired target cell.

[0139] By “vectors” is meant any nucleic acid- and/or viral-based technique used to deliver a desired nucleic acid.

[0140] By “comprising” is meant including, but not limited to, whatever follows the word “comprising”. Thus, use of the term “comprising” indicates that the listed elements are required or mandatory, but that other elements are optional and may or may not be present. By “consisting of” is meant including, and limited to, whatever follows the phrase “consisting of”. Thus, the phrase “consisting of” indicates that the listed elements are required or mandatory, and that no other elements may be present. By “consisting essentially of” is meant including any elements listed after the phrase, and limited to other elements that do not interfere with or contribute to the activity or action specified in the disclosure for the listed elements. Thus, the phrase “consisting essentially of” indicates that the listed elements are required or mandatory, but that other elements are optional and may or may not be present depending upon whether or not they affect the activity or action of the listed elements.

[0141] Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0142] First the drawings will be described briefly.

DRAWINGS

[0143] FIG. 1 shows a non-limiting example of a scheme for the synthesis of siRNA molecules. The complementary siRNA sequence strands, strand 1 and strand 2, are synthesized in tandem and are connected by a cleavable linkage, such as a nucleotide succinate or abasic succinate, which can be the same or different from the cleavable linker used for solid phase synthesis on a solid support. The synthesis can be either solid phase or solution phase, in the example shown, the synthesis is a solid phase synthesis. The synthesis is performed such that a protecting group, such as a dimethoxytrityl group, remains intact on the terminal nucleotide of the tandem oligonucleotide. Upon cleavage and deprotection of the oligonucleotide, the two siRNA strands spontaneously hybridize to form a siRNA duplex, which allows the purification of the duplex by utilizing the properties of the terminal protecting group, for example by applying a trityl on purification method wherein only duplexes/oligonucleotides with the terminal protecting group are isolated.

[0144] FIG. 2 shows a MALDI-TOV mass spectrum of a purified siRNA duplex synthesized by a method of the invention. The two peaks shown correspond to the predicted mass of the separate siRNA sequence strands. This result demonstrates that the siRNA duplex generated from tandem synthesis can be purified as a single entity using a simple trityl-on purification methodology.

[0145] FIG. 3 shows a non-limiting proposed mechanistic representation of target RNA degradation involved in RNAi. Double stranded RNA (dsRNA), which is generated by RNA dependent RNA polymerase (RdRP) from foreign single stranded RNA, for example viral, transposon, or other exogenous RNA, activates the DICER enzyme which in turn generates siRNA duplexes having terminal phosphate groups (P). An active siRNA complex forms which recognizes a target RNA, resulting in degradation of the target RNA by the RISC endonuclease complex or in the synthesis of additional RNA by RNA dependent RNA polymerase (RdRP), which can activate DICER and result in additional siRNA molecules, thereby amplifying the RNAi response.

[0146] FIG. 4 shows non-limiting examples of chemically modified siRNA constructs of the present invention. In the figure, N stands for any nucleotide (adenosine, guanosine, cytosine, uridine, or optionally thymidine, for example thymidine can be substituted in the overhanging regions designated by parenthesis (N N)). Various modifications are shown for the sense and antisense strands of the siRNA constructs. A The sense strand comprises 21 nucleotides having four phosphorothioate 5' and 3'-terminal internucleotide linkages, wherein the two terminal 3'-nucleotides are optionally base paired and wherein all pyrimidine nucleotides that may be present are 2'-O-methyl modified nucleotides except for (N N) nucleotides, which can comprise naturally occurring ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. The antisense strand comprises 21 nucleotides, wherein the two terminal 3'-nucleotides are optionally complementary to the target RNA sequence, and having one 3'-terminal phosphorothioate internucleotide linkage and four 5'-terminal phosphorothioate internucleotide linkages and wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides except for (N N) nucleotides, which can comprise naturally occurring ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. B The sense strand comprises 21 nucleotides wherein the two terminal 3'-nucleotides are optionally base paired and wherein all pyrimidine nucleotides that may be present are 2'-O-methyl modified nucleotides except for (N N) nucleotides, which can comprise naturally occurring ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. The antisense strand comprises 21 nucleotides, wherein the two terminal 3'-nucleotides are optionally complementary to the target RNA sequence, and wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides except for (N N) nucleotides, which can comprise naturally occurring ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. C The sense strand comprises 21 nucleotides having 5'- and 3'-terminal cap moieties wherein the two terminal 3'-nucleotides are optionally base paired and wherein all pyrimidine nucleotides that may be present are 2'-O-methyl modified nucleotides except for (N N) nucleotides, which can comprise naturally occurring ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. D The sense strand comprises 21 nucleotides having five phosphorothioate 5' and 3'-terminal internucleotide linkages, wherein the two terminal 3'-nucleotides are optionally base paired and wherein all nucleotides are ribonucleotides except for (N N) nucleotides, which can comprise naturally occurring ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. E The sense strand comprises 21 nucleotides wherein the two terminal 3'-nucleotides are optionally base paired and wherein all pyrimidine nucleotides that may be present are 2'-O-methyl modified nucleotides except for (N N) nucleotides, which can comprise naturally occurring ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. The antisense strand comprises 21 nucleotides all having phosphorothioate internucleotide linkages, wherein the two terminal 3'-nucleotides are optionally complementary to the target RNA sequence, and wherein all nucleotides are ribonucleotides except for (N N) nucleotides, which can comprise naturally occurring ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. F The sense strand comprises 21 nucleotides having 5'- and 3'-terminal cap moieties, wherein the two terminal 3'-nucleotides are optionally base paired and wherein all pyrimidine nucleotides that may be present are 2'-O-methyl modified nucleotides except for (N N) nucleotides, which can comprise naturally occurring ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. The antisense strand of constructs A-F comprise sequence complementary to target RNA sequence of the invention.

nucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. The antisense strand comprises 21 nucleotides, wherein the two terminal 3'-nucleotides are optionally complementary to the target RNA sequence, and wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides except for (N N) nucleotides, which can comprise naturally occurring ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. D The sense strand comprises 21 nucleotides having five phosphorothioate 5' and 3'-terminal internucleotide linkages, wherein the two terminal 3'-nucleotides are optionally base paired and wherein all nucleotides are ribonucleotides except for (N N) nucleotides, which can comprise naturally occurring ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. The antisense strand comprises 21 nucleotides, wherein the two terminal 3'-nucleotides are optionally complementary to the target RNA sequence, and having one 3'-terminal phosphorothioate internucleotide linkage and five 5'-terminal phosphorothioate internucleotide linkages and wherein all nucleotides are ribonucleotides except for (N N) nucleotides, which can comprise naturally occurring ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. E The sense strand comprises 21 nucleotides wherein the two terminal 3'-nucleotides are optionally base paired and wherein all pyrimidine nucleotides that may be present are 2'-O-methyl modified nucleotides except for (N N) nucleotides, which can comprise naturally occurring ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. The antisense strand comprises 21 nucleotides all having phosphorothioate internucleotide linkages, wherein the two terminal 3'-nucleotides are optionally complementary to the target RNA sequence, and wherein all nucleotides are ribonucleotides except for (N N) nucleotides, which can comprise naturally occurring ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. F The sense strand comprises 21 nucleotides having 5'- and 3'-terminal cap moieties, wherein the two terminal 3'-nucleotides are optionally base paired and wherein all pyrimidine nucleotides that may be present are 2'-O-methyl modified nucleotides except for (N N) nucleotides, which can comprise naturally occurring ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. The antisense strand of constructs A-F comprise sequence complementary to target RNA sequence of the invention.

[0147] FIG. 5 shows non-limiting examples of specific chemically modified siRNA sequences of the invention. A-F applies the chemical modifications described in FIGS. 4A-F to a BACE siRNA sequence.

[0148] FIG. 6 shows non-limiting examples of different siRNA constructs of the invention. The examples shown (constructs 1, 2, and 3) have 19 representative base pairs, however, different embodiments of the invention include

any number of base pairs described herein. Bracketed regions represent nucleotide overhangs, for example comprising between about 1, 2, 3, or 4 nucleotides in length, preferably about 2 nucleotides. Constructs **1** and **2** can be used independently for RNAi activity. Construct **2** can comprise a polynucleotide or non-nucleotide linker, which can optionally be designed as a biodegradable linker. In one embodiment, the loop structure shown in construct **2** can comprise a biodegradable linker that results in the formation of construct **1** in vivo and/or in vitro. In another example, construct **3** can be used to generate construct **2** under the same principle wherein a linker is used to generate the active siRNA construct **2** in vivo and/or in vitro, which can optionally utilize another biodegradable linker to generate the active siRNA construct **1** in vivo and/or in vitro. As such, the stability and/or activity of the siRNA constructs can be modulated based on the design of the siRNA construct for use in vivo or in vitro and/or in vitro.

[0149] Mechanism of Action of Nucleic Acid Molecules of the Invention

[0150] RNA interference refers to the process of sequence specific post transcriptional gene silencing in animals mediated by short interfering RNAs (siRNA) (Fire et al., 1998, *Nature*, 391, 806). The corresponding process in plants is commonly referred to as post transcriptional gene silencing or RNA silencing and is also referred to as quelling in fungi. The process of post transcriptional gene silencing is thought to be an evolutionarily conserved cellular defense mechanism used to prevent the expression of foreign genes which is commonly shared by diverse flora and phyla (Fire et al., 1999, *Trends Genet.*, 15, 358). Such protection from foreign gene expression may have evolved in response to the production of double stranded RNAs (dsRNA) derived from viral infection or the random integration of transposon elements into a host genome via a cellular response that specifically destroys homologous single stranded RNA or viral genomic RNA. The presence of dsRNA in cells triggers the RNAi response though a mechanism that has yet to be fully characterized. This mechanism appears to be different from the interferon response that results from dsRNA mediated activation of protein kinase PKR and 2',5'-oligoadenylate synthetase resulting in non-specific cleavage of mRNA by ribonuclease L.

[0151] The presence of long dsRNAs in cells stimulates the activity of a ribonuclease III enzyme referred to as dicer. Dicer is involved in the processing of the dsRNA into short pieces of dsRNA known as short interfering RNAs (siRNA) (Berstein et al., 2001, *Nature*, 409, 363). Short interfering RNAs derived from dicer activity are typically about 21-23 nucleotides in length and comprise about 19 base pair duplexes. Dicer has also been implicated in the excision of 21 and 22 nucleotide small temporal RNAs (stRNA) from precursor RNA of conserved structure that are implicated in translational control (Hutvagner et al., 2001, *Science*, 293, 834). The RNAi response also features an endonuclease complex containing a siRNA, commonly referred to as an RNA-induced silencing complex (RISC), which mediates cleavage of single stranded RNA having sequence homologous to the siRNA. Cleavage of the target RNA takes place in the middle of the region complementary to the guide sequence of the siRNA duplex (Elbashir et al., 2001, *Genes Dev.*, 15, 188).

[0152] Short interfering RNA mediated RNAi has been studied in a variety of systems. Fire et al., 1998, *Nature*, 391, 806, were the first to observe RNAi in *C. Elegans*. Wianny and Goetz, 1999, *Nature Cell Biol.*, 2, 70, describes RNAi mediated by dsRNA in mouse embryos. Hammond et al., 2000, *Nature*, 404, 293, describe RNAi in *Drosophila* cells transfected with dsRNA. Elbashir et al., 2001, *Nature*, 411, 494, describe RNAi induced by introduction of duplexes of synthetic 21-nucleotide RNAs in cultured mammalian cells including human embryonic kidney and HeLa cells. Recent work in *Drosophila* embryonic lysates has revealed certain requirements for siRNA length, structure, chemical composition, and sequence that are essential to mediate efficient RNAi activity. These studies have shown that 21 nucleotide siRNA duplexes are most active when containing two nucleotide 3'-overhangs. Furthermore, substitution of one or both siRNA strands with 2'-deoxy or 2'-O-methyl nucleotides abolishes RNAi activity, whereas substitution of 3'-terminal siRNA nucleotides with deoxy nucleotides was shown to be tolerated. Mismatch sequences in the center of the siRNA duplex were also shown to abolish RNAi activity. In addition, these studies also indicate that the position of the cleavage site in the target RNA is defined by the 5'-end of the siRNA guide sequence rather than the 3'-end (Elbashir et al., 2001, *EMBO J.*, 20, 6877). Other studies have indicated that a 5'-phosphate on the target-complementary strand of a siRNA duplex is required for siRNA activity and that ATP is utilized to maintain the 5'-phosphate moiety on the siRNA (Nykanen et al., 2001, *Cell*, 107, 309), however siRNA molecules lacking a 5'-phosphate are active when introduced exogenously, suggesting that 5'-phosphorylation of siRNA constructs may occur in vivo.

[0153] Synthesis of Nucleic Acid Molecules

[0154] Synthesis of nucleic acids greater than 100 nucleotides in length is difficult using automated methods, and the therapeutic cost of such molecules is prohibitive. In this invention, small nucleic acid motifs ("small" refers to nucleic acid motifs no more than 100 nucleotides in length, preferably no more than 80 nucleotides in length, and most preferably no more than 50 nucleotides in length; e.g., individual siRNA oligonucleotide sequences or siRNA sequences synthesized in tandem) are preferably used for exogenous delivery. The simple structure of these molecules increases the ability of the nucleic acid to invade targeted regions of protein and/or RNA structure. Exemplary molecules of the instant invention are chemically synthesized, and others can similarly be synthesized.

[0155] Oligonucleotides (e.g., certain modified oligonucleotides or portions of oligonucleotides lacking ribonucleotides) are synthesized using protocols known in the art, for example as described in Caruthers et al., 1992, *Methods in Enzymology* 211, 3-19, Thompson et al., International PCT Publication No. WO 99/54459, Wincott et al., 1995, *Nucleic Acids Res.* 23, 2677-2684, Wincott et al., 1997, *Methods Mol. Bio.*, 74, 59, Brennan et al., 1998, *Biotechnol Bioeng.*, 61, 33-45, and Brennan, U.S. Pat. No. 6,001,311. All of these references are incorporated herein by reference. The synthesis of oligonucleotides makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5'-end, and phosphoramidites at the 3'-end. In a non-limiting example, small scale syntheses are conducted on a 394 Applied Biosystems, Inc. synthesizer using a 0.2 μ mol scale protocol with a 2.5 min coupling step

for 2'-O-methylated nucleotides and a 45 sec coupling step for 2'-deoxy nucleotides or 2'-deoxy-2'-fluoro nucleotides. Table II outlines the amounts and the contact times of the reagents used in the synthesis cycle. Alternatively, syntheses at the 0.2 μ mol scale can be performed on a 96-well plate synthesizer, such as the instrument produced by Protogene (Palo Alto, Calif.) with minimal modification to the cycle. A 33-fold excess (60 μ L of 0.11 M=6.6 μ mol) of 2'-O-methyl phosphoramidite and a 105-fold excess of S-ethyl tetrazole (60 μ L of 0.25 M=15 μ mol) can be used in each coupling cycle of 2'-O-methyl residues relative to polymer-bound 5'-hydroxyl. A 22-fold excess (40 μ L of 0.11 M=4.4 μ mol) of deoxy phosphoramidite and a 70-fold excess of S-ethyl tetrazole (40 μ L of 0.25 M=10 μ mol) can be used in each coupling cycle of deoxy residues relative to polymer-bound 5'-hydroxyl. Average coupling yields on the 394 Applied Biosystems, Inc. synthesizer, determined by colorimetric quantitation of the trityl fractions, are typically 97.5-99%. Other oligonucleotide synthesis reagents for the 394 Applied Biosystems, Inc. synthesizer include the following: detritylation solution is 3% TCA in methylene chloride (ABI); capping is performed with 16% N-methylimidazole in THF (ABI) and 10% acetic anhydride/10% 2,6-lutidine in THF (ABI); and oxidation solution is 16.9 mM I_2 , 49 mM pyridine, 9% water in THF (PERSEPTIVE™). Burdick & Jackson Synthesis Grade acetonitrile is used directly from the reagent bottle. S-Ethyltetrazole solution (0.25 M in acetonitrile) is made up from the solid obtained from American International Chemical, Inc. Alternately, for the introduction of phosphorothioate linkages, Beaucage reagent (3H-1,2-Benzodithiol-3-one 1,1-dioxide, 0.05 M in acetonitrile) is used.

[0156] Deprotection of the DNA-based oligonucleotides is performed as follows: the polymer-bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a solution of 40% aq. methylamine (1 mL) at 65° C. for 10 min. After cooling to -20° C., the supernatant is removed from the polymer support. The support is washed three times with 1.0 mL of EtOH:MeCN:H₂O/3:1:1, vortexed and the supernatant is then added to the first supernatant. The combined supernatants, containing the oligoribonucleotide, are dried to a white powder.

[0157] The method of synthesis used for RNA including certain siRNA molecules of the invention follows the procedure as described in Usman et al., 1987, *J. Am. Chem. Soc.*, 109, 7845; Scaringe et al., 1990, *Nucleic Acids Res.*, 18, 5433; and Wincott et al., 1995, *Nucleic Acids Res.* 23, 2677-2684 Wincott et al., 1997, *Methods Mol. Bio.*, 74, 59, and makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5'-end, and phosphoramidites at the 3'-end. In a non-limiting example, small scale syntheses are conducted on a 394 Applied Biosystems, Inc. synthesizer using a 0.2 μ mol scale protocol with a 7.5 min coupling step for alkylsilyl protected nucleotides and a 2.5 min coupling step for 2'-O-methylated nucleotides. Table II outlines the amounts and the contact times of the reagents used in the synthesis cycle. Alternatively, syntheses at the 0.2 μ mol scale can be done on a 96-well plate synthesizer, such as the instrument produced by Protogene (Palo Alto, Calif.) with minimal modification to the cycle. A 33-fold excess (60 μ L of 0.11 M=6.6 μ mol) of 2'-O-methyl phosphoramidite and a 75-fold excess of S-ethyl tetrazole (60 μ L of 0.25 M=15 μ mol) can be used in each coupling cycle of 2'-O-methyl residues relative to

polymer-bound 5'-hydroxyl. A 66-fold excess (120 μ L of 0.11 M=13.2 μ mol) of alkylsilyl (ribo) protected phosphoramidite and a 150-fold excess of S-ethyl tetrazole (120 μ L of 0.25 M=30 μ mol) can be used in each coupling cycle of ribo residues relative to polymer-bound 5'-hydroxyl. Average coupling yields on the 394 Applied Biosystems, Inc. synthesizer, determined by colorimetric quantitation of the trityl fractions, are typically 97.5-99%. Other oligonucleotide synthesis reagents for the 394 Applied Biosystems, Inc. synthesizer include the following: detritylation solution is 3% TCA in methylene chloride (ABI); capping is performed with 16% N-methylimidazole in THF (ABI) and 10% acetic anhydride/10% 2,6-lutidine in THF (ABI); oxidation solution is 16.9 mM I_2 , 49 mM pyridine, 9% water in THF (PERSEPTIVE™). Burdick & Jackson Synthesis Grade acetonitrile is used directly from the reagent bottle. S-Ethyltetrazole solution (0.25 M in acetonitrile) is made up from the solid obtained from American International Chemical, Inc. Alternately, for the introduction of phosphorothioate linkages, Beaucage reagent (3H-1,2-Benzodithiol-3-one 1,1-dioxide 0.05 M in acetonitrile) is used.

[0158] Deprotection of the RNA is performed using either a two-pot or one-pot protocol. For the two-pot protocol, the polymer-bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a solution of 40% aq. methylamine (1 mL) at 65° C. for 10 min. After cooling to -20° C., the supernatant is removed from the polymer support. The support is washed three times with 1.0 mL of EtOH:MeCN:H₂O/3:1:1, vortexed and the supernatant is then added to the first supernatant. The combined supernatants, containing the oligoribonucleotide, are dried to a white powder. The base deprotected oligoribonucleotide is resuspended in anhydrous TEA/HF/NMP solution (300 μ L of a solution of 1.5 mL N-methylpyrrolidinone, 750 μ L TEA and 1 mL TEA•3HF to provide a 1.4 M HF concentration) and heated to 65° C. After 1.5 h, the oligomer is quenched with 1.5 M NH_4HCO_3 .

[0159] Alternatively, for the one-pot protocol, the polymer-bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a solution of 33% ethanolic methylamine/DMSO: 1/1 (0.8 mL) at 65° C. for 15 min. The vial is brought to r.t. TEA•3HF (0.1 mL) is added and the vial is heated at 65° C. for 15 min. The sample is cooled at -20° C. and then quenched with 1.5 M NH_4HCO_3 .

[0160] For purification of the trityl-on oligomers, the quenched NH_4HCO_3 solution is loaded onto a C-18 containing cartridge that had been prewashed with acetonitrile followed by 50 mM TEAA. After washing the loaded cartridge with water, the RNA is detritylated with 0.5% TFA for 13 min. The cartridge is then washed again with water, salt exchanged with 1 M NaCl and washed with water again. The oligonucleotide is then eluted with 30% acetonitrile.

[0161] The average stepwise coupling yields are typically >98% (Wincott et al., 1995 *Nucleic Acids Res.* 23, 2677-2684). Those of ordinary skill in the art will recognize that the scale of synthesis can be adapted to be larger or smaller than the example described above including but not limited to 96-well format, all that is important is the ratio of chemicals used in the reaction.

[0162] Alternatively, the nucleic acid molecules of the present invention can be synthesized separately and joined together post-synthetically, for example, by ligation (Moore

et al., 1992, *Science* 256, 9923; Draper et al., International PCT publication No. WO 93/23569; Shabarova et al., 1991, *Nucleic Acids Research* 19, 4247; Bellon et al., 1997, *Nucleosides & Nucleotides*, 16, 951; Bellon et al., 1997, *Bioconjugate Chem.* 8, 204), or by hybridization following synthesis and/or deprotection.

[0163] The siRNA molecules of the invention can also be synthesized via a tandem synthesis methodology as described in Example 1 herein, wherein both siRNA strands are synthesized as a single contiguous oligonucleotide fragment or strand separated by a cleavable linker which is subsequently cleaved to provide separate siRNA fragments or strands that hybridize and permit purification of the siRNA duplex. The linker can be a polynucleotide linker or a non-nucleotide linker. The tandem synthesis of siRNA as described herein can be readily adapted to both multiwell/multiplate synthesis platforms such as 96 well or similarly larger multi-well platforms. The tandem synthesis of siRNA as described herein can also be readily adapted to large scale synthesis platforms employing batch reactors, synthesis columns and the like.

[0164] A siRNA molecule can also be assembled from two distinct nucleic acid fragments or strands wherein one fragment includes the sense region and the second fragment includes the antisense region of said siRNA molecule.

[0165] The nucleic acid molecules of the present invention can be modified extensively to enhance stability by modification with nuclease resistant groups, for example, 2'-amino, 2'-C-allyl, 2'-fluoro, 2'-O-methyl, 2'-H (for a review see Usman and Cedergren, 1992, *TIBS* 17, 34; Usman et al., 1994, *Nucleic Acids Symp. Ser.* 31, 163). siRNA constructs can be purified by gel electrophoresis using general methods or can be purified by high pressure liquid chromatography (HPLC; see Wincott et al., supra, the totality of which is hereby incorporated herein by reference) and re-suspended in water.

[0166] In another aspect of the invention, siRNA molecules of the invention are expressed from transcription units inserted into DNA or RNA vectors. The recombinant vectors can be DNA plasmids or viral vectors. siRNA expressing viral vectors can be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus. The recombinant vectors capable of expressing the siRNA molecules can be delivered as described herein, and persist in target cells. Alternatively, viral vectors can be used that provide for transient expression of siRNA molecules.

[0167] Optimizing Activity of the Nucleic Acid Molecule of the Invention.

[0168] Chemically synthesizing nucleic acid molecules with modifications (base, sugar and/or phosphate) can prevent their degradation by serum ribonucleases, which can increase their potency (see e.g., Eckstein et al., International Publication No. WO 92/07065; Perrault et al., 1990 *Nature* 344, 565; Pieken et al., 1991, *Science* 253, 314; Usman and Cedergren, 1992, *Trends in Biochem. Sci.* 17, 334; Usman et al., International Publication No. WO 93/15187; and Rossi et al., International Publication No. WO 91/03162; Sproat, U.S. Pat. No. 5,334,711; Gold et al., U.S. Pat. No. 6,300,074; and Burgin et al., supra; all of which are incorporated by reference herein). All of the above references describe

various chemical modifications that can be made to the base, phosphate and/or sugar moieties of the nucleic acid molecules described herein. Modifications that enhance their efficacy in cells, and removal of bases from nucleic acid molecules to shorten oligonucleotide synthesis times and reduce chemical requirements are desired.

[0169] There are several examples in the art describing sugar, base and phosphate modifications that can be introduced into nucleic acid molecules with significant enhancement in their nuclease stability and efficacy. For example, oligonucleotides are modified to enhance stability and/or enhance biological activity by modification with nuclease resistant groups, for example, 2'-amino, 2'-C-allyl, 2'-fluoro, 2'-O-methyl, 2'-O-allyl, 2'-H, nucleotide base modifications (for a review see Usman and Cedergren, 1992, *TIBS* 17, 34; Usman et al., 1994, *Nucleic Acids Symp. Ser.* 31, 163; Burgin et al., 1996, *Biochemistry*, 35, 14090). Sugar modification of nucleic acid molecules have been extensively described in the art (see Eckstein et al., International Publication PCT No. WO 92/07065; Perrault et al. *Nature*, 1990, 344, 565-568; Pieken et al. *Science*, 1991, 253, 314-317; Usman and Cedergren, *Trends in Biochem. Sci.*, 1992, 17, 334-339; Usman et al. International Publication PCT No. WO 93/15187; Sproat, U.S. Pat. No. 5,334,711 and Beigelman et al., 1995, *J. Biol. Chem.*, 270, 25702; Beigelman et al., International PCT publication No. WO 97/26270; Beigelman et al., U.S. Pat. No. 5,716,824; Usman et al., U.S. Pat. No. 5,627,053; Woolf et al., International PCT Publication No. WO 98/13526; Thompson et al., U.S. S No. 60/082,404 which was filed on Apr. 20, 1998; Karpeisky et al., 1998, *Tetrahedron Lett.*, 39, 1131; Earnshaw and Gait, 1998, *Biopolymers (Nucleic Acid Sciences)*, 48, 39-55; Verma and Eckstein, 1998, *Annu. Rev. Biochem.*, 67, 99-134; and Burlina et al., 1997, *Bioorg. Med. Chem.*, 5, 1999-2010; all of the references are hereby incorporated in their totality by reference herein). Such publications describe general methods and strategies to determine the location of incorporation of sugar, base and/or phosphate modifications and the like into nucleic acid molecules without modulating catalysis, and are incorporated by reference herein. In view of such teachings, similar modifications can be used as described herein to modify the siRNA nucleic acid molecules of the instant invention so long as the ability of siRNA to promote RNAi in cells is not significantly inhibited.

[0170] While chemical modification of oligonucleotide internucleotide linkages with phosphorothioate, phosphorothioate, and/or 5'-methylphosphonate linkages improves stability, excessive modifications can cause some toxicity or decreased activity. Therefore, when designing nucleic acid molecules, the amount of these internucleotide linkages should be minimized. The reduction in the concentration of these linkages should lower toxicity, resulting in increased efficacy and higher specificity of these molecules.

[0171] Small interfering RNA (siRNA) molecules having chemical modifications that maintain or enhance activity are provided. Such a nucleic acid is also generally more resistant to nucleases than an unmodified nucleic acid. Accordingly, the in vitro and/or in vivo activity should not be significantly lowered. In cases in which modulation is the goal, therapeutic nucleic acid molecules delivered exogenously should optimally be stable within cells until translation of the target RNA has been modulated long enough to reduce the levels of the undesirable protein. This period of time varies

between hours to days depending upon the disease state. Improvements in the chemical synthesis of RNA and DNA (Wincott et al., 1995 *Nucleic Acids Res.* 23, 2677; Caruthers et al., 1992, *Methods in Enzymology* 211,3-19 (incorporated by reference herein)) have expanded the ability to modify nucleic acid molecules by introducing nucleotide modifications to enhance their nuclease stability, as described above.

[0172] In one embodiment, nucleic acid molecules of the invention include one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) G-clamp nucleotides. A G-clamp nucleotide is a modified cytosine analog wherein the modifications confer the ability to hydrogen bond both Watson-Crick and Hoogsteen faces of a complementary guanine within a duplex, see for example Lin and Matteucci, 1998, *J. Am. Chem. Soc.*, 120, 8531-8532. A single G-clamp analog substitution within an oligonucleotide can result in substantially enhanced helical thermal stability and mismatch discrimination when hybridized to complementary oligonucleotides. The inclusion of such nucleotides in nucleic acid molecules of the invention results in both enhanced affinity and specificity to nucleic acid targets, complementary sequences, or template strands. In another embodiment, nucleic acid molecules of the invention include one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) LNA "locked nucleic acid" nucleotides such as a 2',4'-C myethylene bicyclo nucleotide (see for example Wengel et al., International PCT Publication No. WO 00/66604 and WO 99/14226).

[0173] In another embodiment, the invention features conjugates and/or complexes of siRNA molecules of the invention. Such conjugates and/or complexes can be used to facilitate delivery of siRNA molecules into a biological system, such as a cell. The conjugates and complexes provided by the instant invention can impart therapeutic activity by transferring therapeutic compounds across cellular membranes, altering the pharmacokinetics, and/or modulating the localization of nucleic acid molecules of the invention. The present invention encompasses the design and synthesis of novel conjugates and complexes for the delivery of molecules, including, but not limited to, small molecules, lipids, phospholipids, nucleosides, nucleotides, nucleic acids, antibodies, toxins, negatively charged polymers and other polymers, for example proteins, peptides, hormones, carbohydrates, polyethylene glycols, or polyamines, across cellular membranes. In general, the transporters described are designed to be used either individually or as part of a multi-component system, with or without degradable linkers. These compounds are expected to improve delivery and/or localization of nucleic acid molecules of the invention into a number of cell types originating from different tissues, in the presence or absence of serum (see Sullenger and Cech, U.S. Pat. No. 5,854,038). Conjugates of the molecules described herein can be attached to biologically active molecules via linkers that are biodegradable, such as biodegradable nucleic acid linker molecules.

[0174] The term "biodegradable nucleic acid linker molecule" as used herein, refers to a nucleic acid molecule that is designed as a biodegradable linker to connect one molecule to another molecule, for example, a biologically active molecule. The stability of the biodegradable nucleic acid linker molecule can be modulated by using various combinations of ribonucleotides, deoxyribonucleotides, and chemically modified nucleotides, for example, 2'-O-methyl,

2'-fluoro, 2'-amino, 2'-O-amino, 2'-C-allyl, 2'-O-allyl, and other 2'-modified or base modified nucleotides. The biodegradable nucleic acid linker molecule can be a dimer, trimer, tetramer or longer nucleic acid molecule, for example, an oligonucleotide of about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides in length, or can comprise a single nucleotide with a phosphorus-based linkage, for example, a phosphoramidate or phosphodiester linkage. The biodegradable nucleic acid linker molecule can also comprise nucleic acid backbone, nucleic acid sugar, or nucleic acid base modifications.

[0175] The term "biodegradable" as used herein, refers to degradation in a biological system, for example enzymatic degradation or chemical degradation.

[0176] The term "biologically active molecule" as used herein, refers to compounds or molecules that are capable of eliciting or modifying a biological response in a system. Non-limiting examples of biologically active siRNA molecules either alone or in combination with other molecules contemplated by the instant invention include therapeutically active molecules such as antibodies, hormones, antivirals, peptides, proteins, chemotherapeutics, small molecules, vitamins, co-factors, nucleosides, nucleotides, oligonucleotides, enzymatic nucleic acids, antisense nucleic acids, triplex forming oligonucleotides, 2,5-A chimeras, siRNA, dsRNA, allozymes, aptamers, decoys and analogs thereof. Biologically active molecules of the invention also include molecules capable of modulating the pharmacokinetics and/or pharmacodynamics of other biologically active molecules, for example, lipids and polymers such as polyamines, polyamides, polyethylene glycol and other polyethers.

[0177] The term "phospholipid" as used herein, refers to a hydrophobic molecule comprising at least one phosphorus group. For example, a phospholipid can comprise a phosphorus-containing group and saturated or unsaturated alkyl group, optionally substituted with OH, COOH, oxo, amine, or substituted or unsubstituted aryl groups.

[0178] Therapeutic nucleic acid molecules (e.g., siRNA molecules) delivered exogenously optimally are stable within cells until reverse transcription of the RNA has been modulated long enough to reduce the levels of the RNA transcript. The nucleic acid molecules are resistant to nucleases in order to function as effective intracellular therapeutic agents. Improvements in the chemical synthesis of nucleic acid molecules described in the instant invention and in the art have expanded the ability to modify nucleic acid molecules by introducing nucleotide modifications to enhance their nuclease stability as described above.

[0179] In yet another embodiment, siRNA molecules having chemical modifications that maintain or enhance enzymatic activity of proteins involved in RNAi are provided. Such nucleic acids are also generally more resistant to nucleases than unmodified nucleic acids. Thus, in vitro and/or in vivo the activity should not be significantly lowered.

[0180] Use of the nucleic acid-based molecules of the invention will lead to better treatment of the disease progression by affording the possibility of combination therapies (e.g., multiple siRNA molecules targeted to different genes; nucleic acid molecules coupled with known small

molecule modulators; or intermittent treatment with combinations of molecules, including different motifs and/or other chemical or biological molecules). The treatment of subjects with siRNA molecules can also include combinations of different types of nucleic acid molecules, such as enzymatic nucleic acid molecules (ribozymes), allozymes, antisense, 2,5-A oligoadenylate, decoys, aptamers etc.

[0181] In another aspect a siRNA molecule of the invention comprises one or more 5' and/or a 3'-cap structure, for example on only the sense siRNA strand, antisense siRNA strand, or both siRNA strands.

[0182] By "cap structure" is meant chemical modifications, which have been incorporated at either terminus of the oligonucleotide (see, for example, Adamic et al., U.S. Pat. No. 5,998,203, incorporated by reference herein). These terminal modifications protect the nucleic acid molecule from exonuclease degradation, and may help in delivery and/or localization within a cell. The cap may be present at the 5'-terminus (5'-cap) or at the 3'-terminal (3'-cap) or may be present on both termini. In non-limiting examples: the 5'-cap is selected from the group comprising inverted abasic residue (moiety); 4',5'-methylene nucleotide; 1-(beta-D-erythrofuranosyl) nucleotide, 4'-thio nucleotide; carbocyclic nucleotide; 1,5-anhydrohexitol nucleotide; L-nucleotides; alpha-nucleotides; modified base nucleotide; phosphorodithioate linkage; threo-pentofuranosyl nucleotide; acyclic 3',4'-seco nucleotide; acyclic 3,4-dihydroxybutyl nucleotide; acyclic 3,5-dihydroxypentyl nucleotide, 3'-3'-inverted nucleotide moiety; 3'-3'-inverted abasic moiety; 3'-2'-inverted nucleotide moiety; 3'-2'-inverted abasic moiety; 1,4-butanediol phosphate; 3'-phosphoramidate; hexylphosphate; aminohexyl phosphate; 3'-phosphate; 3'-phosphorothioate; phosphorodithioate; or bridging or non-bridging methylphosphonate moiety.

[0183] In yet another preferred embodiment, the 3'-cap is selected from a group comprising, 4',5'-methylene nucleotide; 1-(beta-D-erythrofuranosyl) nucleotide; 4'-thio nucleotide, carbocyclic nucleotide; 5'-amino-alkyl phosphate; 1,3-diamino-2-propyl phosphate; 3-aminopropyl phosphate; 6-aminohexyl phosphate; 1,2-aminododecyl phosphate; hydroxypropyl phosphate; 1,5-anhydrohexitol nucleotide; L-nucleotide; alpha-nucleotide; modified base nucleotide; phosphorodithioate; threo-pentofuranosyl nucleotide; acyclic 3',4'-seco nucleotide; 3,4-dihydroxybutyl nucleotide; 3,5-dihydroxypentyl nucleotide, 5'-5'-inverted nucleotide moiety; 5'-5'-inverted abasic moiety; 5'-phosphoramidate; 5'-phosphorothioate; 1,4-butanediol phosphate; 5'-amino; bridging and/or non-bridging 5'-phosphoramidate, phosphorothioate and/or phosphorodithioate, bridging or non bridging methylphosphonate and 5'-mercapto moieties (for more details see Beaucage and Iyer, 1993, *Tetrahedron* 49, 1925; incorporated by reference herein).

[0184] By the term "non-nucleotide" is meant any group or compound which can be incorporated into a nucleic acid chain in the place of one or more nucleotide units, including either sugar and/or phosphate substitutions, and allows the remaining bases to exhibit their enzymatic activity. The group or compound is abasic in that it does not contain a commonly recognized nucleotide base, such as adenosine, guanine, cytosine, uracil or thymine and therefore lacks a base at the 1'-position.

[0185] An "alkyl" group refers to a saturated aliphatic hydrocarbon, including straight-chain, branched-chain, and

cyclic alkyl groups. Preferably, the alkyl group has 1 to 12 carbons. More preferably, it is a lower alkyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkyl group can be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, =O, =S, NO₂ or N(CH₃)₂, amino, or SH. The term also includes alkenyl groups that are unsaturated hydrocarbon groups containing at least one carbon-carbon double bond, including straight-chain, branched-chain, and cyclic groups. Preferably, the alkenyl group has 1 to 12 carbons. More preferably, it is a lower alkenyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkenyl group may be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, =O, =S, NO₂, halogen, N(CH₃)₂, amino, or SH. The term "alkynyl" also includes alkynyl groups that have an unsaturated hydrocarbon group containing at least one carbon-carbon triple bond, including straight-chain, branched-chain, and cyclic groups. Preferably, the alkynyl group has 1 to 12 carbons. More preferably, it is a lower alkynyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkynyl group may be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, =O, =S, NO₂ or N(CH₃)₂, amino or SH.

[0186] Such alkyl groups can also include aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and ester groups. An "aryl" group refers to an aromatic group that has at least one ring having a conjugated pi electron system and includes carbocyclic aryl, heterocyclic aryl and biaryl groups, all of which may be optionally substituted. The preferred substituent(s) of aryl groups are halogen, trihalomethyl, hydroxyl, SH, OH, cyano, alkoxy, alkyl, alkenyl, alkynyl, and amino groups. An "alkylaryl" group refers to an alkyl group (as described above) covalently joined to an aryl group (as described above). Carbocyclic aryl groups are groups wherein the ring atoms on the aromatic ring are all carbon atoms. The carbon atoms are optionally substituted. Heterocyclic aryl groups are groups having from 1 to 3 heteroatoms as ring atoms in the aromatic ring and the remainder of the ring atoms are carbon atoms. Suitable heteroatoms include oxygen, sulfur, and nitrogen, and include furanyl, thienyl, pyridyl, pyrrolyl, N-lower alkyl pyrrolo, pyrimidyl, pyrazinyl, imidazolyl and the like, all optionally substituted. An "amide" refers to an —C(O)—NH—R, where R is either alkyl, aryl, alkylaryl or hydrogen. An "ester" refers to an —C(O)—OR', where R is either alkyl, aryl, alkylaryl or hydrogen.

[0187] By "nucleotide" as used herein is as recognized in the art to include natural bases (standard), and modified bases well known in the art. Such bases are generally located at the 1' position of a nucleotide sugar moiety. Nucleotides generally comprise a base, sugar and a phosphate group. The nucleotides can be unmodified or modified at the sugar, phosphate and/or base moiety, (also referred to interchangeably as nucleotide analogs, modified nucleotides, non-natural nucleotides, non-standard nucleotides and other; see, for example, Usman and McSwiggen, supra; Eckstein et al., International PCT Publication No. WO 92/07065; Usman et al., International PCT Publication No. WO 93/15187; Uhlman & Peyman, supra, all are hereby incorporated by reference herein). There are several examples of modified nucleic acid bases known in the art as summarized by Limbach et al., 1994, *Nucleic Acids Res.* 22, 2183. Some of the non-limiting examples of base modifications that can be

introduced into nucleic acid molecules include, inosine, purine, pyridin-4-one, pyridin-2-one, phenyl, pseudouracil, 2, 4, 6-trimethoxy benzene, 3-methyl uracil, dihydrouridine, naphthyl, aminophenyl, 5-alkylcytidines (e.g., 5-methylcytidine), 5-alkyluridines (e.g., ribothymidine), 5-halouridine (e.g., 5-bromouridine) or 6-azapyrimidines or 6-alkylpyrimidines (e.g. 6-methyluridine), propyne, and others (Burgin et al., 1996, *Biochemistry*, 35, 14090; Uhlman & Peyman, supra). By “modified bases” in this aspect is meant nucleotide bases other than adenine, guanine, cytosine and uracil at 1' position or their equivalents.

[0188] In one embodiment, the invention features modified siRNA molecules, with phosphate backbone modifications comprising one or more phosphorothioate, phosphorodithioate, methylphosphonate, phosphotriester, morpholino, amidate carbamate, carboxymethyl, acetamidate, polyamide, sulfonate, sulfonamide, sulfamate, formacetal, thioformacetal, and/or alkylsilyl, substitutions. For a review of oligonucleotide backbone modifications, see Hunziker and Leumann, 1995, *Nucleic Acid Analogues: Synthesis and Properties*, in *Modern Synthetic Methods*, VCH, 331-417, and Mesmaeker et al., 1994, *Novel Backbone Replacements for Oligonucleotides*, in *Carbohydrate Modifications in Antisense Research*, ACS, 24-39.

[0189] By “abasic” is meant sugar moieties lacking a base or having other chemical groups in place of a base at the 1' position, see for example Adamic et al., U.S. Pat. No. 5,998,203.

[0190] By “unmodified nucleoside” is meant one of the bases adenine, cytosine, guanine, thymine, uracil joined to the 1' carbon of β -D-ribo-furanose.

[0191] By “modified nucleoside” is meant any nucleotide base which contains a modification in the chemical structure of an unmodified nucleotide base, sugar and/or phosphate.

[0192] In connection with 2'-modified nucleotides as described for the present invention, by “amino” is meant 2'-NH₂ or 2'-O—NH₂, which may be modified or unmodified. Such modified groups are described, for example, in Eckstein et al., U.S. Pat. No. 5,672,695 and Matulic-Adamic et al., U.S. Pat. No. 6,248,878, which are both incorporated by reference in their entireties.

[0193] Various modifications to nucleic acid siRNA structure can be made to enhance the utility of these molecules. Such modifications will enhance shelf-life, half-life in vitro, stability, and ease of introduction of such oligonucleotides to the target site, e.g., to enhance penetration of cellular membranes, and confer the ability to recognize and bind to targeted cells.

[0194] Administration of Nucleic Acid Molecules

[0195] A siRNA molecule of the invention can be adapted for use to treat Alzheimer's disease. For example, a siRNA molecule can comprise a delivery vehicle, including liposomes, for administration to a subject, carriers and diluents and their salts, and can be present in pharmaceutically acceptable formulations. Methods for the delivery of nucleic acid molecules are described in Akhtar et al., 1992, *Trends Cell Bio.*, 2, 139; *Delivery Strategies for Antisense Oligonucleotide Therapeutics*, ed. Akhtar, 1995, Maurer et al., 1999, *Mol. Membr. Biol.*, 16, 129-140; Hofland and Huang, 1999, *Handb. Exp. Pharmacol.*, 137, 165-192; and Lee et

al., 2000, *ACS Symp. Ser.*, 752, 184-192, all of which are incorporated herein by reference. Beigelman et al., U.S. Pat. No. 6,395,713 and Sullivan et al., PCT WO 94/02595, further describes the general methods for delivery of nucleic acid molecules. These protocols can be utilized for the delivery of virtually any nucleic acid molecule. Nucleic acid molecules can be administered to cells by a variety of methods known to those of skill in the art, including, but not restricted to, encapsulation in liposomes, by iontophoresis, or by incorporation into other delivery vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres, or by proteinaceous vectors (O'Hare and Normand, International PCT Publication No. WO 00/53722). Alternatively, the nucleic acid/vehicle combination is locally delivered by direct injection or by use of an infusion pump. Direct injection of the nucleic acid molecules of the invention, whether subcutaneous, intramuscular, or intradermal, can take place using standard needle and syringe methodologies, or by needle-free technologies such as those described in Conry et al., 1999, *Clin. Cancer Res.*, 5, 2330-2337 and Barry et al., International PCT Publication No. WO 99/31262. Many examples in the art describe CNS delivery methods of oligonucleotides by osmotic pump, (see Chun et al., 1998, *Neuroscience Letters*, 257, 135-138, D'Aldin et al., 1998, *Mol. Brain Research*, 55, 151-164, Dryden et al., 1998, *J. Endocrinol.*, 157, 169-175, Ghirnikar et al., 1998, *Neuroscience Letters*, 247, 21-24) or direct infusion (Broaddus et al., 1997, *Neurosurg. Focus*, 3, article 4). Other routes of delivery include, but are not limited to oral (tablet or pill form) and/or intrathecal delivery (Gold, 1997, *Neuroscience*, 76, 1153-1158). For a comprehensive review on drug delivery strategies including broad coverage of CNS delivery, see Ho et al., 1999, *Curr. Opin. Mol. Ther.*, 1, 336-343 and Jain, *Drug Delivery Systems: Technologies and Commercial Opportunities*, Decision Resources, 1998 and Groothuis et al., 1997, *J. NeuroVirol.*, 3, 387-400. More detailed descriptions of nucleic acid delivery and administration are provided in Sullivan et al, supra, Draper et al., PCT WO93/23569, Beigelman et al., PCT WO99/05094, and Klimuk et al., PCT WO99/04819 all of which have been incorporated by reference herein.

[0196] Experiments have demonstrated the efficient in vivo uptake of nucleic acids by neurons. As an example of local administration of nucleic acids to nerve cells, Sommer et al., 1998, *Antisense Nuc. Acid Drug Dev.*, 8, 75, describe a study in which a 15mer phosphorothioate antisense nucleic acid molecule to c-fos is administered to rats via microinjection into the brain. Antisense molecules labeled with tetramethylrhodamine-isothiocyanate (TRITC) or fluorescein isothiocyanate (FITC) were taken up by exclusively by neurons thirty minutes post-injection. A diffuse cytoplasmic staining and nuclear staining was observed in these cells. As an example of systemic administration of nucleic acid to nerve cells, Epa et al., 2000, *Antisense Nuc. Acid Drug Dev.*, 10, 469, describe an in vivo mouse study in which beta-cyclodextrin-adamantane-oligonucleotide conjugates were used to target the p75 neurotrophin receptor in neuronally differentiated PC12 cells. Following a two week course of IP administration, pronounced uptake of p75 neurotrophin receptor antisense was observed in dorsal root ganglion (DRG) cells. In addition, a marked and consistent down-regulation of p75 was observed in DRG neurons. Additional approaches to the targeting of nucleic acid to neurons are

described in Broaddus et al., 1998, *J. Neurosurg.*, 88(4), 734; Karle et al., 1997, *Eur. J. Pharmacol.*, 340(2/3), 153; Bannai et al., 1998, *Brain Research*, 784(1,2), 304; Rajakumar et al., 1997, *Synapse*, 26(3), 199; Wu-pong et al., 1999, *BioPharm*, 12(1), 32; Bannai et al., 1998, *Brain Res. Protoc.*, 3(1), 83; Simantov et al., 1996, *Neuroscience*, 74(1), 39. Nucleic acid molecules of the invention are therefore amenable to delivery to and uptake by cells that express BACE, PIN-1, PS-1, and/or PS-2 for modulation of BACE, PIN-1, PS-1, and/or PS-2 expression.

[0197] The delivery of nucleic acid molecules of the invention, targeting BACE, PIN-1, PS-1, and/or PS-2 is provided by a variety of different strategies. Traditional approaches to CNS delivery that can be used include, but are not limited to, intrathecal and intracerebroventricular administration, implantation of catheters and pumps, direct injection or perfusion at the site of injury or lesion, injection into the brain arterial system, or by chemical or osmotic opening of the blood-brain barrier. Other approaches can include the use of various transport and carrier systems, for example though the use of conjugates and biodegradable polymers. Furthermore, gene therapy approaches, for example as described in Kaplitt et al., U.S. Pat. No. 6,180,613, can be used to express nucleic acid molecules in the CNS.

[0198] Thus, the invention features a pharmaceutical composition comprising one or more nucleic acid(s) of the invention in an acceptable carrier, such as a stabilizer, buffer, and the like. The polynucleotides of the invention can be administered (e.g., RNA, DNA or protein) and introduced into a subject by any standard means, with or without stabilizers, buffers, and the like, to form a pharmaceutical composition. When it is desired to use a liposome delivery mechanism, standard protocols for formation of liposomes can be followed. The compositions of the present invention may also be formulated and used as tablets, capsules or elixirs for oral administration, suppositories for rectal administration, sterile solutions, suspensions for injectable administration, and the other compositions known in the art.

[0199] The present invention also includes pharmaceutically acceptable formulations of the compounds described. These formulations include salts of the above compounds, e.g., acid addition salts, for example, salts of hydrochloric, hydrobromic, acetic acid, and benzene sulfonic acid.

[0200] A pharmacological composition or formulation refers to a composition or formulation in a form suitable for administration, e.g., systemic administration, into a cell or subject, including for example a human. Suitable forms, in part, depend upon the use or the route of entry, for example oral, transdermal, or by injection. Such forms should not prevent the composition or formulation from reaching a target cell (i.e., a cell to which the negatively charged nucleic acid is desirable for delivery). For example, pharmacological compositions injected into the blood stream should be soluble. Other factors are known in the art, and include considerations such as toxicity and forms that prevent the composition or formulation from exerting its effect.

[0201] By "systemic administration" is meant in vivo systemic absorption or accumulation of drugs in the blood stream followed by distribution throughout the entire body. Administration routes which lead to systemic absorption include, without limitation: intravenous, subcutaneous, intraperitoneal, inhalation, oral, intrapulmonary and intra-

muscular. Each of these administration routes expose the siRNA molecules of the invention to an accessible diseased tissue. The rate of entry of a drug into the circulation has been shown to be a function of molecular weight or size. The use of a liposome or other drug carrier comprising the compounds of the instant invention can potentially localize the drug, for example, in certain tissue types, such as the tissues of the reticular endothelial system (RES). A liposome formulation that can facilitate the association of drug with the surface of cells, such as, lymphocytes and macrophages is also useful. This approach may provide enhanced delivery of the drug to target cells by taking advantage of the specificity of macrophage and lymphocyte immune recognition of abnormal cells, such as cancer cells.

[0202] By "pharmaceutically acceptable formulation" is meant, a composition or formulation that allows for the effective distribution of the nucleic acid molecules of the instant invention in the physical location most suitable for their desired activity. Non-limiting examples of agents suitable for formulation with the nucleic acid molecules of the instant invention include: P-glycoprotein inhibitors (such as Pluronic P85), which can enhance entry of drugs into the CNS (Jolliet-Riant and Tillement, 1999, *Fundam. Clin. Pharmacol.*, 13, 16-26); biodegradable polymers, such as poly (DL-lactide-coglycolide) microspheres for sustained release delivery after intracerebral implantation (Emerich, D F et al, 1999, *Cell Transplant*, 8, 47-58) (Alkermes, Inc. Cambridge, Mass.); and loaded nanoparticles, such as those made of polybutylcyanoacrylate, which can deliver drugs across the blood brain barrier and can alter neuronal uptake mechanisms (*Prog Neuropsychopharmacol Biol Psychiatry*, 23, 941-949, 1999). Other non-limiting examples of delivery strategies for the nucleic acid molecules of the instant invention include material described in Boado et al., 1998, *J. Pharm. Sci.*, 87, 1308-1315; Tyler et al., 1999, *FEBS Lett.*, 421, 280-284; Pardridge et al., 1995, *PNAS USA.*, 92, 5592-5596; Boado, 1995, *Adv. Drug Delivery Rev.*, 15, 73-107; Aldrian-Herrada et al., 1998, *Nucleic Acids Res.*, 26, 4910-4916; and Tyler et al., 1999, *PNAS USA.*, 96, 7053-7058.

[0203] The invention also features the use of the composition comprising surface-modified liposomes containing poly (ethylene glycol) lipids (PEG-modified, or long-circulating liposomes or stealth liposomes). These formulations offer a method for increasing the accumulation of drugs in target tissues. This class of drug carriers resists opsonization and elimination by the mononuclear phagocytic system (MPS or RES), thereby enabling longer blood circulation times and enhanced tissue exposure for the encapsulated drug (Lasic et al. *Chem. Rev.* 1995, 95, 2601-2627; Ishiwata et al., *Chem. Pharm. Bull.* 1995, 43, 1005-1011). Such liposomes have been shown to accumulate selectively in tumors, presumably by extravasation and capture in the neovascularized target tissues (Lasic et al., *Science* 1995, 267, 1275-1276; Oku et al., 1995, *Biochim. Biophys. Acta*, 1238, 86-90). The long-circulating liposomes enhance the pharmacokinetics and pharmacodynamics of DNA and RNA, particularly compared to conventional cationic liposomes which are known to accumulate in tissues of the MPS (Liu et al., *J. Biol. Chem.* 1995, 42, 24864-24870; Choi et al., International PCT Publication No. WO 96/10391; Ansell et al., International PCT Publication No. WO 96/10390; Holland et al., International PCT Publication No. WO 96/10392). Long-circulating liposomes are also likely to

protect drugs from nuclease degradation to a greater extent compared to cationic liposomes, based on their ability to avoid accumulation in metabolically aggressive MPS tissues such as the liver and spleen.

[0204] The present invention also includes compositions prepared for storage or administration, which include a pharmaceutically effective amount of the desired compounds in a pharmaceutically acceptable carrier or diluent. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in *Remington's Pharmaceutical Sciences*, Mack Publishing Co. (A. R. Gennaro edit. 1985) hereby incorporated by reference herein. For example, preservatives, stabilizers, dyes and flavoring agents may be provided. These include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid. In addition, antioxidants and suspending agents can be used.

[0205] A pharmaceutically effective dose is that dose required to prevent, inhibit the occurrence, or treat (alleviate a symptom to some extent, preferably all of the symptoms) of a disease state. The pharmaceutically effective dose depends on the type of disease, the composition used, the route of administration, the type of mammal being treated, the physical characteristics of the specific mammal under consideration, concurrent medication, and other factors that those skilled in the medical arts will recognize. Generally, an amount between 0.1 mg/kg and 100 mg/kg body weight/day of active ingredients is administered dependent upon potency of the negatively charged polymer.

[0206] The nucleic acid molecules of the invention and formulations thereof can be administered orally, topically, parenterally, by inhalation or spray, or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and/or vehicles. The term parenteral as used herein includes percutaneous, subcutaneous, intravascular (e.g., intravenous), intramuscular, or intrathecal injection or infusion techniques and the like. In addition, there is provided a pharmaceutical formulation comprising a nucleic acid molecule of the invention and a pharmaceutically acceptable carrier. One or more nucleic acid molecules of the invention can be present in association with one or more non-toxic pharmaceutically acceptable carriers and/or diluents and/or adjuvants, and if desired other active ingredients. The pharmaceutical compositions containing nucleic acid molecules of the invention can be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs.

[0207] Compositions intended for oral use can be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more such sweetening agents, flavoring agents, coloring agents or preservative agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets. These excipients can be, for example, inert diluents; such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for

example starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets can be uncoated or they can be coated by known techniques. In some cases such coatings can be prepared by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed.

[0208] Formulations for oral use can also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.

[0209] Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropyl-methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents can be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions can also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.

[0210] Oily suspensions can be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions can contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents and flavoring agents can be added to provide palatable oral preparations. These compositions can be preserved by the addition of an anti-oxidant such as ascorbic acid.

[0211] Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents or suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, can also be present.

[0212] Pharmaceutical compositions of the invention can also be in the form of oil-in-water emulsions. The oily phase can be a vegetable oil or a mineral oil or mixtures of these. Suitable emulsifying agents can be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide,

for example polyoxyethylene sorbitan monooleate. The emulsions can also contain sweetening and flavoring agents.

[0213] Syrups and elixirs can be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol, glucose or sucrose. Such formulations can also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions can be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension can be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents that have been mentioned above. The sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

[0214] The nucleic acid molecules of the invention can also be administered in the form of suppositories, e.g., for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials include cocoa butter and polyethylene glycols.

[0215] Nucleic acid molecules of the invention can be administered parenterally in a sterile medium. The drug, depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as local anesthetics, preservatives and buffering agents can be dissolved in the vehicle.

[0216] Dosage levels of the order of from about 0.1 mg to about 140 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions (about 0.5 mg to about 7 g per subject per day). The amount of active ingredient that can be combined with the carrier materials to produce a single dosage form varies depending upon the host treated and the particular mode of administration. Dosage unit forms generally contain between from about 1 mg to about 500 mg of an active ingredient.

[0217] It is understood that the specific dose level for any particular subject depends upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

[0218] For administration to non-human animals, the composition can also be added to the animal feed or drinking water. It can be convenient to formulate the animal feed and drinking water compositions so that the animal takes in a therapeutically appropriate quantity of the composition along with its diet. It can also be convenient to present the composition as a premix for addition to the feed or drinking water.

[0219] The nucleic acid molecules of the present invention may also be administered to a subject in combination with

other therapeutic compounds to increase the overall therapeutic effect. The use of multiple compounds to treat an indication may increase the beneficial effects while reducing the presence of side effects.

[0220] In one embodiment, the invention compositions suitable for administering nucleic acid molecules of the invention to specific cell types, such as hepatocytes. For example, the asialoglycoprotein receptor (ASGPr) (Wu and Wu, 1987, *J. Biol. Chem.* 262, 4429-4432) is unique to hepatocytes and binds branched galactose-terminal glycoproteins, such as asialoorosomucoid (ASOR). Binding of such glycoproteins or synthetic glycoconjugates to the receptor takes place with an affinity that strongly depends on the degree of branching of the oligosaccharide chain, for example, triantennary structures are bound with greater affinity than biantennary or monoantennary chains (Baenziger and Fiete, 1980, *Cell*, 22, 611-620; Connolly et al., 1982, *J. Biol. Chem.*, 257, 939-945). Lee and Lee, 1987, *Glycoconjugate J.*, 4, 317-328, obtained this high specificity through the use of N-acetyl-D-galactosamine as the carbohydrate moiety, which has higher affinity for the receptor, compared to galactose. This "clustering effect" has also been described for the binding and uptake of mannosyl-terminating glycoproteins or glycoconjugates (Ponpipom et al., 1981, *J. Med. Chem.*, 24, 1388-1395). The use of galactose and galactosamine based conjugates to transport exogenous compounds across cell membranes can provide a targeted delivery approach to the treatment of liver disease such as HBV infection or hepatocellular carcinoma. The use of bioconjugates can also provide a reduction in the required dose of therapeutic compounds required for treatment. Furthermore, therapeutic bioavailability, pharmacodynamics, and pharmacokinetic parameters can be modulated through the use of nucleic acid bioconjugates of the invention.

[0221] Alternatively, certain siRNA molecules of the instant invention can be expressed within cells from eukaryotic promoters (e.g., Izant and Weintraub, 1985, *Science*, 229, 345; McGarry and Lindquist, 1986, *Proc. Natl. Acad. Sci.*, USA 83, 399; Scanlon et al., 1991, *Proc. Natl. Acad. Sci. USA*, 88, 10591-5; Kashani-Sabet et al., 1992, *Antisense Res. Dev.*, 2, 3-15; Dropulic et al., 1992, *J. Virol.*, 66, 1432-41; Weerasinghe et al., 1991, *J. Virol.*, 65, 5531-4; Ojwang et al., 1992, *Proc. Natl. Acad. Sci. USA*, 89, 10802-6; Chen et al., 1992, *Nucleic Acids Res.*, 20, 4581-9; Sarver et al., 1990 *Science*, 247, 1222-1225; Thompson et al., 1995, *Nucleic Acids Res.*, 23, 2259; Good et al., 1997, *Gene Therapy*, 4, 45. Those skilled in the art realize that any nucleic acid can be expressed in eukaryotic cells from the appropriate DNA/RNA vector. The activity of such nucleic acids can be augmented by their release from the primary transcript by a enzymatic nucleic acid (Draper et al., PCT WO 93/23569, and Sullivan et al., PCT WO 94/02595; Ohkawa et al., 1992, *Nucleic Acids Symp. Ser.*, 27, 15-6; Taira et al., 1991, *Nucleic Acids Res.*, 19, 5125-30; Ventura et al., 1993, *Nucleic Acids Res.*, 21, 3249-55; Chowrira et al., 1994, *J. Biol. Chem.*, 269, 25856.

[0222] In another aspect of the invention, RNA molecules of the present invention can be expressed from transcription units (see for example Couture et al., 1996, *TIG.*, 12, 510) inserted into DNA or RNA vectors. The recombinant vectors can be DNA plasmids or viral vectors. siRNA expressing viral vectors can be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavi-

rus. In another embodiment, pol III based constructs are used to express nucleic acid molecules of the invention (see for example Thompson, U.S. Pat. Nos. 5,902,880 and 6,146,886). The recombinant vectors capable of expressing the siRNA molecules can be delivered as described above, and persist in target cells. Alternatively, viral vectors can be used that provide for transient expression of nucleic acid molecules. Such vectors can be repeatedly administered as necessary. Once expressed, the siRNA molecule interacts with the target mRNA and generates an RNAi response. Delivery of siRNA molecule expressing vectors can be systemic, such as by intravenous or intramuscular administration, by administration to target cells ex-planted from a subject followed by reintroduction into the subject, or by any other means that would allow for introduction into the desired target cell (for a review see Couture et al., 1996, *TIG.*, 12, 510).

[0223] In one aspect the invention features an expression vector comprising a nucleic acid sequence encoding at least one siRNA molecule of the instant invention. The expression vector can encode one or both strands of a siRNA duplex, or a single self complementary strand that self hybridizes into a siRNA duplex. The nucleic acid sequences encoding the siRNA molecules of the instant invention can be operably linked in a manner that allows expression of the siRNA molecule (see for example Paul et al., 2002, *Nature Biotechnology*, 19, 505; Miyagishi and Taira, 2002, *Nature Biotechnology*, 19, 497; Lee et al., 2002, *Nature Biotechnology*, 19, 500; and Novina et al., 2002, *Nature Medicine*, advance online publication doi:10.1038/nm725).

[0224] In another aspect, the invention features an expression vector comprising: a) a transcription initiation region (e.g., eukaryotic pol I, II or III initiation region); b) a transcription termination region (e.g., eukaryotic pol I, II or III termination region); and c) a nucleic acid sequence encoding at least one of the siRNA molecules of the instant invention; wherein said sequence is operably linked to said initiation region and said termination region, in a manner that allows expression and/or delivery of the siRNA molecule. The vector can optionally include an open reading frame (ORF) for a protein operably linked on the 5' side or the 3'-side of the sequence encoding the siRNA of the invention; and/or an intron (intervening sequences).

[0225] Transcription of the siRNA molecule sequences can be driven from a promoter for eukaryotic RNA polymerase I (pol I), RNA polymerase II (pol II), or RNA polymerase III (pol III). Transcripts from pol II or pol III promoters are expressed at high levels in all cells; the levels of a given pol II promoter in a given cell type depends on the nature of the gene regulatory sequences (enhancers, silencers, etc.) present nearby. Prokaryotic RNA polymerase promoters are also used, providing that the prokaryotic RNA polymerase enzyme is expressed in the appropriate cells (Elroy-Stein and Moss, 1990, *Proc. Natl. Acad. Sci. USA*, 87, 6743-7; Gao and Huang 1993, *Nucleic Acids Res.*, 21, 2867-72; Lieber et al., 1993, *Methods Enzymol.*, 217, 47-66; Zhou et al., 1990, *Mol. Cell. Biol.*, 10, 4529-37). Several investigators have demonstrated that nucleic acid molecules expressed from such promoters can function in mammalian cells (e.g. Kashani-Sabet et al., 1992, *Antisense Res. Dev.*, 2, 3-15; Ojwang et al., 1992, *Proc. Natl. Acad. Sci. USA*, 89, 10802-6; Chen et al., 1992, *Nucleic Acids Res.*, 20, 4581-9; Yu et al., 1993, *Proc. Natl. Acad. Sci. USA*, 90, 6340-4;

L'Huillier et al., 1992, *EMBO J.*, 11, 4411-8; Lisiewicz et al., 1993, *Proc. Natl. Acad. Sci. U.S.A.*, 90, 8000-4; Thompson et al., 1995, *Nucleic Acids Res.*, 23, 2259; Sullenger & Cech, 1993, *Science*, 262, 1566). More specifically, transcription units such as the ones derived from genes encoding U6 small nuclear (snRNA), transfer RNA (tRNA) and adenovirus VA RNA are useful in generating high concentrations of desired RNA molecules such as siRNA in cells (Thompson et al., supra; Couture and Stinchcomb, 1996, supra; Noonberg et al., 1994, *Nucleic Acid Res.*, 22, 2830; Noonberg et al., U.S. Pat. No. 5,624,803; Good et al., 1997, *Gene Ther.*, 4, 45; Beigelman et al., International PCT Publication No. WO 96/18736. The above siRNA transcription units can be incorporated into a variety of vectors for introduction into mammalian cells, including but not restricted to, plasmid DNA vectors, viral DNA vectors (such as adenovirus or adeno-associated virus vectors), or viral RNA vectors (such as retroviral or alphavirus vectors) (for a review see Couture and Stinchcomb, 1996, supra).

[0226] In another aspect the invention features an expression vector comprising a nucleic acid sequence encoding at least one of the siRNA molecules of the invention, in a manner that allows expression of that siRNA molecule. The expression vector comprises in one embodiment; a) a transcription initiation region; b) a transcription termination region; and c) a nucleic acid sequence encoding at least one strand of the siRNA molecule; wherein the sequence is operably linked to the initiation region and the termination region, in a manner that allows expression and/or delivery of the siRNA molecule.

[0227] In another embodiment the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an open reading frame; and d) a nucleic acid sequence encoding at least one strand of a siRNA molecule, wherein the sequence is operably linked to the 3'-end of the open reading frame; and wherein the sequence is operably linked to the initiation region, the open reading frame and the termination region, in a manner that allows expression and/or delivery of the siRNA molecule. In yet another embodiment the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron; and d) a nucleic acid sequence encoding at least one siRNA molecule; wherein the sequence is operably linked to the initiation region, the intron and the termination region, in a manner which allows expression and/or delivery of the nucleic acid molecule.

[0228] In another embodiment, the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron; d) an open reading frame; and e) a nucleic acid sequence encoding at least one strand of a siRNA molecule, wherein the sequence is operably linked to the 3'-end of the open reading frame; and wherein the sequence is operably linked to the initiation region, the intron, the open reading frame and the termination region, in a manner which allows expression and/or delivery of the siRNA molecule.

EXAMPLES

[0229] The following are non-limiting examples showing the selection, isolation, synthesis and activity of nucleic acids of the instant invention.

Example 1

Tandem Synthesis of siRNA Constructs

[0230] Exemplary siRNA molecules of the invention are synthesized in tandem using a cleavable linker, for example a succinyl-based linker. Tandem synthesis as described herein is followed by a one step purification process that provides RNAi molecules in high yield. This approach is highly amenable to siRNA synthesis in support of high throughput RNAi screening, and can be readily adapted to multi-column or multi-well synthesis platforms.

[0231] After completing a tandem synthesis of an siRNA oligo and its complement in which the 5'-terminal dimethoxytrityl (5'-O-DMT) group remains intact (trityl on synthesis), the oligonucleotides are deprotected as described above. Following deprotection, the siRNA sequence strands are allowed to spontaneously hybridize. This hybridization yields a duplex in which one strand has retained the 5'-O-DMT group while the complementary strand comprises a terminal 5'-hydroxyl. The newly formed duplex to behave as a single molecule during routine solid-phase extraction purification (Trityl-On purification) even though only one molecule has a dimethoxytrityl group. Because the strands form a stable duplex, this dimethoxytrityl group (or an equivalent group, such as other trityl groups or other hydrophobic moieties) is all that is required to purify the pair of oligos, for example by using a C18 cartridge.

[0232] Standard phosphoramidite synthesis chemistry is used up to point of introducing a tandem linker, such as an inverted deoxyabasic succinate linker (see **FIG. 1**) or an equivalent cleavable linker. A non-limiting example of linker coupling conditions that can be used includes a hindered base such as diisopropylethylamine (DIPA) and/or DMAP in the presence of an activator reagent such as Bromotripyrrolidinophosphoniumhexafluorophosphate (PyBrOP). After the linker is coupled, standard synthesis chemistry is utilized to complete synthesis of the second sequence leaving the terminal the 5'-O-DMT intact. Following synthesis, the resulting oligonucleotide is deprotected according to the procedures described herein and quenched with a suitable buffer, for example with 50 mM NaOAc or 1.5M $\text{NH}_4\text{H}_2\text{CO}_3$.

[0233] Purification of the siRNA duplex can be readily accomplished using solid phase extraction, for example using a Waters C18 SepPak 1 g cartridge conditioned with 1 column volume (CV) of acetonitrile, 2 CV H_2O , and 2 CV 50 mM NaOAc. The sample is loaded and then washed with 1 CV H_2O or 50 mM NaOAc. Failure sequences are eluted with 1 CV 14% ACN (Aqueous with 50 mM NaOAc and 50 mM NaCl). The column is then washed, for example with 1 CV H_2O followed by on-column detritylation, for example by passing 1 CV of 1% aqueous trifluoroacetic acid (TFA) over the column, then adding a second CV of 1% aqueous TFA to the column and allowing to stand for approx. 10 minutes. The remaining TFA solution is removed and the column washed with H_2O followed by 1 CV 1M NaCl and additional H_2O . The siRNA duplex product is then eluted, for example using 1 CV 20% aqueous CAN.

[0234] **FIG. 2** provides an example of MALDI-TOV mass spectrometry analysis of a purified siRNA construct in which each peak corresponds to the calculated mass of an individual siRNA strand of the siRNA duplex. The same

purified siRNA provides three peaks when analyzed by capillary gel electrophoresis (CGE), one peak presumably corresponding to the duplex siRNA, and two peaks presumably corresponding to the separate siRNA sequence strands. Ion exchange HPLC analysis of the same siRNA construct only shows a single peak.

Example 2

Identification of Potential siRNA Target Sites in any RNA Sequence

[0235] The sequence of an RNA target of interest, such as a viral or human mRNA transcript, is screened for target sites, for example by using a computer folding algorithm. In a non-limiting example, the sequence of a gene or RNA gene transcript derived from a database, such as Genbank, is used to generate siRNA targets having complementarity to the target. Such sequences can be obtained from a database, or can be determined experimentally as known in the art. Target sites that are known, for example, those target sites determined to be effective target sites based on studies with other nucleic acid molecules, for example ribozymes or antisense, or those targets known to be associated with a disease or condition such as those sites containing mutations or deletions, can be used to design siRNA molecules targeting those sites as well. Various parameters can be used to determine which sites are the most suitable target sites within the target RNA sequence. These parameters include but are not limited to secondary or tertiary RNA structure, the nucleotide base composition of the target sequence, the degree of homology between various regions of the target sequence, or the relative position of the target sequence within the RNA transcript. Based on these determinations, any number of target sites within the RNA transcript can be chosen to screen siRNA molecules for efficacy, for example by using in vitro RNA cleavage assays, cell culture, or animal models. In a non-limiting example, anywhere from 1 to 1000 target sites are chosen within the transcript based on the size of the siRNA construct to be used. High throughput screening assays can be developed for screening siRNA molecules using methods known in the art, such as with multi-well or multi-plate assays to determine efficient reduction in target gene expression.

Example 3

Selection of siRNA Molecule Target Sites in a RNA

[0236] The following non-limiting steps can be used to carry out the selection of siRNAs targeting a given gene sequence or transcript.

[0237] 1. The target sequence is parsed in silico into a list of all fragments or subsequences of a particular length, for example 23 nucleotide fragments, contained within the target sequence. This step is typically carried out using a custom Perl script, but commercial sequence analysis programs such as Oligo, MacVector, or the GCG Wisconsin Package can be employed as well.

[0238] 2. In some instances the siRNAs correspond to more than one target sequence; such would be the case for example in targeting many different strains of a viral sequence, for targeting different transcripts of the same gene, targeting different transcripts of more than one gene, or for

targeting both the human gene and an animal homolog. In this case, a subsequence list of a particular length is generated for each of the targets, and then the lists are compared to find matching sequences in each list. The subsequences are then ranked according to the number of target sequences that contain the given subsequence; the goal is to find subsequences that are present in most or all of the target sequences. Alternately, the ranking can identify subsequences that are unique to a target sequence, such as a mutant target sequence. Such an approach would enable the use of siRNA to target specifically the mutant sequence and not effect the expression of the normal sequence.

[0239] 3. In some instances the siRNA subsequences are absent in one or more sequences while present in the desired target sequence; such would be the case if the siRNA targets a gene with a paralogous family member that is to remain untargeted. As in case 2 above, a subsequence list of a particular length is generated for each of the targets, and then the lists are compared to find sequences that are present in the target gene but are absent in the untargeted paralog.

[0240] 4. The ranked siRNA subsequences can be further analyzed and ranked according to GC content. A preference can be given to sites containing 30-70% GC, with a further preference to sites containing 40-60% GC.

[0241] 5. The ranked siRNA subsequences can be further analyzed and ranked according to self-folding and internal hairpins. Weaker internal folds are preferred; strong hairpin structures are to be avoided.

[0242] 6. The ranked siRNA subsequences can be further analyzed and ranked according to whether they have runs of GGG or CCC in the sequence. GGG (or even more Gs) in either strand can make oligonucleotide synthesis problematic, so it is avoided whenever better sequences are available. CCC is searched in the target strand because that will place GGG in the antisense strand.

[0243] 7. The ranked siRNA subsequences can be further analyzed and ranked according to whether they have the dinucleotide UU (uridine dinucleotide) on the 3' end of the sequence, and/or AA on the 5' end of the sequence (to yield 3' UU on the antisense sequence). These sequences allow one to design siRNA molecules with terminal TT thymidine dinucleotides.

[0244] 8. Four or five target sites are chosen from the ranked list of subsequences as described above. For example, in subsequences having 23 nucleotides, the right 21 nucleotides of each chosen 23-mer subsequence are then designed and synthesized for the upper (sense) strand of the siRNA duplex, while the reverse complement of the left 21 nucleotides of each chosen 23-mer subsequence are then designed and synthesized for the lower (antisense) strand of the siRNA duplex. If terminal TT residues are desired for the sequence (as described in paragraph 7), then the two 3' terminal nucleotides of both the sense and antisense strands are replaced by TT prior to synthesizing the oligos.

[0245] 9. The siRNA molecules are screened in an in vitro, cell culture or animal model system to identify the most active siRNA molecule or the most preferred target site within the target RNA sequence.

Example 4

BACE Targeted siRNA Design

[0246] siRNA target sites were chosen by analyzing sequences of the BACE RNA target and optionally prioritizing the target sites on the basis of folding (structure of any given sequence analyzed to determine siRNA accessibility to the target). siRNA molecules were designed that could bind each target and are optionally individually analyzed by computer folding to assess whether the siRNA molecule can interact with the target sequence. Varying the length of the siRNA molecules can be chosen to optimize activity. Generally, a sufficient number of complementary nucleotide bases are chosen to bind to, or otherwise interact with, the target RNA, but the degree of complementarity can be modulated to accommodate siRNA duplexes or varying length or base composition. By using such methodologies, siRNA molecules can be designed to target sites within any known RNA sequence, for example those RNA sequences corresponding to the any gene transcript.

Example 5

Chemical Synthesis and Purification of siRNA

[0247] siRNA molecules can be designed to interact with various sites in the RNA message, for example target sequences within the RNA sequences described herein. The sequence of one strand of the siRNA molecule(s) are complementary to the target site sequences described above. The siRNA molecules can be chemically synthesized using methods described herein. Inactive siRNA molecules that are used as control sequences can be synthesized by scrambling the sequence of the siRNA molecules such that it is not complementary to the target sequence.

Example 6

RNAi In Vitro Assay to Assess siRNA Activity

[0248] An in vitro assay that recapitulates RNAi in a cell free system is used to evaluate siRNA constructs targeting BACE RNA targets. The assay comprises the system described by Tuschl et al., 1999, *Genes and Development*, 13, 3191-3197 and Zamore et al., 2000, *Cell*, 101, 25-33 adapted for use with BACE target RNA. A *Drosophila* extract derived from syncytial blastoderm is used to reconstitute RNAi activity in vitro. Target RNA is generated via in vitro transcription from an appropriate BACE expressing plasmid using T7 RNA polymerase or via chemical synthesis as described herein. Sense and antisense siRNA strands (for example 20 uM each) are annealed by incubation in buffer (such as 100 mM potassium acetate, 30 mM HEPES-KOH, pH 7.4, 2 mM magnesium acetate) for 1 min. at 90° C. followed by 1 hour at 37° C., then diluted in lysis buffer (for example 100 mM potassium acetate, 30 mM HEPES-KOH at pH 7.4, 2 mM magnesium acetate). Annealing can be monitored by gel electrophoresis on an agarose gel in TBE buffer and stained with ethidium bromide. The *Drosophila* lysate is prepared using zero to two hour old embryos from Oregon R flies collected on yeast molasses agar that are dechorionated and lysed. The lysate is centrifuged and the supernatant isolated. The assay comprises a reaction mixture containing 50% lysate [vol/vol], RNA (10-50 pM final concentration), and 10% [vol/vol] lysis buffer contain-

ing siRNA (10 nM final concentration). The reaction mixture also contains 10 mM creatine phosphate, 10 μ g/ml creatine phosphokinase, 100 μ M GTP, 100 μ M UTP, 100 μ M CTP, 500 μ M ATP, 5 mM DTT, 0.1 U/ μ L RNasin (Promega), and 100 μ M of each amino acid. The final concentration of potassium acetate is adjusted to 100 mM. The reactions are pre-assembled on ice and preincubated at 25° C. for 10 minutes before adding RNA, then incubated at 25° C. for an additional 60 minutes. Reactions are quenched with 4 volumes of 1.25 \times Passive Lysis Buffer (Promega). Target RNA cleavage is assayed by RT-PCR analysis or other methods known in the art and are compared to control reactions in which siRNA is omitted from the reaction.

[0249] Alternately, internally-labeled target RNA for the assay is prepared by in vitro transcription in the presence of [α -³²P] CTP, passed over a G 50 Sephadex column by spin chromatography and used as target RNA without further purification. Optionally, target RNA is 5'-³²P-end labeled using T4 polynucleotide kinase enzyme. Assays are performed as described above and target RNA and the specific RNA cleavage products generated by RNAi are visualized on an autoradiograph of a gel. The percentage of cleavage is determined by Phosphor Imager® quantitation of bands representing intact control RNA or RNA from control reactions without siRNA and the cleavage products generated by the assay.

Example 7

Cell Culture Models

[0250] Vassar et al., 1999, *Science*, 286, 735-741, describe a cell culture model for studying BACE inhibition. Specific antisense nucleic acid molecules targeting BACE mRNA were used for inhibition studies of endogenous BACE expression in 101 cells and APPsw (Swedish type amyloid precursor protein expressing) cells via lipid mediated transfection. Antisense treatment resulted in dramatic reduction of both BACE mRNA by Northern blot analysis, and APPs β sw ("Swedish" type β -secretase cleavage product) by ELISA, with maximum inhibition of both parameters at 75-80%. This model was also used to study the effect of BACE inhibition on amyloid β -peptide production in APPsw cells. Similarly, such a model can be used to screen siRNA molecules of the instant invention for efficacy and potency.

Example 8

Animal Models

[0251] Games et al., 1995, *Nature*, 373, 523-527, describe a transgenic mouse model in which mutant human familial type APP (Phe 717 instead of Val) is overexpressed. This model results in mice that progressively develop many of the pathological hallmarks of Alzheimer's disease, and as such, provides a model for testing therapeutic drugs, including siRNA constructs of the instant invention.

[0252] Indications

[0253] Particular degenerative and disease states that can be associated with BACE expression modulation include but are not limited to Alzheimer's disease, dementia, stroke (CVA) and any other diseases or conditions that are related to the levels of BACE in a cell or tissue, alone or in combination with other therapies. The reduction of BACE expression (specifically BACE RNA levels) and thus reduc-

tion in the level of the respective protein relieves, to some extent, the symptoms of the disease or condition.

[0254] The present body of knowledge in BACE research indicates the need for methods to assay BACE activity and for compounds that can regulate BACE expression for research, diagnostic, and therapeutic use.

[0255] Diagnostic Uses

[0256] The siRNA molecules of the invention can be used in a variety of diagnostic applications, such as in identifying molecular targets such as RNA in a variety of applications, for example, in clinical, industrial, environmental, agricultural and/or research settings. Such diagnostic use of siRNA molecules involves utilizing reconstituted RNAi systems, for example using cellular lysates or partially purified cellular lysates. siRNA molecules of this invention may be used as diagnostic tools to examine genetic drift and mutations within diseased cells or to detect the presence of endogenous or exogenous, for example viral, RNA in a cell. The close relationship between siRNA activity and the structure of the target RNA allows the detection of mutations in any region of the molecule, which alters the base-pairing and three-dimensional structure of the target RNA. By using multiple siRNA molecules described in this invention, one may map nucleotide changes, which are important to RNA structure and function in vitro, as well as in cells and tissues. Cleavage of target RNAs with siRNA molecules can be used to inhibit gene expression and define the role (essentially) of specified gene products in the progression of disease or infection. In this manner, other genetic targets may be defined as important mediators of the disease. These experiments will lead to better treatment of the disease progression by affording the possibility of combination therapies (e.g., multiple siRNA molecules targeted to different genes, siRNA molecules coupled with known small molecule inhibitors, or intermittent treatment with combinations siRNA molecules and/or other chemical or biological molecules). Other in vitro uses of siRNA molecules of this invention are well known in the art, and include detection of the presence of mRNAs associated with a disease, infection, or related condition. Such RNA is detected by determining the presence of a cleavage product after treatment with a siRNA using standard methodologies, for example fluorescence resonance emission transfer (FRET).

[0257] In a specific example, siRNA molecules that can cleave only wild-type or mutant forms of the target RNA are used for the assay. The first siRNA molecule is used to identify wild-type RNA present in the sample and the second siRNA molecule will be used to identify mutant RNA in the sample. As reaction controls, synthetic substrates of both wild-type and mutant RNA will be cleaved by both siRNA molecules to demonstrate the relative siRNA efficiencies in the reactions and the absence of cleavage of the "non-targeted" RNA species. The cleavage products from the synthetic substrates will also serve to generate size markers for the analysis of wild-type and mutant RNAs in the sample population. Thus each analysis will require two siRNA molecules, two substrates and one unknown sample which will be combined into six reactions. The presence of cleavage products will be determined using an RNase protection assay so that full-length and cleavage fragments of each RNA can be analyzed in one lane of a polyacrylamide gel. It is not absolutely required to quantify the results to gain insight into the expression of mutant RNAs and putative risk of the desired phenotypic changes in target cells. The expression of mRNA whose protein product is implicated in

the development of the phenotype (i.e., disease related or infection related) is adequate to establish risk. If probes of comparable specific activity are used for both transcripts, then a qualitative comparison of RNA levels will be adequate and will decrease the cost of the initial diagnosis. Higher mutant form to wild-type ratios will be correlated with higher risk whether RNA levels are compared qualitatively or quantitatively.

[0258] All patents and publications mentioned in the specification are indicative of the levels of skill of those skilled in the art to which the invention pertains. All references cited in this disclosure are incorporated by reference to the same extent as if each reference had been incorporated by reference in its entirety individually.

[0259] One skilled in the art would readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The methods and compositions described herein as presently representative of preferred embodiments are exemplary and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art, which are encompassed within the spirit of the invention, are defined by the scope of the claims.

[0260] It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention. Thus, such additional embodiments are within the scope of the present invention and the following claims.

[0261] The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations that are not specifically disclosed herein. Thus, for example, in each instance herein any of the terms “comprising”, “consisting essentially of” and “consisting of” may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments, optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the description and the appended claims.

[0262] In addition, where features or aspects of the invention are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group or other group.

TABLE I

BACE target and siRNA sequences									
Pos	Target Sequence	Seq ID	UPos	Upper seq	Seq ID	LPos	Lower seq	Seq ID	
1	CGCACUCGUCCCCAGCCCG	1	1	CGCACUCGUCCCCAGCCCG	1	23	GCGUGAGCAGGGGUCGGGC	326	
19	GCCCGGGAGCUGCGAGCCG	2	19	GCCCGGGAGCUGCGAGCCG	2	41	CGGUCGCGAGCUCGCCGGGC	327	
37	GCGAGCUGGAUUAUGGUGG	3	37	GCGAGCUGGAUUAUGGUGG	3	59	CCACCAUAAUCCAGCUCGC	328	
55	GCCUGAGCAGCCAACGCAG	4	55	GCCUGAGCAGCCAACGCAG	4	77	CUGCGUUGGCUCGUCAGGC	329	
73	GCCCGCAGGAGCCCGGAGCC	5	73	GCCCGCAGGAGCCCGGAGCC	5	95	GGCUCGGGCUCGUCGGCC	330	
91	CCUUGCCCCUGCCCGCGCC	6	91	CCUUGCCCCUGCCCGCGCC	6	113	GGCGCGGGCAGGGGCAAGG	331	
109	CGCCGCCCGCCGGGGGAC	7	109	CGCCGCCCGCCGGGGGAC	7	131	GCCCCCGCGGGGGCGGCG	332	
127	CCAGGGAAGCCGCCACCGG	8	127	CCAGGGAAGCCGCCACCGG	8	149	CCGUGGGCGGCUUCCUGG	333	
145	GCCCGCCAUGCCCGCCCU	9	145	GCCCGCCAUGCCCGCCCU	9	167	AGGGGCGGGCAUGGGCGGC	334	
163	UCCAGCCCCGCCGGGAGC	10	163	UCCAGCCCCGCCGGGAGC	10	185	GCUCCGGCGGGGCGUGGA	335	
181	CCCGCGCCCGCUGCCAGG	11	181	CCCGCGCCCGCUGCCAGG	11	203	CCUGGGCAGCGGGCGCGGG	336	
199	GCUGGCCCGCCGCGUGCCG	12	199	GCUGGCCCGCCGCGUGCCG	12	221	CGGCACGGCGGGCGCCAGC	337	
217	GAUGUAGCGGGCUCGGAU	13	217	GAUGUAGCGGGCUCGGAU	13	239	AUCCGGAGCCCGCUACAUC	338	
235	UCCAGCCUCUCCCCUGCU	14	235	UCCAGCCUCUCCCCUGCU	14	257	AGCAGGGGAGAGGCUUGGA	339	
253	UCCCGUGCUCUGCGGAUCU	15	253	UCCCGUGCUCUGCGGAUCU	15	275	AGAUCGCGAGACACGGGA	340	
271	UCCCGUGACCGCUCUCCAC	16	271	UCCCGUGACCGCUCUCCAC	16	293	GUGGAGAGCGGUCAGGGGA	341	
289	CAGCCCGGACCGGGGGCU	17	289	CAGCCCGGACCGGGGGCU	17	311	AGCCCCCGGGUCCGGGCG	342	
307	UGGCCAGGGGCCUGCAGG	18	307	UGGCCAGGGGCCUGCAGG	18	329	CCUGCAGGGCCUGGGCCA	343	
325	GCCUGGGCUGCCUGAUGCC	19	325	GCCUGGGCUGCCUGAUGCC	19	347	GGCAUCAGGACGCCAGGGC	344	
343	CCCCAAGCUCUCCUGCUG	20	343	CCCCAAGCUCUCCUGCUG	20	365	CAGGAGAGGGAGCUUGGGG	345	
361	GAGAAGCCACCAGACCAC	21	361	GAGAAGCCACCAGACCAC	21	383	GUGGUGCGUGGUGGCUUC	346	
379	CCCAGACUUGGGGGCAGG	22	379	CCCAGACUUGGGGGCAGG	22	401	GCCUGCCCCAAGUCUGGG	347	
397	CGCCAGGACGACGUGGG	23	397	CGCCAGGACGACGUGGG	23	419	CCCACGUCGUCUCCUGGCG	348	
415	GCCAGUGCGAGCCAGAGG	24	415	GCCAGUGCGAGCCAGAGG	24	437	CCUCUGGGCUCGCACUGGC	349	
433	GGCCCGAAGGCCGGGGCCC	25	433	GGCCCGAAGGCCGGGGCCC	25	455	GGGCCCCGGCCUUCGGGCC	350	
451	CACCAUGGCCCAAGCCUG	26	451	CACCAUGGCCCAAGCCUG	26	473	CAGGGCUGGGGCCAUGGUG	351	
469	GCCUGGCUCUCCUGUGGG	27	469	GCCUGGCUCUCCUGUGGG	27	491	CCACAGCAGGAGCCAGGGC	352	
487	GAUGGGCGCGGGAGUGCUG	28	487	GAUGGGCGCGGGAGUGCUG	28	509	CAGCACUCCCGCGCCCAUC	353	
505	GCCUGCCACGGCACCCAG	29	505	GCCUGCCACGGCACCCAG	29	527	CUGGGUGCCGUGGGCAGGC	354	
523	GCACGGCAUCCGGCUGCCC	30	523	GCACGGCAUCCGGCUGCCC	30	545	GGGACGCGGAUGCCGUGC	355	
541	CCUGCGCAGCGGCCUGGGG	31	541	CCUGCGCAGCGGCCUGGGG	31	563	CCCCAGGCCGUCGCGAGG	356	

TABLE I-continued

BACE target and siRNA sequences									
Pos	Target Sequence	Seq ID	UPos	Upper seq	Seq ID	LPos	Lower seq	Seq ID	
559	GGGCGCCCCCUGGGGCGUG	32	559	GGGCGCCCCCUGGGGCGUG	32	581	CAGCCCCAGGGGGCGCCC	357	
577	GCGGCGCCCCGGGAGACC	33	577	GCGGCGCCCCGGGAGACC	33	599	GGUCUCCCCGGGGAGCCGC	358	
595	CGACGAAGAGCCCAGGAG	34	595	CGACGAAGAGCCCAGGAG	34	617	CUCCUCGGGCUCUUCGUCG	359	
613	GCCCGGCCGGAGGGGAGC	35	613	GCCCGGCCGGAGGGGAGC	35	635	GUUCCCCCUGGGCGGGC	360	
631	CUUUGUGGAGUUGUGGAC	36	631	CUUUGUGGAGUUGUGGAC	36	653	GUCCACCAUCUCCACAAAG	361	
649	CAACCUGAGGGGCAAGUCG	37	649	CAACCUGAGGGGCAAGUCG	37	671	CGACUUGCCCCUCAGGUUG	362	
667	GGGGCAGGGCUACUACGUG	38	667	GGGGCAGGGCUACUACGUG	38	689	CACGUAGUAGCCUUGCCCC	363	
685	GGAGAUGACCGUGGGGAGC	39	685	GGAGAUGACCGUGGGGAGC	39	707	GUUCCCCACGGUACUUC	364	
703	CCCCCGCAGACGCUAAC	40	703	CCCCCGCAGACGCUAAC	40	725	GUUGAGCGUCUGCGGGGG	365	
721	CAUCCUGUGGAUACAGGC	41	721	CAUCCUGUGGAUACAGGC	41	743	GCCUGAUUCCACAGGAG	366	
739	CAGCAGUAAUUUGCAGUG	42	739	CAGCAGUAAUUUGCAGUG	42	761	CACUGCAAUUUACUGCUG	367	
757	GGGUGUGCCCCCACCCC	43	757	GGGUGUGCCCCCACCCC	43	779	GGGUGGGGGGAGCAGCCC	368	
775	CUUUGACUUGGCUACUAC	44	775	CUUUGACUUGGCUACUAC	44	797	GUAGUAGCGAUGAGGAG	369	
793	CCAGAGGCAGCUGUCCAGC	45	793	CCAGAGGCAGCUGUCCAGC	45	815	GUUGGACAGCUGCCUUGG	370	
811	CACAUACCGGGACUCCGG	46	811	CACAUACCGGGACUCCGG	46	833	CCGGAGGUCCCGGUUAGUG	371	
829	GAAGGUGUGUAUGUGCCC	47	829	GAAGGUGUGUAUGUGCCC	47	851	GGGCACAUACACACCCUUC	372	
847	CUACACCCAGGGCAAGUGG	48	847	CUACACCCAGGGCAAGUGG	48	869	CCACUUGCCUGGGUGUAG	373	
865	GGAAGGGGAGCUGGGCACC	49	865	GGAAGGGGAGCUGGGCACC	49	887	GGUGCCAGCUCUCCUUC	374	
883	CGACCGUUAAGCAUCCCC	50	883	CGACCGUUAAGCAUCCCC	50	905	GGGGAUGCUUACAGGUGC	375	
901	CAUGGCCCAACGUCACU	51	901	CAUGGCCCAACGUCACU	51	923	AGUGACGUUGGGGCCAUGG	376	
919	UGUGCGUGCCAACAUUGCU	52	919	UGUGCGUGCCAACAUUGCU	52	941	AGCAAUGUUGGCACGCACA	377	
937	UGCCAUAUCUGAUAUCAGC	53	937	UGCCAUAUCUGAUAUCAGC	53	959	GUCUGAUUCCAGUAGGCA	378	
955	CAAGUUCUUAUCAACGGC	54	955	CAAGUUCUUAUCAACGGC	54	977	GCCGUUGAUGAAGAACUUG	379	
973	CUCCAACUGGGAAGGCAUC	55	973	CUCCAACUGGGAAGGCAUC	55	995	GAUGCCUUCCCAGUUGGAG	380	
991	CCUGGGGUGGGCUAUGCU	56	991	CCUGGGGUGGGCUAUGCU	56	1013	AGCAUAGGCCAGCCCGAG	381	
1009	UGAGAUGGCCAGGCCUGAC	57	1009	UGAGAUGGCCAGGCCUGAC	57	1031	GUCAGGCCUGGCAAUUCA	382	
1027	CGACUCCUGGAGCCUUUC	58	1027	CGACUCCUGGAGCCUUUC	58	1049	GAAAGGCCUCCAGGGAGUCG	383	
1045	CUUUGACUUCUGGUAAAG	59	1045	CUUUGACUUCUGGUAAAG	59	1067	CUUUAACAGAGAGUCAAG	384	
1063	GCAGACCCAGGUUCCCAAC	60	1063	GCAGACCCAGGUUCCCAAC	60	1085	GUUGGGAAACGUGGGUCUGC	385	
1081	CCUCUUCUCCUGCAGCUU	61	1081	CCUCUUCUCCUGCAGCUU	61	1103	AAGCUGCAGGGAGAAGAGG	386	
1099	UUGUGUGUGUGGCUUCCCC	62	1099	UUGUGUGUGUGGCUUCCCC	62	1121	GGGGAAGCCAGCACCACA	387	
1117	CCUCAACACAGUCUGAAGUG	63	1117	CCUCAACACAGUCUGAAGUG	63	1139	CACUUCAGACUGGUUAGG	388	
1135	GCUGGCCUCUGUCGGAGGG	64	1135	GCUGGCCUCUGUCGGAGGG	64	1157	CCUCCGACAGAGGCCAGC	389	
1153	GAGCAUGAUAUUGGAGGU	65	1153	GAGCAUGAUAUUGGAGGU	65	1175	ACCUCAAUGAUAUGUUC	390	
1171	UAUCGACCACUCGCUGUAC	66	1171	UAUCGACCACUCGCUGUAC	66	1193	CUACAGCGAGUGGUUGUA	391	
1189	CACAGGCAGUCUCUGGUU	67	1189	CACAGGCAGUCUCUGGUU	67	1211	AUACCAGAGACUGCCUGUG	392	
1207	UACACCCAUCGCGGGGAG	68	1207	UACACCCAUCGCGGGGAG	68	1229	CUCCCGCGGAUGGGUGUA	393	
1225	GUGGUUAUUAUGAGGUCAUC	69	1225	GUGGUUAUUAUGAGGUCAUC	69	1247	GAUGACCUCUAUAUACCAC	394	
1243	CAUUGUGCGGGUGGAGAU	70	1243	CAUUGUGCGGGUGGAGAU	70	1265	GAUCCUCCACCGCACAAUG	395	
1261	CAAUGGACAGGAUCUGAAA	71	1261	CAAUGGACAGGAUCUGAAA	71	1283	UUUCAGAUCCUGUCCAUUG	396	
1279	AAUGGACUGCAAGGAGUAC	72	1279	AAUGGACUGCAAGGAGUAC	72	1301	GUACUCCUUGCAGUCCAUU	397	
1297	CAACUAUGACAAGAGCAU	73	1297	CAACUAUGACAAGAGCAU	73	1319	AAUGCUCUUGUCAUAGUUG	398	
1315	UGUGGACAGUUGGCACACC	74	1315	UGUGGACAGUUGGCACACC	74	1337	GGUGGUGCCACUGUCCACA	399	
1333	CAACCUUCGUUUGCCCAAG	75	1333	CAACCUUCGUUUGCCCAAG	75	1355	CUUGGGCAAACGAAGGUUG	400	
1351	GAAAGUGUUUAAGCUGCA	76	1351	GAAAGUGUUUAAGCUGCA	76	1373	UGCAGCUUCAAACACUUC	401	
1369	AGUCAAUAUCCAUACGGCA	77	1369	AGUCAAUAUCCAUACGGCA	77	1391	UGCCUUGAUGGAUUGACU	402	
1387	AGCCUCCUCCACGGAGAA	78	1387	AGCCUCCUCCACGGAGAA	78	1409	CUUCUCCGUGGAGGAGGCU	403	
1405	GUUCCUGAUGGUUUCUGG	79	1405	GUUCCUGAUGGUUUCUGG	79	1427	CCAGAAACCAUCAGGGGAC	404	
1423	GCUAGGAGAGCAUCUGGUG	80	1423	GCUAGGAGAGCAUCUGGUG	80	1445	CACAGCUGCUCUCCUAGC	405	
1441	GUGCUGGCAAGCAGGCACC	81	1441	GUGCUGGCAAGCAGGCACC	81	1463	GGUGCUGCUUGCCAGCAC	406	
1459	CACCCUUGGAACAUAUUUC	82	1459	CACCCUUGGAACAUAUUUC	82	1481	GAAAAUGUCCAGGGGUG	407	
1477	CCCAGUCAUCUCACUCUAC	83	1477	CCCAGUCAUCUCACUCUAC	83	1499	GAUGAGUGAUGAGCUGGG	408	
1495	CCUAAUGGGUGAGGUUACC	84	1495	CCUAAUGGGUGAGGUUACC	84	1517	GGUAAACCUACCAUAUAGG	409	
1513	CAACAGUCCUUCGCAUC	85	1513	CAACAGUCCUUCGCAUC	85	1535	GAUGCGGAAGGACUGGUUG	410	
1531	CACCAUCCUUCGCGACAA	86	1531	CACCAUCCUUCGCGACAA	86	1553	UUGCUGCGGAAGGAGUGUG	411	
1549	AUACCUUGCGCCAGUGGAA	87	1549	AUACCUUGCGCCAGUGGAA	87	1571	UUCACUUGGCGCAGGUU	412	
1567	AGAUGUGGCCACGUCCCAA	88	1567	AGAUGUGGCCACGUCCCAA	88	1589	UUGGACGUGGCCACAUCU	413	
1585	AGACGAGUUAUACAAGUUU	89	1585	AGACGAGUUAUACAAGUUU	89	1607	AAACUUGUAACAGUGUCU	414	
1603	UGCAUCUCACAGUCAUCC	90	1603	UGCAUCUCACAGUCAUCC	90	1625	GGAUGACUGUGAUGGCA	415	
1621	CACGGGCACUGUUAUGGGA	91	1621	CACGGGCACUGUUAUGGGA	91	1643	UCCCAUAACAGUGCCCGUG	416	
1639	AGCUGUUAUACUGGAGGGC	92	1639	AGCUGUUAUACUGGAGGGC	92	1661	GCCUCCAUAGUAACAGCU	417	
1657	CUUCUACGUUGUCUUUGAU	93	1657	CUUCUACGUUGUCUUUGAU	93	1679	AUCAAGACAAACGUAGAAG	418	
1675	UCGGGCCCCAAAACGAAU	94	1675	UCGGGCCCCAAAACGAAU	94	1697	AAUUCGUUUUCGGGCCCA	419	
1693	UUGCUUUGCAGUACGCGU	95	1693	UUGCUUUGCAGUACGCGU	95	1715	AGCGUGACAGCAAGGCA	420	
1711	UUGCCAUUGGCACGAUGAG	96	1711	UUGCCAUUGGCACGAUGAG	96	1733	CUCAUCGUGCACAUUGCAA	421	
1729	GUUCAGGACGGCAGCGGUG	97	1729	GUUCAGGACGGCAGCGGUG	97	1751	CACCGCUGCCGUCUUGAAC	422	
1747	GGAAGGCCCUUUGUACACC	98	1747	GGAAGGCCCUUUGUACACC	98	1769	GGUGACAAAAGGGCCUUC	423	
1765	CUUGGACAUUGGAAGACUGU	99	1765	CUUGGACAUUGGAAGACUGU	99	1787	ACAGUCUUCCAUGUCCAA	424	
1783	UGGCUACAACAUUCCACAG	100	1783	UGGCUACAACAUUCCACAG	100	1805	CUGUGGAAUUGUUGAGCCA	425	
1801	GACAGAUGAGUCAACCCUC	101	1801	GACAGAUGAGUCAACCCUC	101	1823	GAGGGUUGACUACUUGUC	426	
1819	CAUGACCAUAGCCUAUGUC	102	1819	CAUGACCAUAGCCUAUGUC	102	1841	GACAUGGGCUAUGGUCAUG	427	

TABLE I-continued

BACE target and siRNA sequences									
Pos	Target Sequence	Seq ID	UPos	Upper seq	Seq ID	LPos	Lower seq	Seq ID	
1837	CAUGGCGUGCCAUCUGCGCC	103	1837	CAUGGCGUGCCAUCUGCGCC	103	1859	GGCGCAGAUGGCAGCCAU	428	
1855	CCUCUUAUCUGUGCCACUC	104	1855	CCUCUUAUCUGUGCCACUC	104	1877	GAGUGGCAGCAUGAAGAGG	429	
1873	CUGCCUCAUGGUGUGUCAG	105	1873	CUGCCUCAUGGUGUGUCAG	105	1895	CUGACACACCAUGAGGCAG	430	
1891	GUGGCGCUGCCUCCGCGUC	106	1891	GUGGCGCUGCCUCCGCGUC	106	1913	GCAGCGGAGGCAGCGCCAC	431	
1909	CCUGCGCCAGCAGCAUGAU	107	1909	CCUGCGCCAGCAGCAUGAU	107	1931	AUCAUGCUGUGGCGCAGG	432	
1927	UGACUUGUGUGAUGACAUC	108	1927	UGACUUGUGUGAUGACAUC	108	1949	GAUGUCAUCAGCAAGAUCA	433	
1945	CUCCUGCUGAAGUGAGGA	109	1945	CUCCUGCUGAAGUGAGGA	109	1967	UCCUCACUUCAGCAGGGAG	434	
1963	AGGCCCAUGGGCAGAAGAU	110	1963	AGGCCCAUGGGCAGAAGAU	110	1985	AUCUUCUGCCCAUGGGCCU	435	
1981	UAGAGAUUCCCCUGGACCA	111	1981	UAGAGAUUCCCCUGGACCA	111	2003	UGGUCCAGGGGAAUUCUUA	436	
1999	ACACCCUGGUGUACACUU	112	1999	ACACCCUGGUGUACACUU	112	2021	AAGUGAACCCAGGAGGUGU	437	
2017	UUGGUCACAAGUAGGAGAC	113	2017	UUGGUCACAAGUAGGAGAC	113	2039	GUCUCCUACUUGUGACCAA	438	
2035	CACAGAUGGCACCCUGUGGC	114	2035	CACAGAUGGCACCCUGUGGC	114	2057	GCCACAGGUGCCAUUCUGU	439	
2053	CUCGCCAGCCUAGGACCC	115	2053	CUCGCCAGCCUAGGACCC	115	2075	GGGUCCUGAGGUGCCUGG	440	
2071	CUCCCCACCCACCAAUGC	116	2071	CUCCCCACCCACCAAUGC	116	2093	GCAUUGGUGGGUGGGGAG	441	
2089	CCUCUGCCUUGAUGGAGAA	117	2089	CCUCUGCCUUGAUGGAGAA	117	2111	UUCUCCAUCAGGCGAGAG	442	
2107	AGGAAAAGGCGUGGCAAGGU	118	2107	AGGAAAAGGCGUGGCAAGGU	118	2129	ACCUUGCCAGCCUUUCCU	443	
2125	UGGUUUCAGGGACUGUAC	119	2125	UGGUUUCAGGGACUGUAC	119	2147	GUACAGUCCUGGAACCCA	444	
2143	CCUGAUGGAAACAGAAAAG	120	2143	CCUGAUGGAAACAGAAAAG	120	2165	CUUUCUGUUUCCUACAGG	445	
2161	GAGAAAGAAAGACACUCU	121	2161	GAGAAAGAAAGACACUCU	121	2183	AGAGUGCUUCUUUCUUCUC	446	
2179	UGUGGCGGGAUACUCUU	122	2179	UGUGGCGGGAUACUCUU	122	2201	AAGAGAUUCCCCGCCAGCA	447	
2197	UGGUCACCUCAAAUUUAA	123	2197	UGGUCACCUCAAAUUUAA	123	2219	CUUAAAUUUGAGGUGACCA	448	
2215	GUCGGGAAAUUCUGUCGU	124	2215	GUCGGGAAAUUCUGUCGU	124	2237	AGCAGCAGAAUUUCCCGAC	449	
2233	UUGAAACUUCAGCCUGAA	125	2233	UUGAAACUUCAGCCUGAA	125	2255	UUCAGGGCUGAAGUUUCAA	450	
2251	ACCUUUGUCCACCAUCCU	126	2251	ACCUUUGUCCACCAUCCU	126	2273	AGGAAUGGUGGACAAAGGU	451	
2269	UUUAAAUCUCCAACCCAA	127	2269	UUUAAAUCUCCAACCCAA	127	2291	UUGGGUUGGAGAAUUUAAA	452	
2287	AAGUAUUCUUCUUUCUUA	128	2287	AAGUAUUCUUCUUUCUUA	128	2309	UAGAAAAGAAAGAAUACUU	453	
2305	AGUUUCAGAAGAUUCGGCA	129	2305	AGUUUCAGAAGAUUCGGCA	129	2327	UGCCAGUACUUCUGAAACU	454	
2323	AUCACACGCGAGGUUACUU	130	2323	AUCACACGCGAGGUUACUU	130	2345	AAGGUAACCCUGCGUGAU	455	
2341	UGGCGUGUGUCCUGUGGU	131	2341	UGGCGUGUGUCCUGUGGU	131	2363	ACCACAGGGACACACGCCA	456	
2359	UACCCUGGCAGAGAAGAGA	132	2359	UACCCUGGCAGAGAAGAGA	132	2381	UCUCUUCUCUGCCAGGGUA	457	
2377	ACCGGAGUUGUUUCCUGC	133	2377	ACCGGAGUUGUUUCCUGC	133	2399	CAGGGGAAACAAAGCUUGU	458	
2395	CUGGCCAAAGUCAGUAGGA	134	2395	CUGGCCAAAGUCAGUAGGA	134	2417	UCCUACUGAUUUGGCCAG	459	
2413	AGAGGAUGCACAGUUUGCU	135	2413	AGAGGAUGCACAGUUUGCU	135	2435	AGCAAAUCUGUGCAUCCUCU	460	
2431	UAUUUGCUUUAGAGACAGG	136	2431	UAUUUGCUUUAGAGACAGG	136	2453	CCUGUCUCUAAAGCAAAUA	461	
2449	GGACUGUAUAAACAAGCCU	137	2449	GGACUGUAUAAACAAGCCU	137	2471	AGGCUUGUUUAUACAGUCC	462	
2467	UAACAUGGUGCAAAGAUU	138	2467	UAACAUGGUGCAAAGAUU	138	2489	AAUCUUUGCACCAGUUGUA	463	
2485	UGCCUCUUGAAUUAAAAAA	139	2485	UGCCUCUUGAAUUAAAAAA	139	2507	UUUUUAAUUAACAGAGGCA	464	
2503	AAAAAACUAGAUUGACUUA	140	2503	AAAAAACUAGAUUGACUUA	140	2525	AUAGUCAAAUCUAGUUUUUU	465	
2521	UUUAUACAAUUGGGGCGG	141	2521	UUUAUACAAUUGGGGCGG	141	2543	CCGCCCCCAUUUGUAUAAA	466	
2539	GCUGGAAAGAGGAGAAGGA	142	2539	GCUGGAAAGAGGAGAAGGA	142	2561	UCCUUCUCCUCUUUCCAGC	467	
2557	AGAGGGAGUACAAGACAG	143	2557	AGAGGGAGUACAAGACAG	143	2579	CUGUCUUUGUACUCCUCUCU	468	
2575	GGGAAUAGUGGGAUCAAG	144	2575	GGGAAUAGUGGGAUCAAG	144	2597	CUUUGAUCCCAUUAUCCU	469	
2593	CUAGGAAAGGACAGAAACA	145	2593	CUAGGAAAGGACAGAAACA	145	2615	UGUUUCUGCCUUUCCUAGC	470	
2611	ACAACACUCACCCAGUCCU	146	2611	ACAACACUCACCCAGUCCU	146	2633	AGGACUGGUGAGUGGUUGU	471	
2629	UAGUUUAGACCUCAUCUC	147	2629	UAGUUUAGACCUCAUCUC	147	2651	GAGAUGAGGUCUAAAACUA	472	
2647	CCAAGAUAGCAUCCCAUCU	148	2647	CCAAGAUAGCAUCCCAUCU	148	2669	AGAUGGGAUGCUAUUCUGG	473	
2665	UCAGAAGAUUGGUGUUGUU	149	2665	UCAGAAGAUUGGUGUUGUU	149	2687	AACAACACCCAUUCUUGA	474	
2683	UUUCAAUUUUUUUUUUUU	150	2683	UUUCAAUUUUUUUUUUUU	150	2705	AGAAAAGAAAACAUUGAAA	475	
2701	UGUGGUUGCAGCCUGACCA	151	2701	UGUGGUUGCAGCCUGACCA	151	2723	UGGUCAGGCUGCAACACA	476	
2719	AAAAGUGAGAUUGGGAAGGG	152	2719	AAAAGUGAGAUUGGGAAGGG	152	2741	CCCUUCCCAUCUCACUUUU	477	
2737	GCUUUAUCUAGCCAAAGAGC	153	2737	GCUUUAUCUAGCCAAAGAGC	153	2759	GCUUUUUGGCUAGUAAGC	478	
2755	CUCUUUUUAGCUCUCUUA	154	2755	CUCUUUUUAGCUCUCUUA	154	2777	UAAGAGAGCUAAAAAGAG	479	
2773	AAAGUAGUGCCACUAAG	155	2773	AAAGUAGUGCCACUAAG	155	2795	CUUAGUGGGCACUUCAUUU	480	
2791	GAAGUCCACUUAACACAU	156	2791	GAAGUCCACUUAACACAU	156	2813	AUGUGUUAAGUGGAACUUC	481	
2809	UGAAUUUCUGCCAUUUUA	157	2809	UGAAUUUCUGCCAUUUUA	157	2831	UUAAUAUGGCAGAAAUAUA	482	
2827	AUUUCAUUGUCUCUAUCUG	158	2827	AUUUCAUUGUCUCUAUCUG	158	2849	CAGAUAGAGACAAUGAAAU	483	
2845	GAACCACCCUUUAUUCUAC	159	2845	GAACCACCCUUUAUUCUAC	159	2867	GUAGAAUAAAGGUGGUUC	484	
2863	CAUAGUAUAGCAGCACUG	160	2863	CAUAGUAUAGCAGCACUG	160	2885	CAGUGUGCCUUAUUAUUG	485	
2881	GAAAUUCCUUAACCCCUUA	161	2881	GAAAUUCCUUAACCCCUUA	161	2903	UAGGGGUGUAGGAUUAUUA	486	
2899	AAGCUCAGGUGCCUGUG	162	2899	AAGCUCAGGUGCCUGUG	162	2921	CACAGGGCACCUGGAGCUU	487	
2917	GGGAGAGCAACUGGACUUA	163	2917	GGGAGAGCAACUGGACUUA	163	2939	AUAGUCCAGUUGCUCUCC	488	
2935	UAGCAGGGCUGGGCUCUGU	164	2935	UAGCAGGGCUGGGCUCUGU	164	2957	ACAGAGCCAGCCUGCUUA	489	
2953	UCUUCUGGUCUAGGCUC	165	2953	UCUUCUGGUCUAGGCUC	165	2975	GAGCCUUAUGACCAGGAAGA	490	
2971	CACUCUUUCCGCAAAUCU	166	2971	CACUCUUUCCGCAAAUCU	166	2993	AGAUAUUGGGGAAAGAGUG	491	
2989	UUCUCUGGAGCUUUGCAG	167	2989	UUCUCUGGAGCUUUGCAG	167	3011	CUGCAAAGCUCAGAGGAA	492	
3007	GCCAAGGUGCUAAAAGGAA	168	3007	GCCAAGGUGCUAAAAGGAA	168	3029	UUCUUUUUAGCACCUGGC	493	
3025	AUAGGUAGGAGACCUUUC	169	3025	AUAGGUAGGAGACCUUUC	169	3047	GAAGAGGUCUCCUACCUA	494	
3043	CUAUCUAAUCCUUAAAAGC	170	3043	CUAUCUAAUCCUUAAAAGC	170	3065	GUUUUUAAGGAUUAAGUAG	495	
3061	CAUAAUGUUGAACAUUCAU	171	3061	CAUAAUGUUGAACAUUCAU	171	3083	AUGAAUGUUAACAUAUAG	496	
3079	UUCCAACAGCUGAUGCCUA	172	3079	UUCCAACAGCUGAUGCCUA	172	3101	UAGGGCAUCAGCUGUUGAA	497	
3097	AUAACCCUGCCUGGAUUU	173	3097	AUAACCCUGCCUGGAUUU	173	3119	AAUCCAGGCAGGGGUUAU	498	

TABLE I-continued

BACE target and siRNA sequences									
Pos	Target Sequence	Seq ID	UPos	Upper seq	Seq ID	LPos	Lower seq	Seq ID	
3115	UCUUCUUAUUAGGCUAUA	174	3115	UCUUCUUAUUAGGCUAUA	174	3137	UUAUAGCCUAAUAGGAAGA	499	
3133	AGAAGUAGCAAGAUCUUUA	175	3133	AGAAGUAGCAAGAUCUUUA	175	3155	UAAAGAUUCUUGCUACUUCU	500	
3151	ACAUAAUUCAGAGUGGUUU	176	3151	ACAUAAUUCAGAGUGGUUU	176	3173	AAACCACUCUGAAUUAUGU	501	
3169	UCAUUGCCUUCUACCCUC	177	3169	UCAUUGCCUUCUACCCUC	177	3191	GAGGGUAGGAAGGCAUUGA	502	
3187	CUCUAAUGGCCCCUCCA	178	3187	CUCUAAUGGCCCCUCCA	178	3209	AAUGGAGGGGCCAUUAGAG	503	
3205	UUAUUUGACUAAAGCAUCA	179	3205	UUAUUUGACUAAAGCAUCA	179	3227	UGAUGCUUUAGUCAAAUAA	504	
3223	ACACAGUGGCACUAGCAU	180	3223	ACACAGUGGCACUAGCAU	180	3245	AAUGCUAGUGCCACUGUGU	505	
3241	UAUACCAAGAGUAUGAGAA	181	3241	UAUACCAAGAGUAUGAGAA	181	3263	UUCUCAUACUCUUGGUUAU	506	
3259	AAUACAGUGCUUUUAGGCU	182	3259	AAUACAGUGCUUUUAGGCU	182	3281	AGCCAUAAAGCACUGUAU	507	
3277	UCUAAUUAUACUGCCUUA	183	3277	UCUAAUUAUACUGCCUUA	183	3317	UCCAGGCAGCCUUGAUACU	509	
3295	AGUAUCAAGGCUGCCUGGA	184	3295	AGUAUCAAGGCUGCCUGGA	184	3317	UCCAGGCAGCCUUGAUACU	509	
3313	AGAAAGGAUGGCAGCCUCA	185	3313	AGAAAGGAUGGCAGCCUCA	185	3335	UGAGGCGGCCAUCCUUUCU	510	
3331	AGGGCUUCCUUAUGUCCUC	186	3331	AGGGCUUCCUUAUGUCCUC	186	3353	GAGGACAUAAAGGAAGCCU	511	
3349	CCACCACAGAGUCCUUG	187	3349	CCACCACAGAGUCCUUG	187	3371	CAAGGAGCUCUUGUGGUGG	512	
3367	GAUGAAGGUCAUCUUUUUC	188	3367	GAUGAAGGUCAUCUUUUUC	188	2289	GAAAAAGAUAGCCUUAUC	513	
3385	CCCUAUUGCGUUCUCC	189	3385	CCCUAUUGCGUUCUCC	189	3407	GGGAAGAACAGGAUAGGGG	514	
3403	CCUCCCGCUCUUAUUGGU	190	3403	CCUCCCGCUCUUAUUGGU	190	3425	ACCAUAGGAGCGGGGAGG	515	
3421	UACGUGGGUACCCAGGCUG	191	3421	UACGUGGGUACCCAGGCUG	191	3443	CAGCCUGGGUACCCAGCUA	516	
3439	GUUUCUUGGGCUAGGUAGU	192	3439	GUUUCUUGGGCUAGGUAGU	192	3461	ACUACCUAGCCCAAGAACC	517	
3457	UGGGGACCAAGUUAUUAU	193	3457	UGGGGACCAAGUUAUUAU	193	3479	GUAAUGAACUUGGUCCCA	518	
3475	CCUCCCUAUCAGUUCUAGC	194	3475	CCUCCCUAUCAGUUCUAGC	194	3497	GUAGAACUGAUAGGGAGG	519	
3493	CAUAGUAAACUACGGUACC	195	3493	CAUAGUAAACUACGGUACC	195	3515	GGUACCGUAGUUUAUUAUG	520	
3511	CAGUGUUAUGUGGGAAGAGC	196	3511	CAGUGUUAUGUGGGAAGAGC	196	3533	GCUCUCCCAUCUAAACUG	521	
3529	CUGGGUUUCCUAGUAUAC	197	3529	CUGGGUUUCCUAGUAUAC	197	3551	GUUAUCUAGGAAAACCCAG	522	
3547	CCACUGCAUCCUACUCCU	198	3547	CCACUGCAUCCUACUCCU	198	3569	AGGAGUAGGAUGCAGUGGG	523	
3565	UACCUGGUCAAACCCGUGC	199	3565	UACCUGGUCAAACCCGUGC	199	3587	GCAGCGGGUUGACCAGGUA	524	
3583	CUUCCAGGUUAGGGACCUG	200	3583	CUUCCAGGUUAGGGACCUG	200	3605	CAGGUCCCAUACCUGGAAG	525	
3601	GUUUAAGUGUGGAUUAUACU	201	3601	GUUUAAGUGUGGAUUAUACU	201	3623	AGGUAAUUCACACUUAUG	526	
3619	UGUAAGGGAGAGGGGAAU	202	3619	UGUAAGGGAGAGGGGAAU	202	3641	AUUUCCUCUCCUUAUUAU	527	
3637	UACAAGGAGGGCCUCUGGU	203	3637	UACAAGGAGGGCCUCUGGU	203	3659	ACCAGAGGCCUCCUUGUA	528	
3655	UGUUCUGGCGUCCAGCCAG	204	3655	UGUUCUGGCGUCCAGCCAG	204	3677	CUGGCUAGGCGCAGGAACA	529	
3673	GCUGCCCAACAAGCCAUAAA	205	3673	GCUGCCCAACAAGCCAUAAA	205	3695	UUUAUGGCUUGUGGGCAGC	530	
3691	ACCAUAAACAAAGAAUAC	206	3691	ACCAUAAACAAAGAAUAC	206	3713	GUUUUCUUGUUUAUUGGU	531	
3709	CUGAGUCAGUUUUUAUUAU	207	3709	CUGAGUCAGUUUUUAUUAU	207	3731	AGAUAAAAAACUGACUAG	532	
3727	UGGGUUCUCUUAUUAUCCCA	208	3727	UGGGUUCUCUUAUUAUCCCA	208	3749	UGGGAUUGAAGAGAACCCA	533	
3745	ACUGCACUUGGUGCUGCUU	209	3745	ACUGCACUUGGUGCUGCUU	209	3767	AAGCAGCACCAAGUGCAGU	534	
3763	UGGCGUGACUGGGAACACC	210	3763	UGGCGUGACUGGGAACACC	210	3785	GGUUGUCCAGUCAGCCAA	535	
3781	CCCAUAAUACAGAGUCUG	211	3781	CCCAUAAUACAGAGUCUG	211	3803	CAGACUCUGUAGUUUAUGGG	536	
3799	GACAGGAAGACUGGAGACU	212	3799	GACAGGAAGACUGGAGACU	212	3821	AGUCUCCAGUCUCCUGUC	537	
3817	UGUCCACUUCUAGCUCGGA	213	3817	UGUCCACUUCUAGCUCGGA	213	3839	UCCGAGCUAGAAUGUGACA	538	
3835	AACUUAUCUGUUAUUAUAAA	214	3835	AACUUAUCUGUUAUUAUAAA	214	3857	UUUAUUUACACAUAAAGUU	539	
3853	ACUUUCAGAACUGCUACCA	215	3853	ACUUUCAGAACUGCUACCA	215	3875	UGGUAGCAGUUCUGAAAGU	540	
3871	AUGAAUGGAAUUAUUAUUAU	216	3871	AUGAAUGGAAUUAUUAUUAU	216	3893	UGUGGCAUUUUUACUUAU	541	
3889	AUUUUGCUUUUAUUAUUAU	217	3889	AUUUUGCUUUUAUUAUUAU	217	3911	AGAAAUUAUAAAGCAAAAU	542	
3907	UACCCAUUGUUGGAAAAAC	218	3907	UACCCAUUGUUGGAAAAAC	218	3929	GUUUUCCCAACAUUGGUA	543	
3925	UCCGCUUUUUUCCAGCCU	219	3925	UCCGCUUUUUUCCAGCCU	219	3947	AGGCGUGGGAAAAAGCCAG	544	
3943	UUUCCAGGGCAUAAAAACUC	220	3943	UUUCCAGGGCAUAAAAACUC	220	3965	GAGUUUUUAGCCUUGGAAA	545	
3961	CAACCCUUCGUAAGCAAG	221	3961	CAACCCUUCGUAAGCAAG	221	3983	CUUGCUAUCGAAGGGGUUG	546	
3979	GUCCCAUCAGCCUUAUUAU	222	3979	GUCCCAUCAGCCUUAUUAU	222	4001	AAUAAUAGGCUAGUGGCAC	547	
3997	UUUUUUAAGAAAAACUUGC	223	3997	UUUUUUAAGAAAAACUUGC	223	4019	GCAAGUUUUCUUUAAAAAA	548	
4015	CACUUGUUUUUUCUUUUUAC	224	4015	CACUUGUUUUUUCUUUUUAC	224	4037	GUAAAAAGAAAAACAAGUG	549	
4033	CAGUUACUUCUUCUGCC	225	4033	CAGUUACUUCUUCUGCC	225	4055	GGCAGGAAGGAAGUAAUCG	550	
4051	CCCAAAUUAUAAACUCUA	226	4051	CCCAAAUUAUAAACUCUA	226	4073	UAGAGUUUAUAAUUUUGGG	551	
4069	AAGUGUAAAAAAAGUCUU	227	4069	AAGUGUAAAAAAAGUCUU	227	4091	AAGACUUUUUUUACACUU	552	
4087	UAACAACAGGUUCUUGCUU	228	4087	UAACAACAGGUUCUUGCUU	228	4109	AAGCAAGAAAGCUUGUUAU	553	
4105	UGUAAAAAUUAUUAUUAU	229	4105	UGUAAAAAUUAUUAUUAU	229	4127	UAUAAUACAUUUUUUACA	554	
4123	ACAUCUGUAUUUUUAAAUU	230	4123	ACAUCUGUAUUUUUAAAUU	230	4145	AAUUUAAAAAUACAGAUGU	555	
4141	UCUGCUCCUGAAAAUAGAC	231	4141	UCUGCUCCUGAAAAUAGAC	231	4163	GUCAUUUUUCCAGGAGCAGA	556	
4159	CUGUCCCAUUCUCCACUCA	232	4159	CUGUCCCAUUCUCCACUCA	232	4181	UGAGUGGAGAAUGGGACAG	557	
4177	ACUGCAUUUGGGGCCUUUC	233	4177	ACUGCAUUUGGGGCCUUUC	233	4199	GAAAGGCCCAAAUAGCAGU	558	
4195	UUGUUGGUGUAGUAGUCU	234	4195	UUGUUGGUGUAGUAGUCU	234	4217	AGACAUGCAGACCAUAGGG	559	
4213	UUUUAUUAUUGCAGGCCAG	235	4213	UUUUAUUAUUGCAGGCCAG	235	4235	CUGGCCUGCAUUAUAAAA	560	
4231	GUGGACAGAGGGAGAGGG	236	4231	GUGGACAGAGGGAGAGGG	236	4253	CCUUCUCCUUCUGUCCAC	561	
4249	GAGAACAGGGGUCCCAAC	237	4249	GAGAACAGGGGUCCCAAC	237	4271	GUUGGCCAGCCUUGUUCUC	562	
4267	CACUUGUGUUGCUUUCUGA	238	4267	CACUUGUGUUGCUUUCUGA	238	4289	UCAGAAAGCAACACAAGUG	563	
4285	ACUGAUCCUGAACAAAGAA	239	4285	ACUGAUCCUGAACAAAGAA	239	4307	UUUCUUGUUCAGGAUACAGU	564	
4303	AGAGUAAACUAGAGCGCU	240	4303	AGAGUAAACUAGAGCGCU	240	4325	AGCGCCUACAGUUAUCUCU	565	
4321	UCGCUCCCAUGCACAACUC	241	4321	UCGCUCCCAUGCACAACUC	241	4343	GAGUUGUGCAUUGGAGCCA	566	
4339	CUCCAAAACACUUAUCCUC	242	4339	CUCCAAAACACUUAUCCUC	242	4361	GAGGAUAAUGUUUUUGGAG	567	
4357	CCUGCAAGAGUGGGCUUUC	243	4357	CCUGCAAGAGUGGGCUUUC	243	4379	GAAAGCCCAUCUUGCGAGG	568	
4375	CCAGGGUCUUUACUGGGAA	244	4375	CCAGGGUCUUUACUGGGAA	244	4397	UUCCAGUAUAAAGACCCUGG	569	

TABLE I-continued

BACE target and siRNA sequences									
Pos	Target Sequence	Seq ID	UPos	Upper seq	Seq ID	LPos	Lower seq	Seq ID	
4393	AGCAGUUAAGCCCCCUCCU	245	4393	AGCAGUUAAGCCCCCUCCU	245	4415	AGGAGGGGGCUAAACUGCU	570	
4411	UCACCCCUUCCUUUUUUUCU	246	4411	UCACCCCUUCCUUUUUUUCU	246	4433	AGAAAAAGGAAGGGGGUGA	571	
4429	UUUCUUUACUCCUUUGGCU	247	4429	UUUCUUUACUCCUUUGGCU	247	4451	AGCCAAAGGAGUAAAGAAA	572	
4447	UUCAAAGGAUUUUGGAAAA	248	4447	UUCAAAGGAUUUUGGAAAA	248	4469	UUUCCAAAAAUCCUUUGAA	573	
4465	AGAAACAUAUGCUUUUACA	249	4465	AGAAACAUAUGCUUUUACA	249	4487	UGUAAAGCAUAUUGUUUCU	574	
4483	ACUCAUUUUCAAUUUCUAA	250	4483	ACUCAUUUUCAAUUUCUAA	250	4505	UUAGAAAUUGAAAAUGAGU	575	
4501	AAUUUGCAGGGGACUACUGA	251	4501	AAUUUGCAGGGGACUACUGA	251	4523	UCAGUAUCCCCUGCAAAUU	576	
4519	AAAAUAACGGCAGUGGGCC	252	4519	AAAAUAACGGCAGUGGGCC	252	4541	GGCCACUGCCGUUUUUUU	577	
4537	CUAAGGCUGCUGUAAAGUU	253	4537	CUAAGGCUGCUGUAAAGUU	253	4559	AACUUUACACGAGCCUUG	578	
4555	UGAGGGGAGAGGAAAUUCU	254	4555	UGAGGGGAGAGGAAAUUCU	254	4577	AAGAUUCCUCUCGCCUCA	579	
4573	UAAGAUUACAAGAUAUAAAA	255	4573	UAAGAUUACAAGAUAUAAAA	255	4595	UUUUUAUCUUGUAACUUA	580	
4591	AACGAAUCCCUAAACAAA	256	4591	AACGAAUCCCUAAACAAA	256	4613	UUUGUUUAGGGGAUUCGU	581	
4609	AAAGAAACAUAAGUACUGGU	257	4609	AAAGAAACAUAAGUACUGGU	257	4631	ACCAGUUCUAUUGUUUUU	582	
4627	UCUUCCAUUUUGCCACCUU	258	4627	UCUUCCAUUUUGCCACCUU	258	4649	AAGGUGGCAAAUUGGAAGA	583	
4645	UUCUGUUCUAGCAGACGUA	259	4645	UUCUGUUCUAGCAGACGUA	259	4667	UAGCUGUCAUGAACAGGAA	584	
4663	ACUAAACCUGGAGACAGUAA	260	4663	ACUAAACCUGGAGACAGUAA	260	4685	UACUGUCUCCAGGUUAGU	585	
4681	ACAUUUCAUUAACCAAGA	261	4681	ACAUUUCAUUAACCAAGA	261	4703	UCUUUGGUUAAUGAAUUGU	586	
4699	AAAGUGGUCACCUGACCU	262	4699	AAAGUAAUACACCUGACCU	262	4721	AGGUCAGGUGACCCACUUU	587	
4717	UCUGAAGAGCUGAGUACUC	263	4717	UCUGAAGAGCUGAGUACUC	263	4739	GAGUACUCAGCUCUUCAGA	588	
4735	CAGGCCACUCCAAUACCCC	264	4735	CAGGCCACUCCAAUACCCC	264	4757	GGUGAUUGGAGUGGCCUG	589	
4753	CUACAAGAUGCCAAGGAGG	265	4753	CUACAAGAUGCCAAGGAGG	265	4775	CCUCCUUGGCAUCUUGUAG	590	
4771	GUCCCAGGAAGUCCAGCUC	266	4771	GUCCCAGGAAGUCCAGCUC	266	4793	GAGCUGGACUUCUGGGAC	591	
4789	CCUUAACUGACCCUAGUC	267	4789	CCUUAACUGACCCUAGUC	267	4811	GACUAGCGUCAGUUUAAAG	592	
4807	CAUUAACUUGGGCAAGUG	268	4807	CAUUAACUUGGGCAAGUG	268	4829	CACUUGCCCAGGUUUUUG	593	
4825	GAGGCAAGAGAAUUGAGGA	269	4825	GAGGCAAGAGAAUUGAGGA	269	4847	UCCUCAUUUCUCUUGCCUC	594	
4843	AAGAAUCCAUCUGUGAGGU	270	4843	AAGAAUCCAUCUGUGAGGU	270	4865	ACCUCACAGAUUGAUUCUU	595	
4861	UGACAGGCAAGGAUGAAAG	271	4861	UGACAGGCAAGGAUGAAAG	271	4883	CUUUAUCCUUGCCUGUCA	596	
4879	GACAAAGAGCAAAAGAGU	272	4879	GACAAAGAGCAAAAGAGU	272	4901	ACUCUUUUCCUUCUUUGUC	597	
4897	UAUCAAAGGCAGAAAGGAG	273	4897	UAUCAAAGGCAGAAAGGAG	273	4919	CUCUUUUCUGCCUUUGUAU	598	
4915	GAUCAUUUAGUUGGUCUG	274	4915	GAUCAUUUAGUUGGUCUG	274	4937	CAGACCCAACUAAUUGAUC	599	
4933	GAAAGGAAAGUUCUUUGCU	275	4933	GAAAGGAAAGUUCUUUGCU	275	4955	AGCAAGAGCUUUUCCUUC	600	
4951	UAUCCGACAUUACUGCUA	276	4951	UAUCCGACAUUACUGCUA	276	4973	UAGCAGUACAUUGCCGAUA	601	
4969	AGUACCUUUAAGCAUUUUA	277	4969	AGUACCUUUAAGCAUUUUA	277	4991	UAAAAGCUUACAGGUACU	602	
4987	AGGUCCCAAGUUGGAAAAA	278	4987	AGGUCCCAAGUUGGAAAAA	278	5009	UUUUUCCAUCUUGGACCU	603	
5005	AAAAAUACAGCUAUUGGUAA	279	5005	AAAAAUACAGCUAUUGGUAA	279	5027	UUACCAAUAGCUGAUUUUU	604	
5023	AUAUAAUAAUGUCCUUUCC	280	5023	AUAUAAUAAUGUCCUUUCC	280	5045	GGAAGGACAUUUAUUAU	605	
5041	CCUGGAGUCAGUUUUUUUA	281	5041	CCUGGAGUCAGUUUUUUUA	281	5063	UAAAAAAACUGACUCCAGG	606	
5059	AAAAAGUUAACUCUAGUU	282	5059	AAAAAGUUAACUCUAGUU	282	5081	AACUAAGAGUUAACUUUUU	607	
5077	UUUUACUUGUUUAAUUCUA	283	5077	UUUUACUUGUUUAAUUCUA	283	5099	UAGAAUUAACAAGUAAAA	608	
5095	AAAAGAGAAGGGAGCUGAG	284	5095	AAAAGAGAAGGGAGCUGAG	284	5117	CUCAGCUCUCCUUCUUUU	609	
5113	GGCCAUUCUCCUGUAGGAGU	285	5113	GGCCAUUCUCCUGUAGGAGU	285	5135	ACUCCUACAGGGAUUGGCC	610	
5131	UAAAGAUAAAAGGAUAGGA	286	5131	UAAAGAUAAAAGGAUAGGA	286	5153	UCCUAUCCUUUUUUCUUUA	611	
5149	AAAAGAUUCAAAGCUCUAA	287	5149	AAAAGAUUCAAAGCUCUAA	287	5171	UUAGAGCUUUUUAUUCUUU	612	
5167	AUAGAGUCACAGCUUUCCC	288	5167	AUAGAGUCACAGCUUUCCC	288	5189	GGGAAAGCUGGACUCUUAU	613	
5185	CAGGUUAUAAACCUAAAAU	289	5185	CAGGUUAUAAACCUAAAAU	289	5207	AUUUUAGGUUUUAUACCU	614	
5203	UUAGAGAGUACAAUAGCA	290	5203	UUAGAGAGUACAAUAGCA	290	5225	UGCUUAUUGUACUUCUUA	615	
5221	AGAGGUGGAAAAUGAUCUA	291	5221	AGAGGUGGAAAAUGAUCUA	291	5243	UAGAUAUUUUCCACCUUCU	616	
5239	AGUUCUGAUAGCUACCCA	292	5239	AGUUCUGAUAGCUACCCA	292	5261	UGGGUAGCUAUCAGGAACU	617	
5257	ACAGAGCAAGUGAUUUUAU	293	5257	ACAGAGCAAGUGAUUUUAU	293	5279	UAUAAAUACUUGCGUCUGU	618	
5275	AAAUUUGAAAUCCAACUA	294	5275	AAAUUUGAAAUCCAACUA	294	5297	UAGUUUGGAUUUCAAUUUU	619	
5293	ACUUUCUUAUUAUCACUUU	295	5293	ACUUUCUUAUUAUCACUUU	295	5315	AAAGUGAUUUUAGAAAGU	620	
5311	UGGUCCUCAAUUUUCCAG	296	5311	UGGUCCUCAAUUUUCCAG	296	5333	CUGGGAAAAUUGGAGACCA	621	
5329	GGACAGGAAAUUUGUCCCC	297	5329	GGACAGGAAAUUUGUCCCC	297	5351	GGGGACAUAUUUCCUGUCC	622	
5347	CCCCUAAUUCUUGCUUC	298	5347	CCCCUAAUUCUUGCUUC	298	5369	GAAGCAAGAAAGUUAGGGG	623	
5365	CAAAAAUUAUAAUCCAGCA	299	5365	CAAAAAUUAUAAUCCAGCA	299	5387	UGCUGGAUUUUUAAUUUUU	624	
5383	AUCCCAAGAUCAUUCUACA	300	5383	AUCCCAAGAUCAUUCUACA	300	5405	UGUAGAAUGAUUUGGGAU	625	
5401	AAGUAAUUUUGCACAGACA	301	5401	AAGUAAUUUUGCACAGACA	301	5423	UGUCUGUGCAAAAUUACUU	626	
5419	AUCUCCUACACCCAGUGCC	302	5419	AUCUCCUACACCCAGUGCC	302	5441	GGCACUGGGGUGAGGAGAU	627	
5437	CUGUCUGGAGCUCACCCAA	303	5437	CUGUCUGGAGCUCACCCAA	303	5459	UUGGGUGAGCUCAGACAG	628	
5455	AGGUCACCAACAACUUGG	304	5455	AGGUCACCAACAACUUGG	304	5477	CCAAGUUGUUUGGUGACCU	629	
5473	GUUGUGAACCAACUGCCUU	305	5473	GUUGUGAACCAACUGCCUU	305	5495	AAGGCAGUUGGUUACCAAC	630	
5491	UAACCUUCUGGGGGAGGGG	306	5491	UAACCUUCUGGGGGAGGGG	306	5513	CCCCUCCCCAGAGGUUA	631	
5509	GGAUUAGCUAGACUAGGAG	307	5509	GGAUUAGCUAGACUAGGAG	307	5531	CUCCUAGUCUAGCUAAUCC	632	
5527	GACCAAGAGUAGUAGGGAA	308	5527	GACCAAGAGUAGUAGGGAA	308	5549	UUCCAUUCACUUCUGGUC	633	
5545	AAGGGUGAGGACUUCACAA	309	5545	AAGGGUGAGGACUUCACAA	309	5567	UUGUGAAGUCCUACCCUU	634	
5563	AUGUUGGCCUGUCAGAGCU	310	5563	AUGUUGGCCUGUCAGAGCU	310	5585	AGCUCUGACAGGCCAACAU	635	
5581	UUGAUUAGAAGCCAAGACA	311	5581	UUGAUUAGAAGCCAAGACA	311	5603	UGUCUUGGCUUUAUACAA	636	
5599	AGUGGCAGCAAGGAAGAC	312	5599	AGUGGCAGCAAGGAAGAC	312	5621	GUCUCCUUUGUGGCCACU	637	
5617	CUUGGCCAGGAAAAACCU	313	5617	CUUGGCCAGGAAAAACCU	313	5639	AGGUUUUUCUGGGCCAA	638	
5635	UGUGGUUGUGCUAAUUUC	314	5635	UGUGGUUGUGCUAAUUUC	314	5657	GAAAUUAGCACAACCCACA	639	
5653	CUGUCCAGAAAAUAGGGUG	315	5653	CUGUCCAGAAAAUAGGGUG	315	5675	CACCCUAAUUUUCUGGACAG	640	

TABLE I-continued

BACE target and siRNA sequences									
Pos	Target Sequence	Seq ID	UPos	Upper seq	Seq ID	LPos	Lower seq	Seq ID	
5671	GGACAGAAGCUUGUGGGGU	316	5671	GGACAGAAGCUUGUGGGGU	316	5693	ACCCACAAGCUUCUGUCC	641	
5689	UGCAUGGAGGAAUUGGGAC	317	5689	UGCAUGGAGGAAUUGGGAC	317	5711	GUCCCAAUUCUCCAUGCA	642	
5707	CCUGGUUAUGUUGUUAUUC	318	5707	CCUGGUUAUGUUGUUAUUC	318	5729	GAAUACAACAUAACAGG	643	
5725	CUCGGACUGUGAAUUUUGG	319	5725	CUCGGACUGUGAAUUUUGG	319	5747	CCAAAUUCACAGUCCGAG	644	
5743	GUGAUGUAAAACAGAAUUA	320	5743	GUGAUGUAAAACAGAAUUA	320	5765	AUAUUCUGUUUACAUAC	645	
5761	UUCUGUAAACCUAAUGUCU	321	5761	UUCUGUAAACCUAAUGUCU	321	5783	AGACAUUAGGUUACAGAA	646	
5779	UGUAUAAAUAUGAGCGUU	322	5779	UGUAUAAAUAUGAGCGUU	322	5801	AACGCUCAUUAUUUAACA	647	
5797	UAACACAGUAAAUAUUCA	323	5797	UAACACAGUAAAUAUUCA	323	5819	UGAAUUAUUUACUGUGUUA	648	
5815	AAUAAGAAGUCAAAAAAAA	324	5815	AAUAAGAAGUCAAAAAAAA	324	5837	UUUUUUUUGACUUCUUUU	649	
5825	CAAAAAAUAUUUUUUUUUU	325	5825	CAAAAAAUAUUUUUUUUUU	325	5847	UUUUUUUUUUUUUUUUUU	650	

BACE = NM_012104

The 3'-ends of the Upper sequence and the Lower sequence of the siRNA construct can include a overhang sequence, for example about 1, 2, 3, or 4 nucleotides in length, preferably 2 nucleotides in length, wherein the overhanging sequence of the lower sequence is optionally complementary to a portion of the target sequence. The upper sequence is also referred to as the sense strand, whereas the lower sequence is also referred to as the antisense strand.

[0263]

TABLE II

A. 2.5 μ mol Synthesis Cycle ABI 394 Instrument					
Reagent	Equivalents	Amount	Wait Time* DNA	Wait Time* 2'-O-methyl	Wait Time*RNA
Phosphoramidites	6.5	163 μ L	45 sec	2.5 min	7.5 min
S-Ethyl Tetrazole	23.8	238 μ L	45 sec	2.5 min	7.5 min
Acetic Anhydride	100	233 μ L	5 sec	5 sec	5 sec
N-Methyl Imidazole	186	233 μ L	5 sec	5 sec	5 sec
TCA	176	2.3 mL	21 sec	21 sec	21 sec
Iodine	11.2	1.7 mL	45 sec	45 sec	45 sec
Beaucage	12.9	645 μ L	100 sec	300 sec	300 sec
Acetonitrile	NA	6.67 mL	NA	NA	NA
B. 0.2 μ mol Synthesis Cycle ABI 394 Instrument					
Reagent	Equivalents	Amount	Wait Time* DNA	Wait Time* 2'-O-methyl	Wait Time*RNA
Phosphoramidites	15	31 μ L	45 sec	233 sec	465 sec
S-Ethyl Tetrazole	38.7	31 μ L	45 sec	233 min	465 sec
Acetic Anhydride	655	124 μ L	5 sec	5 sec	5 sec
N-Methyl Imidazole	1245	124 μ L	5 sec	5 sec	5 sec
TCA	700	732 μ L	10 sec	10 sec	10 sec
Iodine	20.6	244 μ L	15 sec	15 sec	15 sec
Beaucage	7.7	232 μ L	100 sec	300 sec	300 sec
Acetonitrile	NA	2.64 mL	NA	NA	NA
C. 0.2 μ mol Synthesis Cycle 96 well Instrument					
Reagent	Equivalents:DNA/2'-O-methyl/Ribo	Amount: DNA/2'-O-methyl/Ribo	Wait Time* DNA	Wait Time* 2'-O-methyl	Wait Time* Ribo
Phosphoramidites	22/33/66	40/60/120 μ L	60 sec	180 sec	360 sec
S-Ethyl Tetrazole	70/105/210	40/60/120 μ L	60 sec	180 min	360 sec
Acetic Anhydride	265/265/265	50/50/50 μ L	10 sec	10 sec	10 sec
N-Methyl Imidazole	502/502/502	50/50/50 μ L	10 sec	10 sec	10 sec
TCA	238/475/475	250/500/500 μ L	15 sec	15 sec	15 sec
Iodine	6.8/6.8/6.8	80/80/80 μ L	30 sec	30 sec	30 sec
Beaucage	34/51/51	80/120/120	100 sec	200 sec	200 sec
Acetonitrile	NA	1150/1150/1150 μ L	NA	NA	NA

Wait time does not include contact time during delivery.

Tandem synthesis utilizes double coupling of linker molecule

What we claim is:

1. A short interfering RNA (siRNA) molecule that down regulates expression of a beta site APP-cleaving enzyme (BACE) gene by RNA interference.

2. The siRNA molecule of claim 1, wherein said siRNA molecule is adapted for use to treat Alzheimer's disease.

3. The siRNA molecule of claim 1, wherein said siRNA molecule comprises a sense region and an antisense region and wherein said antisense region comprises sequence complementary to an RNA sequence encoding BACE and the sense region comprises sequence complementary to the antisense region.

4. The siRNA molecule of claim 3, wherein said siRNA molecule is assembled from two nucleic acid fragments wherein one fragment comprises the sense region and the second fragment comprises the antisense region of said siRNA molecule.

5. The siRNA molecule of claim 4, wherein said sense region and antisense region are covalently connected via a linker molecule.

6. The siRNA molecule of claim 5, wherein said linker molecule is a polynucleotide linker.

7. The siRNA molecule of claim 5, wherein said linker molecule is a non-nucleotide linker.

8. The siRNA molecule of claim 3, wherein said antisense region comprises sequence complementary to sequence having any of SEQ ID NOS. 1-325.

9. The siRNA molecule of claim 3, wherein said antisense region comprises sequence having any of SEQ ID NOS. 326-650, 664, 666, 668, 670, 672, or 674.

10. The siRNA molecule of claim 3, wherein said sense region comprises sequence having any of SEQ ID NOS. 1-325, 663, 665, 667, 669, 671, or 673.

11. The siRNA molecule of claim 3, wherein said sense region comprises a sequence of SEQ ID NO. 651 and said antisense region comprises a sequence of SEQ ID NO. 652.

12. The siRNA molecule of claim 3, wherein said sense region comprises a sequence of SEQ ID NO. 653 and said antisense region comprises a sequence of SEQ ID NO. 654.

13. The siRNA molecule of claim 3, wherein said sense region comprises a sequence of SEQ ID NO. 655 and said antisense region comprises a sequence of SEQ ID NO. 656.

14. The siRNA molecule of claim 3, wherein said sense region comprises a sequence of SEQ ID NO. 657 and said antisense region comprises a sequence of SEQ ID NO. 658.

15. The siRNA molecule of claim 3, wherein said sense region comprises a sequence of SEQ ID NO. 659 and said antisense region comprises a sequence of SEQ ID NO. 660.

16. The siRNA molecule of claim 3, wherein said sense region comprises a sequence of SEQ ID NO. 661 and said antisense region comprises a sequence of SEQ ID NO. 662.

17. The siRNA molecule of claim 3, wherein said sense region comprises a 3'-terminal overhang and said antisense region comprises a 3'-terminal overhang.

18. The siRNA molecule of claim 17, wherein said 3'-terminal overhangs each comprise about 2 nucleotides.

19. The siRNA molecule of claim 17, wherein said antisense region 3'-terminal nucleotide overhang is complementary to RNA encoding BACE.

20. The siRNA molecule of claim 3, wherein said sense region comprises one or more 2'-O-methyl modified pyrimidine nucleotides.

21. The siRNA molecule of claim 3, wherein said sense region comprises a terminal cap moiety at the 5'-end, 3'-end, or both 5' and 3' ends of said sense region.

22. The siRNA molecule of claim 3, wherein said antisense region comprises one or more 2'-deoxy-2'-fluoro modified pyrimidine nucleotides.

23. The siRNA molecule of claim 3, wherein said antisense region comprises a phosphorothioate internucleotide linkage at the 3' end of said antisense region.

24. The siRNA molecule of claim 3, wherein said antisense region comprises between about one and about five phosphorothioate internucleotide linkages at the 5' end of said antisense region.


25. The siRNA molecule of claim 17, wherein said 3'-terminal nucleotide overhangs comprise ribonucleotides that are chemically modified at a nucleic acid sugar, base, or backbone.

26. The siRNA molecule of claim 17, wherein said 3'-terminal nucleotide overhangs comprise deoxyribonucleotides that are optionally modified at a nucleic acid sugar, base, or backbone.

27. The siRNA molecule of claim 17, wherein said 3'-terminal nucleotide overhangs comprise one or more universal base ribonucleotides.


28. The siRNA molecule of claim 17, wherein said 3'-terminal nucleotide overhangs comprise one or more acyclic nucleotides.

29. The siRNA molecule of claim 17, wherein said 3'-terminal nucleotide overhangs comprise nucleotides comprising internucleotide linkages having Formula I:



wherein each R1 and R2 is independently any nucleotide, non-nucleotide, or polynucleotide which can be naturally occurring or chemically modified, each X and Y is independently O, S, N, alkyl, or substituted alkyl, each Z and W is independently O, S, N, alkyl, substituted alkyl, O-alkyl, S-alkyl, alkaryl, or aralkyl, and wherein W, X, Y and Z are not all O.

30. The siRNA molecule of claim 17, wherein said 3'-terminal nucleotide overhangs comprise nucleotides or non-nucleotides having Formula II:



wherein each R3, R4, R5, R6, R7, R8, R10, R11 and R12 is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF3, OCF3, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl,

alkyl-O-alkyl, ONO₂, NO₂, N₃, NH₂, aminoalkyl, aminoacid, aminoacyl, ONH₂, O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, or group having Formula I; R₉ is O, S, CH₂, S=O, CHF, or CF₂, and B is a nucleosidic base or any other non-naturally occurring base that can be complementary or non-complementary to BACE RNA or a non-nucleosidic base or any other non-naturally occurring universal base that can be complementary or non-complementary to BACE RNA.

31. An expression vector comprising a nucleic acid sequence encoding at least one siRNA molecule of claim 1 in a manner that allows expression of the nucleic acid molecule.

32. A mammalian cell comprising an expression vector of claim 31.

33. The mammalian cell of claim 32, wherein said mammalian cell is a human cell.

34. The expression vector of claim 31, wherein said siRNA molecule comprises a sense region and an antisense region and wherein said antisense region comprises sequence complementary to an RNA sequence encoding BACE and the sense region comprises sequence complementary to the antisense region.

35. The expression vector of claim 34, wherein said siRNA molecule comprises two distinct strands having complementarity sense and antisense regions.

36. The expression vector of claim 34, wherein said siRNA molecule comprises a single strand having complementary sense and antisense regions.

* * * * *